BindingDB Reactant_set_id Ligand SMILES Ligand InChI Ligand InChI Key BindingDB MonomerID BindingDB Ligand Name Target Name Target Source Organism According to Curator or DataSource Ki (nM) IC50 (nM) Kd (nM) EC50 (nM) kon (M-1-s-1) koff (s-1) pH Temp (C) Curation/DataSource Article DOI BindingDB Entry DOI PMID PubChem AID Patent Number Authors Date of publication Date in BindingDB Institution Link to Ligand in BindingDB Link to Target in BindingDB Link to Ligand-Target Pair in BindingDB Ligand HET ID in PDB PDB ID(s) for Ligand-Target Complex PubChem CID PubChem SID ChEBI ID of Ligand ChEMBL ID of Ligand DrugBank ID of Ligand IUPHAR_GRAC ID of Ligand KEGG ID of Ligand ZINC ID of Ligand Number of Protein Chains in Target (>1 implies a multichain complex) BindingDB Target Chain Sequence 1 PDB ID(s) of Target Chain 1 UniProt (SwissProt) Recommended Name of Target Chain 1 UniProt (SwissProt) Entry Name of Target Chain 1 UniProt (SwissProt) Primary ID of Target Chain 1 UniProt (SwissProt) Secondary ID(s) of Target Chain 1 UniProt (SwissProt) Alternative ID(s) of Target Chain 1 UniProt (TrEMBL) Submitted Name of Target Chain 1 UniProt (TrEMBL) Entry Name of Target Chain 1 UniProt (TrEMBL) Primary ID of Target Chain 1 UniProt (TrEMBL) Secondary ID(s) of Target Chain 1 UniProt (TrEMBL) Alternative ID(s) of Target Chain 1 BindingDB Target Chain Sequence 2 PDB ID(s) of Target Chain 2 UniProt (SwissProt) Recommended Name of Target Chain 2 UniProt (SwissProt) Entry Name of Target Chain 2 UniProt (SwissProt) Primary ID of Target Chain 2 UniProt (SwissProt) Secondary ID(s) of Target Chain 2 UniProt (SwissProt) Alternative ID(s) of Target Chain 2 UniProt (TrEMBL) Submitted Name of Target Chain 2 UniProt (TrEMBL) Entry Name of Target Chain 2 UniProt (TrEMBL) Primary ID of Target Chain 2 UniProt (TrEMBL) Secondary ID(s) of Target Chain 2 UniProt (TrEMBL) Alternative ID(s) of Target Chain 2 BindingDB Target Chain Sequence 3 PDB ID(s) of Target Chain 3 UniProt (SwissProt) Recommended Name of Target Chain 3 UniProt (SwissProt) Entry Name of Target Chain 3 UniProt (SwissProt) Primary ID of Target Chain 3 UniProt (SwissProt) Secondary ID(s) of Target Chain 3 UniProt (SwissProt) Alternative ID(s) of Target Chain 3 UniProt (TrEMBL) Submitted Name of Target Chain 3 UniProt (TrEMBL) Entry Name of Target Chain 3 UniProt (TrEMBL) Primary ID of Target Chain 3 UniProt (TrEMBL) Secondary ID(s) of Target Chain 3 UniProt (TrEMBL) Alternative ID(s) of Target Chain 3 BindingDB Target Chain Sequence 4 PDB ID(s) of Target Chain 4 UniProt (SwissProt) Recommended Name of Target Chain 4 UniProt (SwissProt) Entry Name of Target Chain 4 UniProt (SwissProt) Primary ID of Target Chain 4 UniProt (SwissProt) Secondary ID(s) of Target Chain 4 UniProt (SwissProt) Alternative ID(s) of Target Chain 4 UniProt (TrEMBL) Submitted Name of Target Chain 4 UniProt (TrEMBL) Entry Name of Target Chain 4 UniProt (TrEMBL) Primary ID of Target Chain 4 UniProt (TrEMBL) Secondary ID(s) of Target Chain 4 UniProt (TrEMBL) Alternative ID(s) of Target Chain 4 BindingDB Target Chain Sequence 5 PDB ID(s) of Target Chain 5 UniProt (SwissProt) Recommended Name of Target Chain 5 UniProt (SwissProt) Entry Name of Target Chain 5 UniProt (SwissProt) Primary ID of Target Chain 5 UniProt (SwissProt) Secondary ID(s) of Target Chain 5 UniProt (SwissProt) Alternative ID(s) of Target Chain 5 UniProt (TrEMBL) Submitted Name of Target Chain 5 UniProt (TrEMBL) Entry Name of Target Chain 5 UniProt (TrEMBL) Primary ID of Target Chain 5 UniProt (TrEMBL) Secondary ID(s) of Target Chain 5 UniProt (TrEMBL) Alternative ID(s) of Target Chain 5 BindingDB Target Chain Sequence 6 PDB ID(s) of Target Chain 6 UniProt (SwissProt) Recommended Name of Target Chain 6 UniProt (SwissProt) Entry Name of Target Chain 6 UniProt (SwissProt) Primary ID of Target Chain 6 UniProt (SwissProt) Secondary ID(s) of Target Chain 6 UniProt (SwissProt) Alternative ID(s) of Target Chain 6 UniProt (TrEMBL) Submitted Name of Target Chain 6 UniProt (TrEMBL) Entry Name of Target Chain 6 UniProt (TrEMBL) Primary ID of Target Chain 6 UniProt (TrEMBL) Secondary ID(s) of Target Chain 6 UniProt (TrEMBL) Alternative ID(s) of Target Chain 6 BindingDB Target Chain Sequence 7 PDB ID(s) of Target Chain 7 UniProt (SwissProt) Recommended Name of Target Chain 7 UniProt (SwissProt) Entry Name of Target Chain 7 UniProt (SwissProt) Primary ID of Target Chain 7 UniProt (SwissProt) Secondary ID(s) of Target Chain 7 UniProt (SwissProt) Alternative ID(s) of Target Chain 7 UniProt (TrEMBL) Submitted Name of Target Chain 7 UniProt (TrEMBL) Entry Name of Target Chain 7 UniProt (TrEMBL) Primary ID of Target Chain 7 UniProt (TrEMBL) Secondary ID(s) of Target Chain 7 UniProt (TrEMBL) Alternative ID(s) of Target Chain 7 BindingDB Target Chain Sequence 8 PDB ID(s) of Target Chain 8 UniProt (SwissProt) Recommended Name of Target Chain 8 UniProt (SwissProt) Entry Name of Target Chain 8 UniProt (SwissProt) Primary ID of Target Chain 8 UniProt (SwissProt) Secondary ID(s) of Target Chain 8 UniProt (SwissProt) Alternative ID(s) of Target Chain 8 UniProt (TrEMBL) Submitted Name of Target Chain 8 UniProt (TrEMBL) Entry Name of Target Chain 8 UniProt (TrEMBL) Primary ID of Target Chain 8 UniProt (TrEMBL) Secondary ID(s) of Target Chain 8 UniProt (TrEMBL) Alternative ID(s) of Target Chain 8 BindingDB Target Chain Sequence 9 PDB ID(s) of Target Chain 9 UniProt (SwissProt) Recommended Name of Target Chain 9 UniProt (SwissProt) Entry Name of Target Chain 9 UniProt (SwissProt) Primary ID of Target Chain 9 UniProt (SwissProt) Secondary ID(s) of Target Chain 9 UniProt (SwissProt) Alternative ID(s) of Target Chain 9 UniProt (TrEMBL) Submitted Name of Target Chain 9 UniProt (TrEMBL) Entry Name of Target Chain 9 UniProt (TrEMBL) Primary ID of Target Chain 9 UniProt (TrEMBL) Secondary ID(s) of Target Chain 9 UniProt (TrEMBL) Alternative ID(s) of Target Chain 9 BindingDB Target Chain Sequence 10 PDB ID(s) of Target Chain 10 UniProt (SwissProt) Recommended Name of Target Chain 10 UniProt (SwissProt) Entry Name of Target Chain 10 UniProt (SwissProt) Primary ID of Target Chain 10 UniProt (SwissProt) Secondary ID(s) of Target Chain 10 UniProt (SwissProt) Alternative ID(s) of Target Chain 10 UniProt (TrEMBL) Submitted Name of Target Chain 10 UniProt (TrEMBL) Entry Name of Target Chain 10 UniProt (TrEMBL) Primary ID of Target Chain 10 UniProt (TrEMBL) Secondary ID(s) of Target Chain 10 UniProt (TrEMBL) Alternative ID(s) of Target Chain 10 BindingDB Target Chain Sequence 11 PDB ID(s) of Target Chain 11 UniProt (SwissProt) Recommended Name of Target Chain 11 UniProt (SwissProt) Entry Name of Target Chain 11 UniProt (SwissProt) Primary ID of Target Chain 11 UniProt (SwissProt) Secondary ID(s) of Target Chain 11 UniProt (SwissProt) Alternative ID(s) of Target Chain 11 UniProt (TrEMBL) Submitted Name of Target Chain 11 UniProt (TrEMBL) Entry Name of Target Chain 11 UniProt (TrEMBL) Primary ID of Target Chain 11 UniProt (TrEMBL) Secondary ID(s) of Target Chain 11 UniProt (TrEMBL) Alternative ID(s) of Target Chain 11 BindingDB Target Chain Sequence 12 PDB ID(s) of Target Chain 12 UniProt (SwissProt) Recommended Name of Target Chain 12 UniProt (SwissProt) Entry Name of Target Chain 12 UniProt (SwissProt) Primary ID of Target Chain 12 UniProt (SwissProt) Secondary ID(s) of Target Chain 12 UniProt (SwissProt) Alternative ID(s) of Target Chain 12 UniProt (TrEMBL) Submitted Name of Target Chain 12 UniProt (TrEMBL) Entry Name of Target Chain 12 UniProt (TrEMBL) Primary ID of Target Chain 12 UniProt (TrEMBL) Secondary ID(s) of Target Chain 12 UniProt (TrEMBL) Alternative ID(s) of Target Chain 12 BindingDB Target Chain Sequence 13 PDB ID(s) of Target Chain 13 UniProt (SwissProt) Recommended Name of Target Chain 13 UniProt (SwissProt) Entry Name of Target Chain 13 UniProt (SwissProt) Primary ID of Target Chain 13 UniProt (SwissProt) Secondary ID(s) of Target Chain 13 UniProt (SwissProt) Alternative ID(s) of Target Chain 13 UniProt (TrEMBL) Submitted Name of Target Chain 13 UniProt (TrEMBL) Entry Name of Target Chain 13 UniProt (TrEMBL) Primary ID of Target Chain 13 UniProt (TrEMBL) Secondary ID(s) of Target Chain 13 UniProt (TrEMBL) Alternative ID(s) of Target Chain 13 BindingDB Target Chain Sequence 14 PDB ID(s) of Target Chain 14 UniProt (SwissProt) Recommended Name of Target Chain 14 UniProt (SwissProt) Entry Name of Target Chain 14 UniProt (SwissProt) Primary ID of Target Chain 14 UniProt (SwissProt) Secondary ID(s) of Target Chain 14 UniProt (SwissProt) Alternative ID(s) of Target Chain 14 UniProt (TrEMBL) Submitted Name of Target Chain 14 UniProt (TrEMBL) Entry Name of Target Chain 14 UniProt (TrEMBL) Primary ID of Target Chain 14 UniProt (TrEMBL) Secondary ID(s) of Target Chain 14 UniProt (TrEMBL) Alternative ID(s) of Target Chain 14 BindingDB Target Chain Sequence 15 PDB ID(s) of Target Chain 15 UniProt (SwissProt) Recommended Name of Target Chain 15 UniProt (SwissProt) Entry Name of Target Chain 15 UniProt (SwissProt) Primary ID of Target Chain 15 UniProt (SwissProt) Secondary ID(s) of Target Chain 15 UniProt (SwissProt) Alternative ID(s) of Target Chain 15 UniProt (TrEMBL) Submitted Name of Target Chain 15 UniProt (TrEMBL) Entry Name of Target Chain 15 UniProt (TrEMBL) Primary ID of Target Chain 15 UniProt (TrEMBL) Secondary ID(s) of Target Chain 15 UniProt (TrEMBL) Alternative ID(s) of Target Chain 15 BindingDB Target Chain Sequence 16 PDB ID(s) of Target Chain 16 UniProt (SwissProt) Recommended Name of Target Chain 16 UniProt (SwissProt) Entry Name of Target Chain 16 UniProt (SwissProt) Primary ID of Target Chain 16 UniProt (SwissProt) Secondary ID(s) of Target Chain 16 UniProt (SwissProt) Alternative ID(s) of Target Chain 16 UniProt (TrEMBL) Submitted Name of Target Chain 16 UniProt (TrEMBL) Entry Name of Target Chain 16 UniProt (TrEMBL) Primary ID of Target Chain 16 UniProt (TrEMBL) Secondary ID(s) of Target Chain 16 UniProt (TrEMBL) Alternative ID(s) of Target Chain 16 BindingDB Target Chain Sequence 17 PDB ID(s) of Target Chain 17 UniProt (SwissProt) Recommended Name of Target Chain 17 UniProt (SwissProt) Entry Name of Target Chain 17 UniProt (SwissProt) Primary ID of Target Chain 17 UniProt (SwissProt) Secondary ID(s) of Target Chain 17 UniProt (SwissProt) Alternative ID(s) of Target Chain 17 UniProt (TrEMBL) Submitted Name of Target Chain 17 UniProt (TrEMBL) Entry Name of Target Chain 17 UniProt (TrEMBL) Primary ID of Target Chain 17 UniProt (TrEMBL) Secondary ID(s) of Target Chain 17 UniProt (TrEMBL) Alternative ID(s) of Target Chain 17 BindingDB Target Chain Sequence 18 PDB ID(s) of Target Chain 18 UniProt (SwissProt) Recommended Name of Target Chain 18 UniProt (SwissProt) Entry Name of Target Chain 18 UniProt (SwissProt) Primary ID of Target Chain 18 UniProt (SwissProt) Secondary ID(s) of Target Chain 18 UniProt (SwissProt) Alternative ID(s) of Target Chain 18 UniProt (TrEMBL) Submitted Name of Target Chain 18 UniProt (TrEMBL) Entry Name of Target Chain 18 UniProt (TrEMBL) Primary ID of Target Chain 18 UniProt (TrEMBL) Secondary ID(s) of Target Chain 18 UniProt (TrEMBL) Alternative ID(s) of Target Chain 18 BindingDB Target Chain Sequence 19 PDB ID(s) of Target Chain 19 UniProt (SwissProt) Recommended Name of Target Chain 19 UniProt (SwissProt) Entry Name of Target Chain 19 UniProt (SwissProt) Primary ID of Target Chain 19 UniProt (SwissProt) Secondary ID(s) of Target Chain 19 UniProt (SwissProt) Alternative ID(s) of Target Chain 19 UniProt (TrEMBL) Submitted Name of Target Chain 19 UniProt (TrEMBL) Entry Name of Target Chain 19 UniProt (TrEMBL) Primary ID of Target Chain 19 UniProt (TrEMBL) Secondary ID(s) of Target Chain 19 UniProt (TrEMBL) Alternative ID(s) of Target Chain 19 BindingDB Target Chain Sequence 20 PDB ID(s) of Target Chain 20 UniProt (SwissProt) Recommended Name of Target Chain 20 UniProt (SwissProt) Entry Name of Target Chain 20 UniProt (SwissProt) Primary ID of Target Chain 20 UniProt (SwissProt) Secondary ID(s) of Target Chain 20 UniProt (SwissProt) Alternative ID(s) of Target Chain 20 UniProt (TrEMBL) Submitted Name of Target Chain 20 UniProt (TrEMBL) Entry Name of Target Chain 20 UniProt (TrEMBL) Primary ID of Target Chain 20 UniProt (TrEMBL) Secondary ID(s) of Target Chain 20 UniProt (TrEMBL) Alternative ID(s) of Target Chain 20 BindingDB Target Chain Sequence 21 PDB ID(s) of Target Chain 21 UniProt (SwissProt) Recommended Name of Target Chain 21 UniProt (SwissProt) Entry Name of Target Chain 21 UniProt (SwissProt) Primary ID of Target Chain 21 UniProt (SwissProt) Secondary ID(s) of Target Chain 21 UniProt (SwissProt) Alternative ID(s) of Target Chain 21 UniProt (TrEMBL) Submitted Name of Target Chain 21 UniProt (TrEMBL) Entry Name of Target Chain 21 UniProt (TrEMBL) Primary ID of Target Chain 21 UniProt (TrEMBL) Secondary ID(s) of Target Chain 21 UniProt (TrEMBL) Alternative ID(s) of Target Chain 21 BindingDB Target Chain Sequence 22 PDB ID(s) of Target Chain 22 UniProt (SwissProt) Recommended Name of Target Chain 22 UniProt (SwissProt) Entry Name of Target Chain 22 UniProt (SwissProt) Primary ID of Target Chain 22 UniProt (SwissProt) Secondary ID(s) of Target Chain 22 UniProt (SwissProt) Alternative ID(s) of Target Chain 22 UniProt (TrEMBL) Submitted Name of Target Chain 22 UniProt (TrEMBL) Entry Name of Target Chain 22 UniProt (TrEMBL) Primary ID of Target Chain 22 UniProt (TrEMBL) Secondary ID(s) of Target Chain 22 UniProt (TrEMBL) Alternative ID(s) of Target Chain 22 BindingDB Target Chain Sequence 23 PDB ID(s) of Target Chain 23 UniProt (SwissProt) Recommended Name of Target Chain 23 UniProt (SwissProt) Entry Name of Target Chain 23 UniProt (SwissProt) Primary ID of Target Chain 23 UniProt (SwissProt) Secondary ID(s) of Target Chain 23 UniProt (SwissProt) Alternative ID(s) of Target Chain 23 UniProt (TrEMBL) Submitted Name of Target Chain 23 UniProt (TrEMBL) Entry Name of Target Chain 23 UniProt (TrEMBL) Primary ID of Target Chain 23 UniProt (TrEMBL) Secondary ID(s) of Target Chain 23 UniProt (TrEMBL) Alternative ID(s) of Target Chain 23 BindingDB Target Chain Sequence 24 PDB ID(s) of Target Chain 24 UniProt (SwissProt) Recommended Name of Target Chain 24 UniProt (SwissProt) Entry Name of Target Chain 24 UniProt (SwissProt) Primary ID of Target Chain 24 UniProt (SwissProt) Secondary ID(s) of Target Chain 24 UniProt (SwissProt) Alternative ID(s) of Target Chain 24 UniProt (TrEMBL) Submitted Name of Target Chain 24 UniProt (TrEMBL) Entry Name of Target Chain 24 UniProt (TrEMBL) Primary ID of Target Chain 24 UniProt (TrEMBL) Secondary ID(s) of Target Chain 24 UniProt (TrEMBL) Alternative ID(s) of Target Chain 24 BindingDB Target Chain Sequence 25 PDB ID(s) of Target Chain 25 UniProt (SwissProt) Recommended Name of Target Chain 25 UniProt (SwissProt) Entry Name of Target Chain 25 UniProt (SwissProt) Primary ID of Target Chain 25 UniProt (SwissProt) Secondary ID(s) of Target Chain 25 UniProt (SwissProt) Alternative ID(s) of Target Chain 25 UniProt (TrEMBL) Submitted Name of Target Chain 25 UniProt (TrEMBL) Entry Name of Target Chain 25 UniProt (TrEMBL) Primary ID of Target Chain 25 UniProt (TrEMBL) Secondary ID(s) of Target Chain 25 UniProt (TrEMBL) Alternative ID(s) of Target Chain 25 BindingDB Target Chain Sequence 26 PDB ID(s) of Target Chain 26 UniProt (SwissProt) Recommended Name of Target Chain 26 UniProt (SwissProt) Entry Name of Target Chain 26 UniProt (SwissProt) Primary ID of Target Chain 26 UniProt (SwissProt) Secondary ID(s) of Target Chain 26 UniProt (SwissProt) Alternative ID(s) of Target Chain 26 UniProt (TrEMBL) Submitted Name of Target Chain 26 UniProt (TrEMBL) Entry Name of Target Chain 26 UniProt (TrEMBL) Primary ID of Target Chain 26 UniProt (TrEMBL) Secondary ID(s) of Target Chain 26 UniProt (TrEMBL) Alternative ID(s) of Target Chain 26 BindingDB Target Chain Sequence 27 PDB ID(s) of Target Chain 27 UniProt (SwissProt) Recommended Name of Target Chain 27 UniProt (SwissProt) Entry Name of Target Chain 27 UniProt (SwissProt) Primary ID of Target Chain 27 UniProt (SwissProt) Secondary ID(s) of Target Chain 27 UniProt (SwissProt) Alternative ID(s) of Target Chain 27 UniProt (TrEMBL) Submitted Name of Target Chain 27 UniProt (TrEMBL) Entry Name of Target Chain 27 UniProt (TrEMBL) Primary ID of Target Chain 27 UniProt (TrEMBL) Secondary ID(s) of Target Chain 27 UniProt (TrEMBL) Alternative ID(s) of Target Chain 27 BindingDB Target Chain Sequence 28 PDB ID(s) of Target Chain 28 UniProt (SwissProt) Recommended Name of Target Chain 28 UniProt (SwissProt) Entry Name of Target Chain 28 UniProt (SwissProt) Primary ID of Target Chain 28 UniProt (SwissProt) Secondary ID(s) of Target Chain 28 UniProt (SwissProt) Alternative ID(s) of Target Chain 28 UniProt (TrEMBL) Submitted Name of Target Chain 28 UniProt (TrEMBL) Entry Name of Target Chain 28 UniProt (TrEMBL) Primary ID of Target Chain 28 UniProt (TrEMBL) Secondary ID(s) of Target Chain 28 UniProt (TrEMBL) Alternative ID(s) of Target Chain 28 BindingDB Target Chain Sequence 29 PDB ID(s) of Target Chain 29 UniProt (SwissProt) Recommended Name of Target Chain 29 UniProt (SwissProt) Entry Name of Target Chain 29 UniProt (SwissProt) Primary ID of Target Chain 29 UniProt (SwissProt) Secondary ID(s) of Target Chain 29 UniProt (SwissProt) Alternative ID(s) of Target Chain 29 UniProt (TrEMBL) Submitted Name of Target Chain 29 UniProt (TrEMBL) Entry Name of Target Chain 29 UniProt (TrEMBL) Primary ID of Target Chain 29 UniProt (TrEMBL) Secondary ID(s) of Target Chain 29 UniProt (TrEMBL) Alternative ID(s) of Target Chain 29 BindingDB Target Chain Sequence 30 PDB ID(s) of Target Chain 30 UniProt (SwissProt) Recommended Name of Target Chain 30 UniProt (SwissProt) Entry Name of Target Chain 30 UniProt (SwissProt) Primary ID of Target Chain 30 UniProt (SwissProt) Secondary ID(s) of Target Chain 30 UniProt (SwissProt) Alternative ID(s) of Target Chain 30 UniProt (TrEMBL) Submitted Name of Target Chain 30 UniProt (TrEMBL) Entry Name of Target Chain 30 UniProt (TrEMBL) Primary ID of Target Chain 30 UniProt (TrEMBL) Secondary ID(s) of Target Chain 30 UniProt (TrEMBL) Alternative ID(s) of Target Chain 30 BindingDB Target Chain Sequence 31 PDB ID(s) of Target Chain 31 UniProt (SwissProt) Recommended Name of Target Chain 31 UniProt (SwissProt) Entry Name of Target Chain 31 UniProt (SwissProt) Primary ID of Target Chain 31 UniProt (SwissProt) Secondary ID(s) of Target Chain 31 UniProt (SwissProt) Alternative ID(s) of Target Chain 31 UniProt (TrEMBL) Submitted Name of Target Chain 31 UniProt (TrEMBL) Entry Name of Target Chain 31 UniProt (TrEMBL) Primary ID of Target Chain 31 UniProt (TrEMBL) Secondary ID(s) of Target Chain 31 UniProt (TrEMBL) Alternative ID(s) of Target Chain 31 BindingDB Target Chain Sequence 32 PDB ID(s) of Target Chain 32 UniProt (SwissProt) Recommended Name of Target Chain 32 UniProt (SwissProt) Entry Name of Target Chain 32 UniProt (SwissProt) Primary ID of Target Chain 32 UniProt (SwissProt) Secondary ID(s) of Target Chain 32 UniProt (SwissProt) Alternative ID(s) of Target Chain 32 UniProt (TrEMBL) Submitted Name of Target Chain 32 UniProt (TrEMBL) Entry Name of Target Chain 32 UniProt (TrEMBL) Primary ID of Target Chain 32 UniProt (TrEMBL) Secondary ID(s) of Target Chain 32 UniProt (TrEMBL) Alternative ID(s) of Target Chain 32 BindingDB Target Chain Sequence 33 PDB ID(s) of Target Chain 33 UniProt (SwissProt) Recommended Name of Target Chain 33 UniProt (SwissProt) Entry Name of Target Chain 33 UniProt (SwissProt) Primary ID of Target Chain 33 UniProt (SwissProt) Secondary ID(s) of Target Chain 33 UniProt (SwissProt) Alternative ID(s) of Target Chain 33 UniProt (TrEMBL) Submitted Name of Target Chain 33 UniProt (TrEMBL) Entry Name of Target Chain 33 UniProt (TrEMBL) Primary ID of Target Chain 33 UniProt (TrEMBL) Secondary ID(s) of Target Chain 33 UniProt (TrEMBL) Alternative ID(s) of Target Chain 33 BindingDB Target Chain Sequence 34 PDB ID(s) of Target Chain 34 UniProt (SwissProt) Recommended Name of Target Chain 34 UniProt (SwissProt) Entry Name of Target Chain 34 UniProt (SwissProt) Primary ID of Target Chain 34 UniProt (SwissProt) Secondary ID(s) of Target Chain 34 UniProt (SwissProt) Alternative ID(s) of Target Chain 34 UniProt (TrEMBL) Submitted Name of Target Chain 34 UniProt (TrEMBL) Entry Name of Target Chain 34 UniProt (TrEMBL) Primary ID of Target Chain 34 UniProt (TrEMBL) Secondary ID(s) of Target Chain 34 UniProt (TrEMBL) Alternative ID(s) of Target Chain 34 BindingDB Target Chain Sequence 35 PDB ID(s) of Target Chain 35 UniProt (SwissProt) Recommended Name of Target Chain 35 UniProt (SwissProt) Entry Name of Target Chain 35 UniProt (SwissProt) Primary ID of Target Chain 35 UniProt (SwissProt) Secondary ID(s) of Target Chain 35 UniProt (SwissProt) Alternative ID(s) of Target Chain 35 UniProt (TrEMBL) Submitted Name of Target Chain 35 UniProt (TrEMBL) Entry Name of Target Chain 35 UniProt (TrEMBL) Primary ID of Target Chain 35 UniProt (TrEMBL) Secondary ID(s) of Target Chain 35 UniProt (TrEMBL) Alternative ID(s) of Target Chain 35 BindingDB Target Chain Sequence 36 PDB ID(s) of Target Chain 36 UniProt (SwissProt) Recommended Name of Target Chain 36 UniProt (SwissProt) Entry Name of Target Chain 36 UniProt (SwissProt) Primary ID of Target Chain 36 UniProt (SwissProt) Secondary ID(s) of Target Chain 36 UniProt (SwissProt) Alternative ID(s) of Target Chain 36 UniProt (TrEMBL) Submitted Name of Target Chain 36 UniProt (TrEMBL) Entry Name of Target Chain 36 UniProt (TrEMBL) Primary ID of Target Chain 36 UniProt (TrEMBL) Secondary ID(s) of Target Chain 36 UniProt (TrEMBL) Alternative ID(s) of Target Chain 36 BindingDB Target Chain Sequence 37 PDB ID(s) of Target Chain 37 UniProt (SwissProt) Recommended Name of Target Chain 37 UniProt (SwissProt) Entry Name of Target Chain 37 UniProt (SwissProt) Primary ID of Target Chain 37 UniProt (SwissProt) Secondary ID(s) of Target Chain 37 UniProt (SwissProt) Alternative ID(s) of Target Chain 37 UniProt (TrEMBL) Submitted Name of Target Chain 37 UniProt (TrEMBL) Entry Name of Target Chain 37 UniProt (TrEMBL) Primary ID of Target Chain 37 UniProt (TrEMBL) Secondary ID(s) of Target Chain 37 UniProt (TrEMBL) Alternative ID(s) of Target Chain 37 BindingDB Target Chain Sequence 38 PDB ID(s) of Target Chain 38 UniProt (SwissProt) Recommended Name of Target Chain 38 UniProt (SwissProt) Entry Name of Target Chain 38 UniProt (SwissProt) Primary ID of Target Chain 38 UniProt (SwissProt) Secondary ID(s) of Target Chain 38 UniProt (SwissProt) Alternative ID(s) of Target Chain 38 UniProt (TrEMBL) Submitted Name of Target Chain 38 UniProt (TrEMBL) Entry Name of Target Chain 38 UniProt (TrEMBL) Primary ID of Target Chain 38 UniProt (TrEMBL) Secondary ID(s) of Target Chain 38 UniProt (TrEMBL) Alternative ID(s) of Target Chain 38 BindingDB Target Chain Sequence 39 PDB ID(s) of Target Chain 39 UniProt (SwissProt) Recommended Name of Target Chain 39 UniProt (SwissProt) Entry Name of Target Chain 39 UniProt (SwissProt) Primary ID of Target Chain 39 UniProt (SwissProt) Secondary ID(s) of Target Chain 39 UniProt (SwissProt) Alternative ID(s) of Target Chain 39 UniProt (TrEMBL) Submitted Name of Target Chain 39 UniProt (TrEMBL) Entry Name of Target Chain 39 UniProt (TrEMBL) Primary ID of Target Chain 39 UniProt (TrEMBL) Secondary ID(s) of Target Chain 39 UniProt (TrEMBL) Alternative ID(s) of Target Chain 39 BindingDB Target Chain Sequence 40 PDB ID(s) of Target Chain 40 UniProt (SwissProt) Recommended Name of Target Chain 40 UniProt (SwissProt) Entry Name of Target Chain 40 UniProt (SwissProt) Primary ID of Target Chain 40 UniProt (SwissProt) Secondary ID(s) of Target Chain 40 UniProt (SwissProt) Alternative ID(s) of Target Chain 40 UniProt (TrEMBL) Submitted Name of Target Chain 40 UniProt (TrEMBL) Entry Name of Target Chain 40 UniProt (TrEMBL) Primary ID of Target Chain 40 UniProt (TrEMBL) Secondary ID(s) of Target Chain 40 UniProt (TrEMBL) Alternative ID(s) of Target Chain 40 BindingDB Target Chain Sequence 41 PDB ID(s) of Target Chain 41 UniProt (SwissProt) Recommended Name of Target Chain 41 UniProt (SwissProt) Entry Name of Target Chain 41 UniProt (SwissProt) Primary ID of Target Chain 41 UniProt (SwissProt) Secondary ID(s) of Target Chain 41 UniProt (SwissProt) Alternative ID(s) of Target Chain 41 UniProt (TrEMBL) Submitted Name of Target Chain 41 UniProt (TrEMBL) Entry Name of Target Chain 41 UniProt (TrEMBL) Primary ID of Target Chain 41 UniProt (TrEMBL) Secondary ID(s) of Target Chain 41 UniProt (TrEMBL) Alternative ID(s) of Target Chain 41 BindingDB Target Chain Sequence 42 PDB ID(s) of Target Chain 42 UniProt (SwissProt) Recommended Name of Target Chain 42 UniProt (SwissProt) Entry Name of Target Chain 42 UniProt (SwissProt) Primary ID of Target Chain 42 UniProt (SwissProt) Secondary ID(s) of Target Chain 42 UniProt (SwissProt) Alternative ID(s) of Target Chain 42 UniProt (TrEMBL) Submitted Name of Target Chain 42 UniProt (TrEMBL) Entry Name of Target Chain 42 UniProt (TrEMBL) Primary ID of Target Chain 42 UniProt (TrEMBL) Secondary ID(s) of Target Chain 42 UniProt (TrEMBL) Alternative ID(s) of Target Chain 42 BindingDB Target Chain Sequence 43 PDB ID(s) of Target Chain 43 UniProt (SwissProt) Recommended Name of Target Chain 43 UniProt (SwissProt) Entry Name of Target Chain 43 UniProt (SwissProt) Primary ID of Target Chain 43 UniProt (SwissProt) Secondary ID(s) of Target Chain 43 UniProt (SwissProt) Alternative ID(s) of Target Chain 43 UniProt (TrEMBL) Submitted Name of Target Chain 43 UniProt (TrEMBL) Entry Name of Target Chain 43 UniProt (TrEMBL) Primary ID of Target Chain 43 UniProt (TrEMBL) Secondary ID(s) of Target Chain 43 UniProt (TrEMBL) Alternative ID(s) of Target Chain 43 BindingDB Target Chain Sequence 44 PDB ID(s) of Target Chain 44 UniProt (SwissProt) Recommended Name of Target Chain 44 UniProt (SwissProt) Entry Name of Target Chain 44 UniProt (SwissProt) Primary ID of Target Chain 44 UniProt (SwissProt) Secondary ID(s) of Target Chain 44 UniProt (SwissProt) Alternative ID(s) of Target Chain 44 UniProt (TrEMBL) Submitted Name of Target Chain 44 UniProt (TrEMBL) Entry Name of Target Chain 44 UniProt (TrEMBL) Primary ID of Target Chain 44 UniProt (TrEMBL) Secondary ID(s) of Target Chain 44 UniProt (TrEMBL) Alternative ID(s) of Target Chain 44 BindingDB Target Chain Sequence 45 PDB ID(s) of Target Chain 45 UniProt (SwissProt) Recommended Name of Target Chain 45 UniProt (SwissProt) Entry Name of Target Chain 45 UniProt (SwissProt) Primary ID of Target Chain 45 UniProt (SwissProt) Secondary ID(s) of Target Chain 45 UniProt (SwissProt) Alternative ID(s) of Target Chain 45 UniProt (TrEMBL) Submitted Name of Target Chain 45 UniProt (TrEMBL) Entry Name of Target Chain 45 UniProt (TrEMBL) Primary ID of Target Chain 45 UniProt (TrEMBL) Secondary ID(s) of Target Chain 45 UniProt (TrEMBL) Alternative ID(s) of Target Chain 45 BindingDB Target Chain Sequence 46 PDB ID(s) of Target Chain 46 UniProt (SwissProt) Recommended Name of Target Chain 46 UniProt (SwissProt) Entry Name of Target Chain 46 UniProt (SwissProt) Primary ID of Target Chain 46 UniProt (SwissProt) Secondary ID(s) of Target Chain 46 UniProt (SwissProt) Alternative ID(s) of Target Chain 46 UniProt (TrEMBL) Submitted Name of Target Chain 46 UniProt (TrEMBL) Entry Name of Target Chain 46 UniProt (TrEMBL) Primary ID of Target Chain 46 UniProt (TrEMBL) Secondary ID(s) of Target Chain 46 UniProt (TrEMBL) Alternative ID(s) of Target Chain 46 BindingDB Target Chain Sequence 47 PDB ID(s) of Target Chain 47 UniProt (SwissProt) Recommended Name of Target Chain 47 UniProt (SwissProt) Entry Name of Target Chain 47 UniProt (SwissProt) Primary ID of Target Chain 47 UniProt (SwissProt) Secondary ID(s) of Target Chain 47 UniProt (SwissProt) Alternative ID(s) of Target Chain 47 UniProt (TrEMBL) Submitted Name of Target Chain 47 UniProt (TrEMBL) Entry Name of Target Chain 47 UniProt (TrEMBL) Primary ID of Target Chain 47 UniProt (TrEMBL) Secondary ID(s) of Target Chain 47 UniProt (TrEMBL) Alternative ID(s) of Target Chain 47 BindingDB Target Chain Sequence 48 PDB ID(s) of Target Chain 48 UniProt (SwissProt) Recommended Name of Target Chain 48 UniProt (SwissProt) Entry Name of Target Chain 48 UniProt (SwissProt) Primary ID of Target Chain 48 UniProt (SwissProt) Secondary ID(s) of Target Chain 48 UniProt (SwissProt) Alternative ID(s) of Target Chain 48 UniProt (TrEMBL) Submitted Name of Target Chain 48 UniProt (TrEMBL) Entry Name of Target Chain 48 UniProt (TrEMBL) Primary ID of Target Chain 48 UniProt (TrEMBL) Secondary ID(s) of Target Chain 48 UniProt (TrEMBL) Alternative ID(s) of Target Chain 48 BindingDB Target Chain Sequence 49 PDB ID(s) of Target Chain 49 UniProt (SwissProt) Recommended Name of Target Chain 49 UniProt (SwissProt) Entry Name of Target Chain 49 UniProt (SwissProt) Primary ID of Target Chain 49 UniProt (SwissProt) Secondary ID(s) of Target Chain 49 UniProt (SwissProt) Alternative ID(s) of Target Chain 49 UniProt (TrEMBL) Submitted Name of Target Chain 49 UniProt (TrEMBL) Entry Name of Target Chain 49 UniProt (TrEMBL) Primary ID of Target Chain 49 UniProt (TrEMBL) Secondary ID(s) of Target Chain 49 UniProt (TrEMBL) Alternative ID(s) of Target Chain 49 BindingDB Target Chain Sequence 50 PDB ID(s) of Target Chain 50 UniProt (SwissProt) Recommended Name of Target Chain 50 UniProt (SwissProt) Entry Name of Target Chain 50 UniProt (SwissProt) Primary ID of Target Chain 50 UniProt (SwissProt) Secondary ID(s) of Target Chain 50 UniProt (SwissProt) Alternative ID(s) of Target Chain 50 UniProt (TrEMBL) Submitted Name of Target Chain 50 UniProt (TrEMBL) Entry Name of Target Chain 50 UniProt (TrEMBL) Primary ID of Target Chain 50 UniProt (TrEMBL) Secondary ID(s) of Target Chain 50 UniProt (TrEMBL) Alternative ID(s) of Target Chain 50 1115584 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C30H30ClN3O7/c1-30(2,3)41-12-11-24(28(36)33-20-8-5-18(6-9-20)29(37)38)34-16-26(39-4)23(14-27(34)35)22-13-19(31)7-10-21(22)25-15-32-17-40-25/h5-10,13-17,24H,11-12H2,1-4H3,(H,33,36)(H,37,38) WPCCHOKPWHOVEL-UHFFFAOYSA-N 413602 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 1::US11180471, Example 1 Coagulation factor XI Homo sapiens 1.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413602 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413602&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205829 433913710 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115585 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C31H32ClN5O5/c1-31(2,3)42-11-10-26(30(39)34-21-7-9-25-19(12-21)16-36(4)35-25)37-17-28(40-5)24(14-29(37)38)23-13-20(32)6-8-22(23)27-15-33-18-41-27/h6-9,12-18,26H,10-11H2,1-5H3,(H,34,39) XCQGMIZGIJYINH-UHFFFAOYSA-N 413603 4-tert-Butoxy-2-{4-[5-chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 2::US11180471, Example 2 Coagulation factor XI Homo sapiens 9.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413603 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413603&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205678 433913711 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115586 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C26H22ClN3O6/c1-3-21(25(32)29-17-7-4-15(5-8-17)26(33)34)30-13-23(35-2)20(11-24(30)31)19-10-16(27)6-9-18(19)22-12-28-14-36-22/h4-14,21H,3H2,1-2H3,(H,29,32)(H,33,34) IXCUXZHAJIAIIU-UHFFFAOYSA-N 413604 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 3::US11180471, Example 3 Coagulation factor XI Homo sapiens 4.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413604 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413604&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205676 433913712 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115587 COc1cn(C(CCOC(F)(F)F)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C27H21ClF3N3O7/c1-39-23-13-34(24(35)11-20(23)19-10-16(28)4-7-18(19)22-12-32-14-40-22)21(8-9-41-27(29,30)31)25(36)33-17-5-2-15(3-6-17)26(37)38/h2-7,10-14,21H,8-9H2,1H3,(H,33,36)(H,37,38) BNAZVDSXUSMSQR-UHFFFAOYSA-N 413605 4-{[2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-(trifluoromethoxy)butanoyl]amino}benzoic acid (Racemate)::US10421742, Example 4::US11180471, Example 4 Coagulation factor XI Homo sapiens 3.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413605 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413605&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204648 433913713 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115588 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C30H28ClN3O7/c1-39-27-16-34(28(35)14-24(27)23-12-19(31)7-10-22(23)26-15-32-17-41-26)25(13-21-4-2-3-11-40-21)29(36)33-20-8-5-18(6-9-20)30(37)38/h5-10,12,14-17,21,25H,2-4,11,13H2,1H3,(H,33,36)(H,37,38)/t21-,25?/m0/s1 DIXCLZVJKSCYHJ-BWDMCYIDSA-N 413608 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Mixture of Enantiomerically Pure Diastereomers)::US10421742, Example 5::US11180471, Example 5 Coagulation factor XI Homo sapiens 1.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413608 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413608&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205983 433913716 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115589 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C27H24ClN3O7/c1-36-10-9-22(26(33)30-18-6-3-16(4-7-18)27(34)35)31-14-24(37-2)21(12-25(31)32)20-11-17(28)5-8-19(20)23-13-29-15-38-23/h3-8,11-15,22H,9-10H2,1-2H3,(H,30,33)(H,34,35) SEWAOULYQTXIQF-UHFFFAOYSA-N 413609 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 6::US11180471, Example 6 Coagulation factor XI Homo sapiens 1.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413609 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413609&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204684 433913717 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115590 COCC[C@@H](C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C27H24ClN3O7/c1-36-10-9-22(26(33)30-18-6-3-16(4-7-18)27(34)35)31-14-24(37-2)21(12-25(31)32)20-11-17(28)5-8-19(20)23-13-29-15-38-23/h3-8,11-15,22H,9-10H2,1-2H3,(H,30,33)(H,34,35)/t22-/m0/s1 SEWAOULYQTXIQF-QFIPXVFZSA-N 413610 4-{[(2S)-2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl]amino}benzoic acid (Enantiomer 2)::US10421742, Example 7::US11180471, Example 7 Coagulation factor XI Homo sapiens 0.400 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413610 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413610&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205514 433913718 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115591 COCCC(C(=O)Nc1ccc(s1)C(=O)NC1CC1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C28H27ClN4O6S/c1-37-10-9-21(27(35)32-25-8-7-24(40-25)28(36)31-17-4-5-17)33-14-23(38-2)20(12-26(33)34)19-11-16(29)3-6-18(19)22-13-30-15-39-22/h3,6-8,11-15,17,21H,4-5,9-10H2,1-2H3,(H,31,36)(H,32,35) QJNOMWVCKLXXGM-UHFFFAOYSA-N 413612 5-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-N-cyclopropylthiophen-2-carboxamide (Racemate)::US10421742, Example 8::US11180471, Example 8 Coagulation factor XI Homo sapiens 9.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413612 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413612&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205789 433913720 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115592 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C28H26ClN5O5/c1-33-14-17-10-19(5-7-23(17)32-33)31-28(36)24(8-9-37-2)34-15-26(38-3)22(12-27(34)35)21-11-18(29)4-6-20(21)25-13-30-16-39-25/h4-7,10-16,24H,8-9H2,1-3H3,(H,31,36) NAFNAAZYCZFUNR-UHFFFAOYSA-N 413613 2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 9::US11180471, Example 9 Coagulation factor XI Homo sapiens 2.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413613 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413613&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205704 433913721 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115593 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2cnco2)cn1 InChI=1S/C27H26ClN5O6/c1-29-26(35)21-7-5-17(12-31-21)32-27(36)22(8-9-37-2)33-14-24(38-3)20(11-25(33)34)19-10-16(28)4-6-18(19)23-13-30-15-39-23/h4-7,10-15,22H,8-9H2,1-3H3,(H,29,35)(H,32,36) BVTWDIIYCUBXNG-UHFFFAOYSA-N 413614 5-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 10::US11180471, Example 10 Coagulation factor XI Homo sapiens 4.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413614 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413614&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205982 433913722 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115594 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C27H24ClFN4O6/c1-37-8-7-22(27(36)32-16-4-6-18(26(30)35)21(29)10-16)33-13-24(38-2)20(11-25(33)34)19-9-15(28)3-5-17(19)23-12-31-14-39-23/h3-6,9-14,22H,7-8H2,1-2H3,(H2,30,35)(H,32,36) IQJRZUBQZPMNPH-UHFFFAOYSA-N 413615 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 11::US11180471, Example 11 Coagulation factor XI Homo sapiens 4.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413615 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413615&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205451 433913723 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115595 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C28H28ClN5O5/c1-33-15-17-12-19(5-7-23(17)31-33)30-28(36)25(9-10-37-2)34-16-26(38-3)22(14-27(34)35)21-13-18(29)4-6-20(21)24-8-11-39-32-24/h4-7,12-16,25H,8-11H2,1-3H3,(H,30,36) NMQHQLHZXFJBKV-UHFFFAOYSA-N 413616 2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 12::US11180471, Example 12 Coagulation factor XI Homo sapiens 4.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413616 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413616&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204747 433913724 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115596 COCC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C28H28ClN5O5/c1-33-15-17-12-19(5-7-23(17)31-33)30-28(36)25(9-10-37-2)34-16-26(38-3)22(14-27(34)35)21-13-18(29)4-6-20(21)24-8-11-39-32-24/h4-7,12-16,25H,8-11H2,1-3H3,(H,30,36)/t25-/m0/s1 NMQHQLHZXFJBKV-VWLOTQADSA-N 413617 (2S)-2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Enantiomer 2)::US10421742, Example 13::US11180471, Example 13 Coagulation factor XI Homo sapiens 4.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413617 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413617&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205289 433913725 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115597 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C27H26ClFN4O6/c1-37-9-8-23(27(36)31-16-4-6-18(26(30)35)21(29)12-16)33-14-24(38-2)20(13-25(33)34)19-11-15(28)3-5-17(19)22-7-10-39-32-22/h3-6,11-14,23H,7-10H2,1-2H3,(H2,30,35)(H,31,36) DABAFGKGZQBJDK-UHFFFAOYSA-N 413618 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 14::US11180471, Example 14 Coagulation factor XI Homo sapiens 9.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413618 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413618&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205928 433913726 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115598 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C27H26ClN3O7/c1-36-11-10-23(26(33)29-18-6-3-16(4-7-18)27(34)35)31-15-24(37-2)21(14-25(31)32)20-13-17(28)5-8-19(20)22-9-12-38-30-22/h3-8,13-15,23H,9-12H2,1-2H3,(H,29,33)(H,34,35) LOUUMSPZPZILMW-UHFFFAOYSA-N 413620 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 15::US11180471, Example 15 Coagulation factor XI Homo sapiens 1.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413620 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413620&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205416 433913727 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115599 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2C2=NOCC2)cc1F InChI=1S/C28H28ClFN4O6/c1-31-27(36)19-7-5-17(13-22(19)30)32-28(37)24(9-10-38-2)34-15-25(39-3)21(14-26(34)35)20-12-16(29)4-6-18(20)23-8-11-40-33-23/h4-7,12-15,24H,8-11H2,1-3H3,(H,31,36)(H,32,37) JFECOVHUSFKCIW-UHFFFAOYSA-N 413622 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluoro-N-methylbenzamide (Racemate)::US10421742, Example 16::US11180471, Example 16 Coagulation factor XI Homo sapiens 9.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413622 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413622&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205842 433913728 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115600 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCCO1 InChI=1S/C26H26ClN5O7/c1-36-8-7-21(25(35)30-16-4-6-20(24(28)34)29-13-16)32-14-22(37-2)19(12-23(32)33)18-11-15(27)3-5-17(18)26-31-39-10-9-38-26/h3-6,11-14,21H,7-10H2,1-2H3,(H2,28,34)(H,30,35) KGGJSEUIYZFMSZ-UHFFFAOYSA-N 413623 5-[(2-{4-[5-Chloro-2-(5,6-dihydro-1,4,2-dioxazin-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]pyridine-2-carboxamide (Racemate)::US10421742, Example 17::US11180471, Example 17 Coagulation factor XI Homo sapiens 22.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413623 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413623&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205954 433913729 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115601 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCCO1 InChI=1S/C28H28ClN5O6/c1-33-15-17-12-19(5-7-23(17)31-33)30-27(36)24(8-9-37-2)34-16-25(38-3)22(14-26(34)35)21-13-18(29)4-6-20(21)28-32-40-11-10-39-28/h4-7,12-16,24H,8-11H2,1-3H3,(H,30,36) RGUMZXDJADTTSV-UHFFFAOYSA-N 413624 2-{4-[5-Chloro-2-(5,6-dihydro-1,4,2-dioxazin-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 18::US11180471, Example 18 Coagulation factor XI Homo sapiens 15.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413624 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413624&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205290 433913730 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115602 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H25ClN8O4/c1-33-13-16-10-18(5-6-21(16)30-33)29-26(37)23(8-9-38-2)34-14-24(39-3)20(12-25(34)36)19-11-17(27)4-7-22(19)35-15-28-31-32-35/h4-7,10-15,23H,8-9H2,1-3H3,(H,29,37) UUIHUWPHJJSKFX-UHFFFAOYSA-N 413625 2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 19::US11180471, Example 19 Coagulation factor XI Homo sapiens 0.260 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413625 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413625&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205820 433913731 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115603 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H23ClFN7O5/c1-38-8-7-21(25(37)30-15-4-5-16(24(28)36)19(27)10-15)33-12-22(39-2)18(11-23(33)35)17-9-14(26)3-6-20(17)34-13-29-31-32-34/h3-6,9-13,21H,7-8H2,1-2H3,(H2,28,36)(H,30,37) IICMIKXBIINPOO-UHFFFAOYSA-N 413626 4-[(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-butanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 20::US11180471, Example 20 Coagulation factor XI Homo sapiens 0.340 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413626 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413626&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205703 433913732 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115604 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1ccnc1 InChI=1S/C27H25ClN4O6/c1-37-12-9-23(26(34)30-19-6-3-17(4-7-19)27(35)36)32-15-24(38-2)21(14-25(32)33)20-13-18(28)5-8-22(20)31-11-10-29-16-31/h3-8,10-11,13-16,23H,9,12H2,1-2H3,(H,30,34)(H,35,36) QAOJLVDDEDCBPJ-UHFFFAOYSA-N 413627 4-[(2-{4-[5-Chloro-2-(1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 21::US11180471, Example 21 Coagulation factor XI Homo sapiens 1.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413627 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413627&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205879 433913733 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115605 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1ccnc1 InChI=1S/C27H25ClFN5O5/c1-38-10-7-23(27(37)32-17-4-5-18(26(30)36)21(29)12-17)34-14-24(39-2)20(13-25(34)35)19-11-16(28)3-6-22(19)33-9-8-31-15-33/h3-6,8-9,11-15,23H,7,10H2,1-2H3,(H2,30,36)(H,32,37) NHVDXTRNBLJMKL-UHFFFAOYSA-N 413628 4-[(2-{4-[5-Chloro-2-(1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-butanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 22::US11180471, Example 22 Coagulation factor XI Homo sapiens 3.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413628 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413628&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205815 433913734 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115606 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1ccnc1 InChI=1S/C28H27ClN6O4/c1-33-15-18-12-20(5-6-23(18)32-33)31-28(37)25(8-11-38-2)35-16-26(39-3)22(14-27(35)36)21-13-19(29)4-7-24(21)34-10-9-30-17-34/h4-7,9-10,12-17,25H,8,11H2,1-3H3,(H,31,37) HEMONLHVVQNSEO-UHFFFAOYSA-N 413629 2-{4-[5-Chloro-2-(1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1 (2f)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 23::US11180471, Example 23 Coagulation factor XI Homo sapiens 1.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413629 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413629&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205442 433913735 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115607 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cocn1 InChI=1S/C27H24ClFN4O6/c1-37-8-7-23(27(36)32-16-4-6-18(26(30)35)21(29)10-16)33-12-24(38-2)20(11-25(33)34)19-9-15(28)3-5-17(19)22-13-39-14-31-22/h3-6,9-14,23H,7-8H2,1-2H3,(H2,30,35)(H,32,36) WWYXXZQZSPIQLH-UHFFFAOYSA-N 413630 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1 (2N)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 24::US11180471, Example 24 Coagulation factor XI Homo sapiens 88.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413630 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413630&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211514 433913736 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115608 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cocn1 InChI=1S/C28H26ClN5O5/c1-33-13-17-10-19(5-7-23(17)32-33)31-28(36)25(8-9-37-2)34-14-26(38-3)22(12-27(34)35)21-11-18(29)4-6-20(21)24-15-39-16-30-24/h4-7,10-16,25H,8-9H2,1-3H3,(H,31,36) LMABFZNOSCTFBL-UHFFFAOYSA-N 413631 2-{4-[5-Chloro-2-(1,3-oxazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 25::US11180471, Example 25 Coagulation factor XI Homo sapiens 39.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413631 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413631&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206017 433913737 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115609 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cocn1 InChI=1S/C27H24ClN3O7/c1-36-10-9-23(26(33)30-18-6-3-16(4-7-18)27(34)35)31-13-24(37-2)21(12-25(31)32)20-11-17(28)5-8-19(20)22-14-38-15-29-22/h3-8,11-15,23H,9-10H2,1-2H3,(H,30,33)(H,34,35) DDOXVBZTTPBKNS-UHFFFAOYSA-N 413632 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 26::US11180471, Example 26 Coagulation factor XI Homo sapiens 10.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413632 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413632&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205923 433913738 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115610 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnco1 InChI=1S/C26H23ClN4O7/c1-36-10-9-21(24(33)29-17-6-3-15(4-7-17)26(34)35)31-13-22(37-2)20(12-23(31)32)19-11-16(27)5-8-18(19)25-30-28-14-38-25/h3-8,11-14,21H,9-10H2,1-2H3,(H,29,33)(H,34,35) QIURUUZJCMOSSC-UHFFFAOYSA-N 413633 4-[(2-{4-[5-Chloro-2-(1,3,4-oxadiazol-2-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 27::US11180471, Example 27 Coagulation factor XI Homo sapiens 0.700 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413633 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413633&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205873 433913739 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115611 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnco1 InChI=1S/C26H23ClFN5O6/c1-37-8-7-21(25(36)31-15-4-6-17(24(29)35)20(28)10-15)33-12-22(38-2)19(11-23(33)34)18-9-14(27)3-5-16(18)26-32-30-13-39-26/h3-6,9-13,21H,7-8H2,1-2H3,(H2,29,35)(H,31,36) UISHCWSATBUTQA-UHFFFAOYSA-N 413634 4-[(2-{4-[5-Chloro-2-(1,3,4-oxadiazol-2-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 28::US11180471, Example 28 Coagulation factor XI Homo sapiens 5.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413634 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413634&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205855 433913740 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115612 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-n2cc(F)cn2)cn1 InChI=1S/C27H26ClFN6O5/c1-30-26(37)21-6-5-18(13-31-21)33-27(38)23(8-9-39-2)34-15-24(40-3)20(11-25(34)36)19-10-16(28)4-7-22(19)35-14-17(29)12-32-35/h4-7,10-15,23H,8-9H2,1-3H3,(H,30,37)(H,33,38) VTZPJMDYPXOBMS-UHFFFAOYSA-N 413635 5-[(2-{4-[5-Chloro-2-(4-fluoro-1H-pyrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2N)-yl}-4-methoxybutanoyl)amino]-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 29::US11180471, Example 29 Coagulation factor XI Homo sapiens 37.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413635 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413635&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211518 433913741 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115613 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnco1 InChI=1S/C27H25ClN6O5/c1-33-13-16-10-18(5-7-22(16)32-33)30-26(36)23(8-9-37-2)34-14-24(38-3)21(12-25(34)35)20-11-17(28)4-6-19(20)27-31-29-15-39-27/h4-7,10-15,23H,8-9H2,1-3H3,(H,30,36) VWKPWXZBFLVGCL-UHFFFAOYSA-N 413636 2-{4-[5-Chloro-2-(1,3,4-oxadiazol-2-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 30::US11180471, Example 30 Coagulation factor XI Homo sapiens 4.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413636 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413636&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205971 433913742 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115614 COc1cn(C(CC2COCCO2)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H28ClN5O6/c1-39-28-16-36(29(37)15-23(28)22-12-18(31)2-4-21(22)24-6-9-42-35-24)27(14-20-17-40-10-11-41-20)30(38)34-19-3-5-25-26(13-19)33-8-7-32-25/h2-5,7-8,12-13,15-16,20,27H,6,9-11,14,17H2,1H3,(H,34,38) GRVRMTKUMARYRR-UHFFFAOYSA-N 413637 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-(1,4-dioxan-2-yl)propanamide (Diastereomer Mixture)::US10421742, Example 31::US11180471, Example 31 Coagulation factor XI Homo sapiens 4.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413637 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413637&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205330 433913743 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115615 COc1cn(C(CC2COCCO2)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H30ClN5O6/c1-35-15-18-11-20(4-6-25(18)33-35)32-30(38)27(13-21-17-40-9-10-41-21)36-16-28(39-2)24(14-29(36)37)23-12-19(31)3-5-22(23)26-7-8-42-34-26/h3-6,11-12,14-16,21,27H,7-10,13,17H2,1-2H3,(H,32,38) NOYWIPLIXQSLPY-UHFFFAOYSA-N 413638 2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-(1,4-dioxan-2-yl)-N-(2-methyl-2H-indazol-5-yl)propanamide (Diastereomer Mixture)::US10421742, Example 32::US11180471, Example 32 Coagulation factor XI Homo sapiens 4.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413638 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413638&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205291 433913744 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115616 COc1cn(C(CC2COCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C29H28ClN3O8/c1-38-26-15-33(27(34)14-23(26)22-12-18(30)4-7-21(22)24-8-9-41-32-24)25(13-20-16-39-10-11-40-20)28(35)31-19-5-2-17(3-6-19)29(36)37/h2-7,12,14-15,20,25H,8-11,13,16H2,1H3,(H,31,35)(H,36,37) DVWWRIVKJVUPDO-UHFFFAOYSA-N 413639 4-{[2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-(1,4-dioxan-2-yl)propanoyl]amino}benzoic acid (Diastereomer Mixture)::US10421742, Example 33::US11180471, Example 33 Coagulation factor XI Homo sapiens 2.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413639 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413639&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205538 433913745 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115617 CNC(=O)c1ccc(NC(=O)C(CC2COCCO2)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2C2=NOCC2)cn1 InChI=1S/C29H30ClN5O7/c1-31-28(37)24-6-4-18(14-32-24)33-29(38)25(12-19-16-40-9-10-41-19)35-15-26(39-2)22(13-27(35)36)21-11-17(30)3-5-20(21)23-7-8-42-34-23/h3-6,11,13-15,19,25H,7-10,12,16H2,1-2H3,(H,31,37)(H,33,38) DEFNAUKAAWHGKT-UHFFFAOYSA-N 413640 5-{[2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-(1,4-dioxan-2-yl)propanoyl]amino}-N-methylpyridine-2-carboxamide (Diastereomer Mixture)::US10421742, Example 34::US11180471, Example 34 Coagulation factor XI Homo sapiens 6.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413640 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413640&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205531 433913746 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115618 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H30ClN3O7/c1-39-27-17-34(28(35)16-24(27)23-14-19(31)7-10-22(23)25-11-13-41-33-25)26(15-21-4-2-3-12-40-21)29(36)32-20-8-5-18(6-9-20)30(37)38/h5-10,14,16-17,21,26H,2-4,11-13,15H2,1H3,(H,32,36)(H,37,38)/t21-,26?/m0/s1 DSSYHGODIQPLGT-GVNKFJBHSA-N 413641 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 35::US10421742, Example 36::US11180471, Example 36 Coagulation factor XI Homo sapiens 0.830 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413641 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413641&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205730 433913747 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115619 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H30ClN3O7/c1-39-27-17-34(28(35)16-24(27)23-14-19(31)7-10-22(23)25-11-13-41-33-25)26(15-21-4-2-3-12-40-21)29(36)32-20-8-5-18(6-9-20)30(37)38/h5-10,14,16-17,21,26H,2-4,11-13,15H2,1H3,(H,32,36)(H,37,38)/t21-,26?/m0/s1 DSSYHGODIQPLGT-GVNKFJBHSA-N 413641 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 35::US10421742, Example 36::US11180471, Example 36 Coagulation factor XI Homo sapiens 1.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413641 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413641&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205730 433913747 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115620 CNC(=O)c1ccc(NC(=O)C(C[C@@H]2CCCCO2)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2C2=NOCC2)cn1 InChI=1S/C30H32ClN5O6/c1-32-29(38)25-9-7-19(16-33-25)34-30(39)26(14-20-5-3-4-11-41-20)36-17-27(40-2)23(15-28(36)37)22-13-18(31)6-8-21(22)24-10-12-42-35-24/h6-9,13,15-17,20,26H,3-5,10-12,14H2,1-2H3,(H,32,38)(H,34,39)/t20-,26?/m0/s1 YJLNILRUWJVMCG-DQUNLGLBSA-N 413643 5-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]-N-methylpyridine-2-carboxamide (Diastereomer Mixture)::US10421742, Example 37::US11180471, Example 37 Coagulation factor XI Homo sapiens 3.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413643 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413643&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205449 433913748 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115621 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C31H32ClN5O5/c1-36-17-19-13-21(7-9-26(19)34-36)33-31(39)28(15-22-5-3-4-11-41-22)37-18-29(40-2)25(16-30(37)38)24-14-20(32)6-8-23(24)27-10-12-42-35-27/h6-9,13-14,16-18,22,28H,3-5,10-12,15H2,1-2H3,(H,33,39)/t22-,28?/m0/s1 LNIZEAPOEAZWLH-XYXHBKGXSA-N 413644 2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanamide (Diastereomer Mixture)::US10421742, Example 38::US11180471, Example 38 Coagulation factor XI Homo sapiens 1.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413644 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413644&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205844 433913749 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115622 COc1cn(C(C[C@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H30ClN3O7/c1-39-27-17-34(28(35)16-24(27)23-14-19(31)7-10-22(23)25-11-13-41-33-25)26(15-21-4-2-3-12-40-21)29(36)32-20-8-5-18(6-9-20)30(37)38/h5-10,14,16-17,21,26H,2-4,11-13,15H2,1H3,(H,32,36)(H,37,38)/t21-,26?/m1/s1 DSSYHGODIQPLGT-OSMGYRLQSA-N 413645 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2R)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 39::US11180471, Example 39 Coagulation factor XI Homo sapiens 4.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413645 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413645&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205996 433913750 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115623 COc1cn(C(C[C@H]2CCCCO2)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C31H32ClN5O5/c1-36-17-19-13-21(7-9-26(19)34-36)33-31(39)28(15-22-5-3-4-11-41-22)37-18-29(40-2)25(16-30(37)38)24-14-20(32)6-8-23(24)27-10-12-42-35-27/h6-9,13-14,16-18,22,28H,3-5,10-12,15H2,1-2H3,(H,33,39)/t22-,28?/m1/s1 LNIZEAPOEAZWLH-WZOMIXFGSA-N 413646 2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)-3-[(2R)-tetrahydro-2H-pyran-2-yl]propanamide (Diastereomer Mixture)::US10421742, Example 40::US11180471, Example 40 Coagulation factor XI Homo sapiens 11.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413646 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413646&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205645 433913751 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115624 COc1cn(C(C[C@H]2CCCCO2)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H30ClFN4O6/c1-40-27-16-36(28(37)15-23(27)22-12-17(31)5-7-20(22)25-9-11-42-35-25)26(14-19-4-2-3-10-41-19)30(39)34-18-6-8-21(29(33)38)24(32)13-18/h5-8,12-13,15-16,19,26H,2-4,9-11,14H2,1H3,(H2,33,38)(H,34,39)/t19-,26?/m1/s1 BKMNWKMPOGYRQA-ICCFGIFFSA-N 413647 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2R)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]-2-fluorobenzamide (Diastereomer Mixture)::US10421742, Example 41::US11180471, Example 41 Coagulation factor XI Homo sapiens 16.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413647 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413647&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205771 433913752 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115625 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2ccon2)cn1 InChI=1S/C27H26ClN5O6/c1-29-26(35)22-7-5-17(14-30-22)31-27(36)23(9-10-37-2)33-15-24(38-3)20(13-25(33)34)19-12-16(28)4-6-18(19)21-8-11-39-32-21/h4-8,11-15,23H,9-10H2,1-3H3,(H,29,35)(H,31,36) DGUWRYFZSHPSRF-UHFFFAOYSA-N 413648 5-[(2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-N-methylpyridin-2-carboxamide (Racemate)::US10421742, Example 42::US11180471, Example 42 Coagulation factor XI Homo sapiens 2.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413648 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413648&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206087 433913753 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115626 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C28H26ClN5O5/c1-33-15-17-12-19(5-7-23(17)31-33)30-28(36)25(9-10-37-2)34-16-26(38-3)22(14-27(34)35)21-13-18(29)4-6-20(21)24-8-11-39-32-24/h4-8,11-16,25H,9-10H2,1-3H3,(H,30,36) MQPMEUJFEVBLRJ-UHFFFAOYSA-N 413649 2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 43::US11180471, Example 43 Coagulation factor XI Homo sapiens 2.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413649 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413649&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206020 433913754 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115627 CNC(=O)c1ccc(NC(=O)C(CCOC(C)(C)C)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2ccon2)cn1 InChI=1S/C30H32ClN5O6/c1-30(2,3)41-12-11-25(29(39)34-19-7-9-24(33-16-19)28(38)32-4)36-17-26(40-5)22(15-27(36)37)21-14-18(31)6-8-20(21)23-10-13-42-35-23/h6-10,13-17,25H,11-12H2,1-5H3,(H,32,38)(H,34,39) XQIJVKWEUWNLCF-UHFFFAOYSA-N 413650 5-[(4-tert-Butoxy-2-{4-[5-chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 44::US11180471, Example 44 Coagulation factor XI Homo sapiens 2.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413650 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413650&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205942 433913755 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115628 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C30H30ClN3O7/c1-30(2,3)40-13-12-25(28(36)32-20-8-5-18(6-9-20)29(37)38)34-17-26(39-4)23(16-27(34)35)22-15-19(31)7-10-21(22)24-11-14-41-33-24/h5-11,14-17,25H,12-13H2,1-4H3,(H,32,36)(H,37,38) XVQJXIHGEMVIBL-UHFFFAOYSA-N 413651 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 45::US11180471, Example 45 Coagulation factor XI Homo sapiens 1.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413651 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413651&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205454 433913756 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115629 COc1cn([C@@H](CCOC(C)(C)C)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C30H30ClN3O7/c1-30(2,3)40-13-12-25(28(36)32-20-8-5-18(6-9-20)29(37)38)34-17-26(39-4)23(16-27(34)35)22-15-19(31)7-10-21(22)24-11-14-41-33-24/h5-11,14-17,25H,12-13H2,1-4H3,(H,32,36)(H,37,38)/t25-/m0/s1 XVQJXIHGEMVIBL-VWLOTQADSA-N 413652 4-{[(2S)-4-tert-Butoxy-2-{4-[5-chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl]amino}benzoic acid (Enantiomer 2)::US10421742, Example 46::US11180471, Example 46 Coagulation factor XI Homo sapiens 0.530 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413652 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413652&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205453 433913757 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115630 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C31H28ClN5O5/c1-40-29-18-37(30(38)17-24(29)23-14-19(32)5-7-22(23)25-9-13-42-36-25)28(16-21-4-2-3-12-41-21)31(39)35-20-6-8-26-27(15-20)34-11-10-33-26/h5-11,13-15,17-18,21,28H,2-4,12,16H2,1H3,(H,35,39)/t21-,28?/m0/s1 QHFRLRVXSRUUOC-QDLLFRBVSA-N 413653 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanamide (Diastereomer Mixture)::US10421742, Example 47::US11180471, Example 47 Coagulation factor XI Homo sapiens 4.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413653 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413653&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205254 433913758 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115631 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C30H28ClN3O7/c1-39-27-17-34(28(35)16-24(27)23-14-19(31)7-10-22(23)25-11-13-41-33-25)26(15-21-4-2-3-12-40-21)29(36)32-20-8-5-18(6-9-20)30(37)38/h5-11,13-14,16-17,21,26H,2-4,12,15H2,1H3,(H,32,36)(H,37,38)/t21-,26?/m0/s1 RTTPBBKILQCFGH-GVNKFJBHSA-N 413654 4-[(2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 48::US10421742, Example 49::US11180471, Example 49 Coagulation factor XI Homo sapiens 1.000 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413654 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413654&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205526 433913759 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115632 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C30H28ClN3O7/c1-39-27-17-34(28(35)16-24(27)23-14-19(31)7-10-22(23)25-11-13-41-33-25)26(15-21-4-2-3-12-40-21)29(36)32-20-8-5-18(6-9-20)30(37)38/h5-11,13-14,16-17,21,26H,2-4,12,15H2,1H3,(H,32,36)(H,37,38)/t21-,26?/m0/s1 RTTPBBKILQCFGH-GVNKFJBHSA-N 413654 4-[(2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 48::US10421742, Example 49::US11180471, Example 49 Coagulation factor XI Homo sapiens 0.360 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413654 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413654&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205526 433913759 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115633 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(F)c1 InChI=1S/C28H26ClFN6O4/c1-34-13-17-10-19(5-6-22(17)33-34)32-28(38)24(8-9-39-2)36-14-25(40-3)21(12-27(36)37)20-11-18(29)4-7-23(20)35-15-26(30)31-16-35/h4-7,10-16,24H,8-9H2,1-3H3,(H,32,38) XXIIEASKYLNDLZ-UHFFFAOYSA-N 413656 2-{4-[5-Chloro-2-(4-fluoro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 50::US11180471, Example 50 Coagulation factor XI Homo sapiens 17.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413656 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413656&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206014 433913760 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115634 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(F)c1 InChI=1S/C27H24ClFN4O6/c1-38-10-9-22(26(35)31-18-6-3-16(4-7-18)27(36)37)33-13-23(39-2)20(12-25(33)34)19-11-17(28)5-8-21(19)32-14-24(29)30-15-32/h3-8,11-15,22H,9-10H2,1-2H3,(H,31,35)(H,36,37) LQOPQTHAZLUPRF-UHFFFAOYSA-N 413657 4-[(2-{4-[5-Chloro-2-(4-fluoro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 51::US11180471, Example 51 Coagulation factor XI Homo sapiens 1.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413657 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413657&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205822 433913761 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115635 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C28H26Cl2N6O4/c1-34-13-17-10-19(5-6-22(17)33-34)32-28(38)24(8-9-39-2)36-14-25(40-3)21(12-27(36)37)20-11-18(29)4-7-23(20)35-15-26(30)31-16-35/h4-7,10-16,24H,8-9H2,1-3H3,(H,32,38) VHDZGIZYASTKPK-UHFFFAOYSA-N 413658 2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 52::US11180471, Example 52 Coagulation factor XI Homo sapiens 3.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413658 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413658&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205518 433913762 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115636 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C27H24Cl2N4O6/c1-38-10-9-22(26(35)31-18-6-3-16(4-7-18)27(36)37)33-13-23(39-2)20(12-25(33)34)19-11-17(28)5-8-21(19)32-14-24(29)30-15-32/h3-8,11-15,22H,9-10H2,1-2H3,(H,31,35)(H,36,37) ATCFLROFGUZFNA-UHFFFAOYSA-N 413659 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 53::US11180471, Example 53 Coagulation factor XI Homo sapiens 1.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413659 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413659&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206033 433913763 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115637 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-n2cnc(Cl)c2)cn1 InChI=1S/C27H26Cl2N6O5/c1-30-26(37)20-6-5-17(12-31-20)33-27(38)22(8-9-39-2)35-13-23(40-3)19(11-25(35)36)18-10-16(28)4-7-21(18)34-14-24(29)32-15-34/h4-7,10-15,22H,8-9H2,1-3H3,(H,30,37)(H,33,38) ILXCPIBUCWIAMK-UHFFFAOYSA-N 413660 5-[(2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 54::US11180471, Example 54 Coagulation factor XI Homo sapiens 4.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413660 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413660&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206034 433913764 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115638 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C28H24Cl2N6O4/c1-39-10-7-24(28(38)34-18-4-5-21-22(12-18)32-9-8-31-21)36-14-25(40-2)20(13-27(36)37)19-11-17(29)3-6-23(19)35-15-26(30)33-16-35/h3-6,8-9,11-16,24H,7,10H2,1-2H3,(H,34,38) FCJJBIBALYUNQH-UHFFFAOYSA-N 413661 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanamide (Racemate)::US10421742, Example 55::US11180471, Example 55 Coagulation factor XI Homo sapiens 3.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413661 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413661&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205710 433913765 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115639 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnc1 InChI=1S/C26H24ClFN6O5/c1-38-8-7-22(26(37)32-16-4-5-17(25(29)36)20(28)10-16)34-12-23(39-2)19(11-24(34)35)18-9-15(27)3-6-21(18)33-13-30-31-14-33/h3-6,9-14,22H,7-8H2,1-2H3,(H2,29,36)(H,32,37) YIFQLPJMHMOWFU-UHFFFAOYSA-N 413662 4-[(2-{4-[5-Chloro-2-(4H-1,2,4-triazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 56::US11180471, Example 56 Coagulation factor XI Homo sapiens 4.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413662 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413662&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205108 433913766 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115640 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnc1 InChI=1S/C27H24ClN7O4/c1-38-10-7-24(27(37)33-18-4-5-21-22(12-18)30-9-8-29-21)35-14-25(39-2)20(13-26(35)36)19-11-17(28)3-6-23(19)34-15-31-32-16-34/h3-6,8-9,11-16,24H,7,10H2,1-2H3,(H,33,37) QEUZUPMZRYSKJR-UHFFFAOYSA-N 413663 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4H-1,2,4-triazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanamide (Racemate)::US10421742, Example 57::US11180471, Example 57 Coagulation factor XI Homo sapiens 2.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413663 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413663&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205805 433913767 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115641 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnc1 InChI=1S/C26H24ClN5O6/c1-37-10-9-22(25(34)30-18-6-3-16(4-7-18)26(35)36)32-13-23(38-2)20(12-24(32)33)19-11-17(27)5-8-21(19)31-14-28-29-15-31/h3-8,11-15,22H,9-10H2,1-2H3,(H,30,34)(H,35,36) BABSEGOQVMFTTL-UHFFFAOYSA-N 413664 4-[(2-{4-[5-Chloro-2-(4H-1,2,4-triazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 58::US11180471, Example 58 Coagulation factor XI Homo sapiens 1.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413664 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413664&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205192 433913768 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115642 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnc1 InChI=1S/C27H26ClN7O4/c1-33-13-17-10-19(5-6-22(17)32-33)31-27(37)24(8-9-38-2)35-14-25(39-3)21(12-26(35)36)20-11-18(28)4-7-23(20)34-15-29-30-16-34/h4-7,10-16,24H,8-9H2,1-3H3,(H,31,37) FGCCTMXHTZVEGP-UHFFFAOYSA-N 413665 2-{4-[5-Chloro-2-(4H-1,2,4-triazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 59::US11180471, Example 59 Coagulation factor XI Homo sapiens 4.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413665 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413665&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206021 433913769 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115643 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H24ClF2N7O4/c1-41-10-7-24(28(40)34-17-4-5-20-21(12-17)33-9-8-32-20)37-15-25(42-2)19(13-26(37)39)18-11-16(29)3-6-23(18)38-14-22(27(30)31)35-36-38/h3-6,8-9,11-15,24,27H,7,10H2,1-2H3,(H,34,40) SSZTYGHNKCZYAF-UHFFFAOYSA-N 528079 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanamide (racemate)::US11180471, Example 60 Coagulation factor XI Homo sapiens 1.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528079 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528079&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 163200076 463791634 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115644 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)F InChI=1S/C29H25ClF2N6O4/c1-41-10-7-25(29(40)36-18-4-5-21-22(12-18)34-9-8-33-21)38-15-26(42-2)20(13-27(38)39)19-11-17(30)3-6-24(19)37-14-23(28(31)32)35-16-37/h3-6,8-9,11-16,25,28H,7,10H2,1-2H3,(H,36,40) JXACRAOKHLGFCC-UHFFFAOYSA-N 413667 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanamide (Racemate)::US10421742, Example 61::US11180471, Example 61 Coagulation factor XI Homo sapiens 5.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413667 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413667&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205843 433913771 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115645 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)F InChI=1S/C28H25ClF2N4O6/c1-40-10-9-23(27(37)33-18-6-3-16(4-7-18)28(38)39)35-14-24(41-2)20(12-25(35)36)19-11-17(29)5-8-22(19)34-13-21(26(30)31)32-15-34/h3-8,11-15,23,26H,9-10H2,1-2H3,(H,33,37)(H,38,39) RXURALNQBFWKQS-UHFFFAOYSA-N 413668 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Racemate)::US10421742, Example 62::US11180471, Example 62 Coagulation factor XI Homo sapiens 3.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413668 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413668&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205732 433913772 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115646 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)F InChI=1S/C28H25ClF3N5O5/c1-41-8-7-23(28(40)35-16-4-5-17(27(33)39)20(30)10-16)37-13-24(42-2)19(11-25(37)38)18-9-15(29)3-6-22(18)36-12-21(26(31)32)34-14-36/h3-6,9-14,23,26H,7-8H2,1-2H3,(H2,33,39)(H,35,40) LOOFPSIULDNXTC-UHFFFAOYSA-N 413669 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 63::US11180471, Example 63 Coagulation factor XI Homo sapiens 22.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413669 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413669&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205511 433913773 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115647 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)F InChI=1S/C27H25ClF2N6O5/c1-40-8-7-22(27(39)34-16-4-5-19(26(31)38)32-11-16)36-13-23(41-2)18(10-24(36)37)17-9-15(28)3-6-21(17)35-12-20(25(29)30)33-14-35/h3-6,9-14,22,25H,7-8H2,1-2H3,(H2,31,38)(H,34,39) SRNOHCLEBDLQNM-UHFFFAOYSA-N 413670 5-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 64::US11180471, Example 64 Coagulation factor XI Homo sapiens 22.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413670 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413670&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205917 433913774 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115648 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-n2cnc(c2)C(F)F)cn1 InChI=1S/C28H27ClF2N6O5/c1-32-27(39)20-6-5-17(12-33-20)35-28(40)23(8-9-41-2)37-14-24(42-3)19(11-25(37)38)18-10-16(29)4-7-22(18)36-13-21(26(30)31)34-15-36/h4-7,10-15,23,26H,8-9H2,1-3H3,(H,32,39)(H,35,40) BZGWCVVHLRMNJS-UHFFFAOYSA-N 413671 5-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 65::US11180471, Example 65 Coagulation factor XI Homo sapiens 20.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413671 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413671&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211501 433913775 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115649 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)F InChI=1S/C29H27ClF2N6O4/c1-36-13-17-10-19(5-6-22(17)35-36)34-29(40)25(8-9-41-2)38-15-26(42-3)21(12-27(38)39)20-11-18(30)4-7-24(20)37-14-23(28(31)32)33-16-37/h4-7,10-16,25,28H,8-9H2,1-3H3,(H,34,40) RVACDGDJWAWWGJ-UHFFFAOYSA-N 413672 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 66::US11180471, Example 66 Coagulation factor XI Homo sapiens 8.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413672 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413672&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211559 433913776 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115650 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(C)no1 InChI=1S/C28H26ClN3O7/c1-16-12-24(39-31-16)20-9-6-18(29)13-21(20)22-14-26(33)32(15-25(22)38-3)23(10-11-37-2)27(34)30-19-7-4-17(5-8-19)28(35)36/h4-9,12-15,23H,10-11H2,1-3H3,(H,30,34)(H,35,36) KHIKDAHZRTYQLP-UHFFFAOYSA-N 413673 4-[(2-{4-[5-Chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 67::US11180471, Example 67 Coagulation factor XI Homo sapiens 1.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413673 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413673&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205834 433913777 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115651 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(C)no1 InChI=1S/C27H26ClN5O6/c1-15-10-23(39-32-15)18-6-4-16(28)11-19(18)20-12-25(34)33(14-24(20)38-3)22(8-9-37-2)27(36)31-17-5-7-21(26(29)35)30-13-17/h4-7,10-14,22H,8-9H2,1-3H3,(H2,29,35)(H,31,36) MJTYRMTXTRTXFO-UHFFFAOYSA-N 413674 5-[(2-{4-[5-Chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]pyridine-2-carboxamide (Racemate)::US10421742, Example 68::US11180471, Example 68 Coagulation factor XI Homo sapiens 4.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413674 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413674&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205583 433913778 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115652 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(C)no1 InChI=1S/C28H26ClFN4O6/c1-15-10-24(40-33-15)18-6-4-16(29)11-20(18)21-13-26(35)34(14-25(21)39-3)23(8-9-38-2)28(37)32-17-5-7-19(27(31)36)22(30)12-17/h4-7,10-14,23H,8-9H2,1-3H3,(H2,31,36)(H,32,37) IOKBSWHNAJFKBB-UHFFFAOYSA-N 413675 4-[(2-{4-[5-Chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 69::US11180471, Example 69 Coagulation factor XI Homo sapiens 6.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413675 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413675&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205883 433913779 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115653 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(C)no1 InChI=1S/C29H28ClN5O5/c1-17-11-26(40-33-17)21-7-5-19(30)13-22(21)23-14-28(36)35(16-27(23)39-4)25(9-10-38-3)29(37)31-20-6-8-24-18(12-20)15-34(2)32-24/h5-8,11-16,25H,9-10H2,1-4H3,(H,31,37) YKKFWRCDYBEJHT-UHFFFAOYSA-N 528089 2-{4-[5-Chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (racemate)::US11180471, Example 70 Coagulation factor XI Homo sapiens 2.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528089 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528089&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 140885364 463791643 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115654 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2cc(C)no2)cn1 InChI=1S/C28H28ClN5O6/c1-16-11-24(40-33-16)19-7-5-17(29)12-20(19)21-13-26(35)34(15-25(21)39-4)23(9-10-38-3)28(37)32-18-6-8-22(31-14-18)27(36)30-2/h5-8,11-15,23H,9-10H2,1-4H3,(H,30,36)(H,32,37) ROFGROGQJVVGAV-UHFFFAOYSA-N 413677 5-[(2-{4-[5-Chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 71::US11180471, Example 71 Coagulation factor XI Homo sapiens 4.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413677 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413677&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205793 433913781 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115655 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(C)no1 InChI=1S/C29H26ClN5O5/c1-17-12-26(40-34-17)20-6-4-18(30)13-21(20)22-15-28(36)35(16-27(22)39-3)25(8-11-38-2)29(37)33-19-5-7-23-24(14-19)32-10-9-31-23/h4-7,9-10,12-16,25H,8,11H2,1-3H3,(H,33,37) BOMMICKHAGJNKQ-UHFFFAOYSA-N 413678 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanamide (Racemate)::US10421742, Example 72::US11180471, Example 72 Coagulation factor XI Homo sapiens 4.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413678 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413678&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205700 433913782 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115656 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C26H22ClF3N6O6/c1-40-8-7-19(23(39)33-14-4-6-18(22(31)38)32-11-14)36-12-20(41-2)17(10-21(36)37)16-9-13(27)3-5-15(16)24-34-35-25(42-24)26(28,29)30/h3-6,9-12,19H,7-8H2,1-2H3,(H2,31,38)(H,33,39) LICUUHCNECQSQW-UHFFFAOYSA-N 413679 5-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 73::US11180471, Example 73 Coagulation factor XI Homo sapiens 5.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413679 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413679&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205765 433913783 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115657 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C27H22ClF4N5O6/c1-41-8-7-20(24(40)34-14-4-6-16(23(33)39)19(29)10-14)37-12-21(42-2)18(11-22(37)38)17-9-13(28)3-5-15(17)25-35-36-26(43-25)27(30,31)32/h3-6,9-12,20H,7-8H2,1-2H3,(H2,33,39)(H,34,40) FGIRAZNDJOPUAW-UHFFFAOYSA-N 413680 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 74::US11180471, Example 74 Coagulation factor XI Homo sapiens 4.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413680 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413680&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205473 433913784 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115658 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C28H24ClF3N6O5/c1-37-13-15-10-17(5-7-21(15)36-37)33-25(40)22(8-9-41-2)38-14-23(42-3)20(12-24(38)39)19-11-16(29)4-6-18(19)26-34-35-27(43-26)28(30,31)32/h4-7,10-14,22H,8-9H2,1-3H3,(H,33,40) YOTPLZPCUXHOMZ-UHFFFAOYSA-N 413681 2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 75::US11180471, Example 75 Coagulation factor XI Homo sapiens 2.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413681 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413681&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205440 433913785 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115659 COCC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C28H24ClF3N6O5/c1-37-13-15-10-17(5-7-21(15)36-37)33-25(40)22(8-9-41-2)38-14-23(42-3)20(12-24(38)39)19-11-16(29)4-6-18(19)26-34-35-27(43-26)28(30,31)32/h4-7,10-14,22H,8-9H2,1-3H3,(H,33,40)/t22-/m0/s1 YOTPLZPCUXHOMZ-QFIPXVFZSA-N 413682 (2S)-2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Enantiomer 2)::US10421742, Example 76::US11180471, Example 76 Coagulation factor XI Homo sapiens 2.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413682 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413682&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205552 433913786 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115660 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2nnc(o2)C(F)(F)F)cn1 InChI=1S/C27H24ClF3N6O6/c1-32-23(39)19-7-5-15(12-33-19)34-24(40)20(8-9-41-2)37-13-21(42-3)18(11-22(37)38)17-10-14(28)4-6-16(17)25-35-36-26(43-25)27(29,30)31/h4-7,10-13,20H,8-9H2,1-3H3,(H,32,39)(H,34,40) NUOFQPYZYCWJHB-UHFFFAOYSA-N 413683 5-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 77::US11180471, Example 77 Coagulation factor XI Homo sapiens 3.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413683 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413683&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206080 433913787 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115661 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C28H22ClF3N6O5/c1-41-10-7-22(25(40)35-16-4-6-20-21(12-16)34-9-8-33-20)38-14-23(42-2)19(13-24(38)39)18-11-15(29)3-5-17(18)26-36-37-27(43-26)28(30,31)32/h3-6,8-9,11-14,22H,7,10H2,1-2H3,(H,35,40) RLFXIFOZOPMNCY-UHFFFAOYSA-N 413684 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanamide (Racemate)::US10421742, Example 78::US11180471, Example 78 Coagulation factor XI Homo sapiens 3.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413684 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413684&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205675 433913788 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115662 COCC[C@@H](C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C28H22ClF3N6O5/c1-41-10-7-22(25(40)35-16-4-6-20-21(12-16)34-9-8-33-20)38-14-23(42-2)19(13-24(38)39)18-11-15(29)3-5-17(18)26-36-37-27(43-26)28(30,31)32/h3-6,8-9,11-14,22H,7,10H2,1-2H3,(H,35,40)/t22-/m0/s1 RLFXIFOZOPMNCY-QFIPXVFZSA-N 413685 N-(Quinoxalin-6-yl)-(2S)-2-[4-{5-chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanamide (Enantiomer 2)::US10421742, Example 79::US11180471, Example 79 Coagulation factor XI Homo sapiens 1.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413685 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413685&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205803 433913789 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115663 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C27H23ClF2N4O7/c1-39-10-9-20(24(36)31-16-6-3-14(4-7-16)27(37)38)34-13-21(40-2)19(12-22(34)35)18-11-15(28)5-8-17(18)25-32-33-26(41-25)23(29)30/h3-8,11-13,20,23H,9-10H2,1-2H3,(H,31,36)(H,37,38) XNHWHTYAEJBBSE-UHFFFAOYSA-N 413686 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Racemate)::US10421742, Example 80::US11180471, Example 80 Coagulation factor XI Homo sapiens 1.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413686 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413686&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205800 433913790 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115664 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C26H23ClF2N6O6/c1-39-8-7-19(24(38)32-14-4-6-18(23(30)37)31-11-14)35-12-20(40-2)17(10-21(35)36)16-9-13(27)3-5-15(16)25-33-34-26(41-25)22(28)29/h3-6,9-12,19,22H,7-8H2,1-2H3,(H2,30,37)(H,32,38) MDWVKPVBVQCTPE-UHFFFAOYSA-N 413687 5-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 81::US11180471, Example 81 Coagulation factor XI Homo sapiens 6.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413687 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413687&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206035 433913791 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115665 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C27H23ClF3N5O6/c1-40-8-7-20(25(39)33-14-4-6-16(24(32)38)19(29)10-14)36-12-21(41-2)18(11-22(36)37)17-9-13(28)3-5-15(17)26-34-35-27(42-26)23(30)31/h3-6,9-12,20,23H,7-8H2,1-2H3,(H2,32,38)(H,33,39) ZFLRJTQBCYIFEA-UHFFFAOYSA-N 413688 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 82::US11180471, Example 82 Coagulation factor XI Homo sapiens 6.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413688 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413688&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205342 433913792 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115666 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C28H25ClF2N6O5/c1-36-13-15-10-17(5-7-21(15)35-36)32-26(39)22(8-9-40-2)37-14-23(41-3)20(12-24(37)38)19-11-16(29)4-6-18(19)27-33-34-28(42-27)25(30)31/h4-7,10-14,22,25H,8-9H2,1-3H3,(H,32,39) OYMYFSRVCJZGAS-UHFFFAOYSA-N 413689 2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 83::US11180471, Example 83 Coagulation factor XI Homo sapiens 2.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413689 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413689&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205398 433913793 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115667 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2nnc(o2)C(F)F)cn1 InChI=1S/C27H25ClF2N6O6/c1-31-24(38)19-7-5-15(12-32-19)33-25(39)20(8-9-40-2)36-13-21(41-3)18(11-22(36)37)17-10-14(28)4-6-16(17)26-34-35-27(42-26)23(29)30/h4-7,10-13,20,23H,8-9H2,1-3H3,(H,31,38)(H,33,39) HOPVUQHXIRDKQQ-UHFFFAOYSA-N 413690 5-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 84::US11180471, Example 84 Coagulation factor XI Homo sapiens 5.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413690 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413690&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205828 433913794 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115668 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C28H23ClF2N6O5/c1-40-10-7-22(26(39)34-16-4-6-20-21(12-16)33-9-8-32-20)37-14-23(41-2)19(13-24(37)38)18-11-15(29)3-5-17(18)27-35-36-28(42-27)25(30)31/h3-6,8-9,11-14,22,25H,7,10H2,1-2H3,(H,34,39) XQGAAZGSIZFZJH-UHFFFAOYSA-N 413691 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanamide (Racemate)::US10421742, Example 85::US11180471, Example 85 Coagulation factor XI Homo sapiens 1.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413691 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413691&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205474 433913795 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115669 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(c1)C(F)F InChI=1S/C28H25ClF2N4O6/c1-40-10-9-23(26(37)33-19-6-3-16(4-7-19)27(38)39)34-15-24(41-2)22(12-25(34)36)21-11-18(29)5-8-20(21)17-13-32-35(14-17)28(30)31/h3-8,11-15,23,28H,9-10H2,1-2H3,(H,33,37)(H,38,39) KPDQGYYQHYCMAC-UHFFFAOYSA-N 413692 4-({2-[4-{5-Chloro-2-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Racemate)::US10421742, Example 86::US11180471, Example 86 Coagulation factor XI Homo sapiens 1.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413692 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413692&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205712 433913796 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115670 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(c1)C(F)F InChI=1S/C29H27ClF2N6O4/c1-36-14-17-10-20(5-7-24(17)35-36)34-28(40)25(8-9-41-2)37-16-26(42-3)23(12-27(37)39)22-11-19(30)4-6-21(22)18-13-33-38(15-18)29(31)32/h4-7,10-16,25,29H,8-9H2,1-3H3,(H,34,40) FLLYAGGTZNJKNW-UHFFFAOYSA-N 413693 2-[4-{5-Chloro-2-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 87::US11180471, Example 87 Coagulation factor XI Homo sapiens 4.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413693 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413693&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205794 433913797 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115671 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(c1)C(F)F InChI=1S/C27H25ClF2N6O5/c1-40-8-7-22(26(39)34-17-4-6-21(25(31)38)32-12-17)35-14-23(41-2)20(10-24(35)37)19-9-16(28)3-5-18(19)15-11-33-36(13-15)27(29)30/h3-6,9-14,22,27H,7-8H2,1-2H3,(H2,31,38)(H,34,39) ZDGFODUVDKHNBN-UHFFFAOYSA-N 413694 5-({2-[4-{5-Chloro-2-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 88::US11180471, Example 88 Coagulation factor XI Homo sapiens 7.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413694 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413694&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205957 433913798 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115672 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C27H25ClFN5O6/c1-14-31-27(40-33-14)17-6-4-15(28)10-19(17)20-12-24(35)34(13-23(20)39-3)22(8-9-38-2)26(37)32-16-5-7-18(25(30)36)21(29)11-16/h4-7,10-13,22H,8-9H2,1-3H3,(H2,30,36)(H,32,37) KXEKQPUKVUVDQB-UHFFFAOYSA-N 413695 4-[(2-{4-[5-Chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 89::US11180471, Example 89 Coagulation factor XI Homo sapiens 7.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413695 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413695&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205626 433913799 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115673 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C27H25ClN4O7/c1-15-29-26(39-31-15)19-9-6-17(28)12-20(19)21-13-24(33)32(14-23(21)38-3)22(10-11-37-2)25(34)30-18-7-4-16(5-8-18)27(35)36/h4-9,12-14,22H,10-11H2,1-3H3,(H,30,34)(H,35,36) NOYZMHMPNZKENJ-UHFFFAOYSA-N 413696 4-[(2-{4-[5-Chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 90::US11180471, Example 90 Coagulation factor XI Homo sapiens 0.920 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413696 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413696&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205964 433913800 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115674 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C28H27ClN6O5/c1-16-30-28(40-33-16)20-7-5-18(29)12-21(20)22-13-26(36)35(15-25(22)39-4)24(9-10-38-3)27(37)31-19-6-8-23-17(11-19)14-34(2)32-23/h5-8,11-15,24H,9-10H2,1-4H3,(H,31,37) AKPADQIFUKNACD-UHFFFAOYSA-N 413697 2-{4-[5-Chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 91::US11180471, Example 91 Coagulation factor XI Homo sapiens 3.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413697 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413697&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204923 433913801 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115675 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C31H31ClN6O5/c1-18-35-30(43-37-18)21-8-6-19(32)14-22(21)23-16-28(39)38(17-27(23)41-5)26(10-13-42-31(2,3)4)29(40)36-20-7-9-24-25(15-20)34-12-11-33-24/h6-9,11-12,14-17,26H,10,13H2,1-5H3,(H,36,40) WHJFAHUWUMDVIH-UHFFFAOYSA-N 413699 4-tert-Butoxy-N-(quinoxalin-6-yl)-2-{4-[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanamide (Racemate)::US10421742, Example 92::US11180471, Example 92 Coagulation factor XI Homo sapiens 7.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413699 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413699&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205417 433913802 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115676 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C30H31ClFN5O6/c1-16-34-29(43-36-16)19-8-6-17(31)12-21(19)22-14-26(38)37(15-25(22)41-5)24(10-11-42-30(2,3)4)28(40)35-18-7-9-20(27(33)39)23(32)13-18/h6-9,12-15,24H,10-11H2,1-5H3,(H2,33,39)(H,35,40) NZUPFRNOGBEVPO-UHFFFAOYSA-N 413700 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 93::US11180471, Example 93 Coagulation factor XI Homo sapiens 9.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413700 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413700&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205738 433913803 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115677 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C30H31ClN4O7/c1-17-32-28(42-34-17)21-11-8-19(31)14-22(21)23-15-26(36)35(16-25(23)40-5)24(12-13-41-30(2,3)4)27(37)33-20-9-6-18(7-10-20)29(38)39/h6-11,14-16,24H,12-13H2,1-5H3,(H,33,37)(H,38,39) ZWRNKDXMIOGALM-UHFFFAOYSA-N 413701 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 94::US11180471, Example 94 Coagulation factor XI Homo sapiens 1.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413701 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413701&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205935 433913804 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115678 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C31H33ClN6O5/c1-18-33-30(43-36-18)22-9-7-20(32)14-23(22)24-15-28(39)38(17-27(24)41-6)26(11-12-42-31(2,3)4)29(40)34-21-8-10-25-19(13-21)16-37(5)35-25/h7-10,13-17,26H,11-12H2,1-6H3,(H,34,40) QVRAHCXUFLLOFP-UHFFFAOYSA-N 413702 4-tert-Butoxy-2-{4-[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 95::US11180471, Example 95 Coagulation factor XI Homo sapiens 3.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413702 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413702&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205986 433913805 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115679 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(CC(F)(F)F)c1 InChI=1S/C29H26ClF3N4O6/c1-42-10-9-24(27(39)35-20-6-3-17(4-7-20)28(40)41)37-15-25(43-2)23(12-26(37)38)22-11-19(30)5-8-21(22)18-13-34-36(14-18)16-29(31,32)33/h3-8,11-15,24H,9-10,16H2,1-2H3,(H,35,39)(H,40,41) RUCWELAAUNKPGR-UHFFFAOYSA-N 413703 4-({2-[4-{5-Chloro-2-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Racemate)::US10421742, Example 96::US11180471, Example 96 Coagulation factor XI Homo sapiens 6.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413703 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413703&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211517 433913806 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115680 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2cnn(CC(F)(F)F)c2)cn1 InChI=1S/C29H28ClF3N6O5/c1-34-27(41)23-7-5-19(13-35-23)37-28(42)24(8-9-43-2)39-15-25(44-3)22(11-26(39)40)21-10-18(30)4-6-20(21)17-12-36-38(14-17)16-29(31,32)33/h4-7,10-15,24H,8-9,16H2,1-3H3,(H,34,41)(H,37,42) BSBZPHKWOOZTDV-UHFFFAOYSA-N 413704 5-({2-[4-{5-Chloro-2-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 97::US11180471, Example 97 Coagulation factor XI Homo sapiens 39.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413704 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413704&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211552 433913807 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115681 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(CC(F)(F)F)c1 InChI=1S/C30H28ClF3N6O4/c1-38-14-18-10-21(5-7-25(18)37-38)36-29(42)26(8-9-43-2)40-16-27(44-3)24(12-28(40)41)23-11-20(31)4-6-22(23)19-13-35-39(15-19)17-30(32,33)34/h4-7,10-16,26H,8-9,17H2,1-3H3,(H,36,42) SSDUONDHEXQWQO-UHFFFAOYSA-N 413705 2-[4-{5-Chloro-2-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 98::US11180471, Example 98 Coagulation factor XI Homo sapiens 27.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413705 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413705&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205464 433913808 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115682 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O4/c1-34-13-16-10-18(5-6-21(16)32-34)30-27(38)23(8-9-39-2)35-14-24(40-3)20(12-26(35)37)19-11-17(28)4-7-22(19)36-15-25(29)31-33-36/h4-7,10-15,23H,8-9H2,1-3H3,(H,30,38) HQFBMTXLTXVRAL-UHFFFAOYSA-N 413706 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 99::US11180471, Example 99 Coagulation factor XI Homo sapiens 0.960 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413706 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413706&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205773 433913809 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115683 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2FN6O5/c1-39-8-7-21(26(38)31-15-4-5-16(25(30)37)19(29)10-15)34-12-22(40-2)18(11-24(34)36)17-9-14(27)3-6-20(17)35-13-23(28)32-33-35/h3-6,9-13,21H,7-8H2,1-2H3,(H2,30,37)(H,31,38) AITUBRIGGLTKMQ-UHFFFAOYSA-N 413707 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 100::US11180471, Example 100 Coagulation factor XI Homo sapiens 1.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413707 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413707&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206029 433913810 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115684 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2N5O6/c1-38-10-9-21(25(35)29-17-6-3-15(4-7-17)26(36)37)32-13-22(39-2)19(12-24(32)34)18-11-16(27)5-8-20(18)33-14-23(28)30-31-33/h3-8,11-14,21H,9-10H2,1-2H3,(H,29,35)(H,36,37) WCANIIANZRELQI-UHFFFAOYSA-N 413708 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 101::US11180471, Example 101 Coagulation factor XI Homo sapiens 1.000 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413708 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413708&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205978 433913811 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115685 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C29H29Cl2FN6O5/c1-29(2,3)43-10-9-23(28(41)34-17-6-7-18(27(33)40)21(32)12-17)37-14-24(42-4)20(13-26(37)39)19-11-16(30)5-8-22(19)38-15-25(31)35-36-38/h5-8,11-15,23H,9-10H2,1-4H3,(H2,33,40)(H,34,41) JFTPUCJHGXFNAL-UHFFFAOYSA-N 413709 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 102::US11180471, Example 102 Coagulation factor XI Homo sapiens 1.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413709 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413709&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205886 433913812 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115686 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C30H31Cl2N7O4/c1-30(2,3)43-11-10-25(29(41)33-20-7-8-23-18(12-20)15-37(4)35-23)38-16-26(42-5)22(14-28(38)40)21-13-19(31)6-9-24(21)39-17-27(32)34-36-39/h6-9,12-17,25H,10-11H2,1-5H3,(H,33,41) ZAKSQHPNZWUBFJ-UHFFFAOYSA-N 413710 4-tert-Butoxy-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 103::US11180471, Example 103 Coagulation factor XI Homo sapiens 1.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413710 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413710&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205159 433913813 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115687 CCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(F)c1 InChI=1S/C27H24ClFN4O5/c1-3-4-22(26(35)31-18-8-5-16(6-9-18)27(36)37)33-13-23(38-2)20(12-25(33)34)19-11-17(28)7-10-21(19)32-14-24(29)30-15-32/h5-15,22H,3-4H2,1-2H3,(H,31,35)(H,36,37) UEDRHDRNPGYCFA-UHFFFAOYSA-N 413711 4-{[2-{4-[5-Chloro-2-(4-fluoro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}benzoic acid (Racemate)::US10421742, Example 104::US11180471, Example 104 Coagulation factor XI Homo sapiens 3.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413711 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413711&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205818 433913814 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115688 CCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(F)c1 InChI=1S/C28H24ClFN6O3/c1-3-4-24(28(38)34-18-6-7-21-22(12-18)32-10-9-31-21)36-14-25(39-2)20(13-27(36)37)19-11-17(29)5-8-23(19)35-15-26(30)33-16-35/h5-16,24H,3-4H2,1-2H3,(H,34,38) ZJEBCRXBTDTSDY-UHFFFAOYSA-N 413712 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-fluoro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanamide (Racemate)::US10421742, Example 105::US11180471, Example 105 Coagulation factor XI Homo sapiens 14.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413712 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413712&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205899 433913815 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115689 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(F)c1 InChI=1S/C28H26ClFN6O3/c1-4-5-24(28(38)32-19-7-8-22-17(10-19)13-34(2)33-22)36-14-25(39-3)21(12-27(36)37)20-11-18(29)6-9-23(20)35-15-26(30)31-16-35/h6-16,24H,4-5H2,1-3H3,(H,32,38) ZFHCCWVEIZPKIK-UHFFFAOYSA-N 413713 2-{4-[5-Chloro-2-(4-fluoro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 106::US11180471, Example 106 Coagulation factor XI Homo sapiens 18.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413713 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413713&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205875 433913816 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115690 CCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C26H24Cl2N6O4/c1-3-4-21(26(37)32-16-6-7-19(25(29)36)30-11-16)34-12-22(38-2)18(10-24(34)35)17-9-15(27)5-8-20(17)33-13-23(28)31-14-33/h5-14,21H,3-4H2,1-2H3,(H2,29,36)(H,32,37) ZZSYBTPQPYGNKT-UHFFFAOYSA-N 413714 5-{[2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}pyridine-2-carboxamide (Racemate)::US10421742, Example 107::US11180471, Example 107 Coagulation factor XI Homo sapiens 22.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413714 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413714&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205208 433913817 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115691 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C28H26Cl2N6O3/c1-4-5-24(28(38)32-19-7-8-22-17(10-19)13-34(2)33-22)36-14-25(39-3)21(12-27(36)37)20-11-18(29)6-9-23(20)35-15-26(30)31-16-35/h6-16,24H,4-5H2,1-3H3,(H,32,38) GJZFNUOEHXFLPK-UHFFFAOYSA-N 413715 2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 108::US11180471, Example 108 Coagulation factor XI Homo sapiens 15.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413715 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413715&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205633 433913818 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115692 CCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C27H24Cl2N4O5/c1-3-4-22(26(35)31-18-8-5-16(6-9-18)27(36)37)33-13-23(38-2)20(12-25(33)34)19-11-17(28)7-10-21(19)32-14-24(29)30-15-32/h5-15,22H,3-4H2,1-2H3,(H,31,35)(H,36,37) PYCOXKADFBYSOX-UHFFFAOYSA-N 413716 4-{[2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}benzoic acid (Racemate)::US10421742, Example 109::US11180471, Example 109 Coagulation factor XI Homo sapiens 3.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413716 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413716&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205936 433913819 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115693 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)(F)F InChI=1S/C28H24ClF4N5O5/c1-42-8-7-22(27(41)36-16-4-5-17(26(34)40)20(30)10-16)38-12-23(43-2)19(11-25(38)39)18-9-15(29)3-6-21(18)37-13-24(35-14-37)28(31,32)33/h3-6,9-14,22H,7-8H2,1-2H3,(H2,34,40)(H,36,41) NDZYZAAAWXQARZ-UHFFFAOYSA-N 413717 4-({2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 110::US11180471, Example 110 Coagulation factor XI Homo sapiens 21.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413717 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413717&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205099 433913820 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115694 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)(F)F InChI=1S/C29H26ClF3N6O4/c1-37-13-17-10-19(5-6-22(17)36-37)35-28(41)24(8-9-42-2)39-14-25(43-3)21(12-27(39)40)20-11-18(30)4-7-23(20)38-15-26(34-16-38)29(31,32)33/h4-7,10-16,24H,8-9H2,1-3H3,(H,35,41) MCUQCQLBAAKRPX-UHFFFAOYSA-N 413718 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 111::US11180471, Example 111 Coagulation factor XI Homo sapiens 8.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413718 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413718&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205640 433913821 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115695 CCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H23ClN6O5/c1-3-4-21(24(34)28-17-8-5-15(6-9-17)25(35)36)31-13-22(37-2)19(12-23(31)33)18-11-16(26)7-10-20(18)32-14-27-29-30-32/h5-14,21H,3-4H2,1-2H3,(H,28,34)(H,35,36) KXLAWRVDSZAFKG-UHFFFAOYSA-N 413719 4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}benzoic acid (Racemate)::US10421742, Example 112::US11180471, Example 112 Coagulation factor XI Homo sapiens 0.360 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413719 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413719&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205582 433913822 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115696 CCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H23ClFN7O4/c1-3-4-21(25(37)30-15-6-7-16(24(28)36)19(27)10-15)33-12-22(38-2)18(11-23(33)35)17-9-14(26)5-8-20(17)34-13-29-31-32-34/h5-13,21H,3-4H2,1-2H3,(H2,28,36)(H,30,37) CZWHJSKWMSOPRC-UHFFFAOYSA-N 413720 4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-2-fluorobenzamide (Racemate)::US10421742, Example 113::US11180471, Example 113 Coagulation factor XI Homo sapiens 0.550 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413720 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413720&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205931 433913823 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115697 CCC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H23ClFN7O4/c1-3-4-21(25(37)30-15-6-7-16(24(28)36)19(27)10-15)33-12-22(38-2)18(11-23(33)35)17-9-14(26)5-8-20(17)34-13-29-31-32-34/h5-13,21H,3-4H2,1-2H3,(H2,28,36)(H,30,37)/t21-/m0/s1 CZWHJSKWMSOPRC-NRFANRHFSA-N 413721 4-{[(2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-2-fluorobenzamide (Enantiomer 1)::US10421742, Example 114::US11180471, Example 114 Coagulation factor XI Homo sapiens 0.310 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413721 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413721&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205929 433913824 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115698 CCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C24H23ClN8O4/c1-3-4-20(24(36)29-15-6-7-18(23(26)35)27-11-15)32-12-21(37-2)17(10-22(32)34)16-9-14(25)5-8-19(16)33-13-28-30-31-33/h5-13,20H,3-4H2,1-2H3,(H2,26,35)(H,29,36) AWLPKPUSDZNVQR-UHFFFAOYSA-N 413722 5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}pyridine-2-carboxamide (Racemate)::US10421742, Example 115::US11180471, Example 115 Coagulation factor XI Homo sapiens 0.460 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413722 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413722&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205390 433913825 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115699 CCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H25ClN8O4/c1-4-5-21(25(37)30-16-7-8-19(28-12-16)24(36)27-2)33-13-22(38-3)18(11-23(33)35)17-10-15(26)6-9-20(17)34-14-29-31-32-34/h6-14,21H,4-5H2,1-3H3,(H,27,36)(H,30,37) NZYSNSQHJHYDEI-UHFFFAOYSA-N 413723 5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]-amino}-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 116::US11180471, Example 116 Coagulation factor XI Homo sapiens 0.660 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413723 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413723&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205823 433913826 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115700 CCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H23ClN8O3/c1-3-4-23(26(37)31-17-6-7-20-21(12-17)29-10-9-28-20)34-14-24(38-2)19(13-25(34)36)18-11-16(27)5-8-22(18)35-15-30-32-33-35/h5-15,23H,3-4H2,1-2H3,(H,31,37) BSNRZZUTVDCZAA-UHFFFAOYSA-N 413724 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanamide (Racemate)::US10421742, Example 117::US11180471, Example 117 Coagulation factor XI Homo sapiens 0.560 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413724 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413724&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205052 433913827 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115701 CCC[C@@H](C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H23ClN8O3/c1-3-4-23(26(37)31-17-6-7-20-21(12-17)29-10-9-28-20)34-14-24(38-2)19(13-25(34)36)18-11-16(27)5-8-22(18)35-15-30-32-33-35/h5-15,23H,3-4H2,1-2H3,(H,31,37)/t23-/m0/s1 BSNRZZUTVDCZAA-QHCPKHFHSA-N 413725 N-(Quinoxalin-6-yl)-(2S)-2-{4-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanamide (Enantiomer 2)::US10421742, Example 118::US11180471, Example 118 Coagulation factor XI Homo sapiens 0.260 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413725 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413725&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211528 433913828 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115702 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H25ClN8O3/c1-4-5-23(26(37)29-18-7-8-21-16(10-18)13-33(2)30-21)34-14-24(38-3)20(12-25(34)36)19-11-17(27)6-9-22(19)35-15-28-31-32-35/h6-15,23H,4-5H2,1-3H3,(H,29,37) DROSFHKHAAIBHD-UHFFFAOYSA-N 413726 2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 119::US11180471, Example 119 Coagulation factor XI Homo sapiens 0.500 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413726 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413726&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204930 433913829 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115703 CCC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H25ClN8O3/c1-4-5-23(26(37)29-18-7-8-21-16(10-18)13-33(2)30-21)34-14-24(38-3)20(12-25(34)36)19-11-17(27)6-9-22(19)35-15-28-31-32-35/h6-15,23H,4-5H2,1-3H3,(H,29,37)/t23-/m0/s1 DROSFHKHAAIBHD-QHCPKHFHSA-N 413727 (2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Enantiomer 2)::US10421742, Example 120::US11180471, Example 120 Coagulation factor XI Homo sapiens 0.340 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413727 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413727&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204928 433913830 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115704 CCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H24ClF3N6O4/c1-3-4-22(27(40)33-15-6-7-16(26(32)39)19(29)10-15)36-13-23(41-2)18(11-24(36)38)17-9-14(28)5-8-21(17)37-12-20(25(30)31)34-35-37/h5-13,22,25H,3-4H2,1-2H3,(H2,32,39)(H,33,40) WZUXJAUBKKDABN-UHFFFAOYSA-N 413728 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 121::US11180471, Example 121 Coagulation factor XI Homo sapiens 6.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413728 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413728&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205311 433913831 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115705 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H26ClF2N7O3/c1-4-5-24(28(40)32-18-7-8-21-16(10-18)13-36(2)34-21)37-15-25(41-3)20(12-26(37)39)19-11-17(29)6-9-23(19)38-14-22(27(30)31)33-35-38/h6-15,24,27H,4-5H2,1-3H3,(H,32,40) TZKJUKFMINMKSP-UHFFFAOYSA-N 413729 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 122::US11180471, Example 122 Coagulation factor XI Homo sapiens 3.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413729 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413729&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205690 433913832 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115706 CCC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H26ClF2N7O3/c1-4-5-24(28(40)32-18-7-8-21-16(10-18)13-36(2)34-21)37-15-25(41-3)20(12-26(37)39)19-11-17(29)6-9-23(19)38-14-22(27(30)31)33-35-38/h6-15,24,27H,4-5H2,1-3H3,(H,32,40)/t24-/m0/s1 TZKJUKFMINMKSP-DEOSSOPVSA-N 413730 (2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)pentanamide (Enantiomer 2)::US10421742, Example 123::US11180471, Example 123 Coagulation factor XI Homo sapiens 1.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413730 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413730&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205688 433913833 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115707 CCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H26ClF2N7O4/c1-4-5-22(27(40)33-16-7-8-19(32-12-16)26(39)31-2)36-14-23(41-3)18(11-24(36)38)17-10-15(28)6-9-21(17)37-13-20(25(29)30)34-35-37/h6-14,22,25H,4-5H2,1-3H3,(H,31,39)(H,33,40) ZZXQOEFXCPENDW-UHFFFAOYSA-N 413731 5-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 124::US11180471, Example 124 Coagulation factor XI Homo sapiens 5.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413731 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413731&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204627 433913834 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115708 CCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2FN6O4/c1-3-4-21(26(38)31-15-6-7-16(25(30)37)19(29)10-15)34-12-22(39-2)18(11-24(34)36)17-9-14(27)5-8-20(17)35-13-23(28)32-33-35/h5-13,21H,3-4H2,1-2H3,(H2,30,37)(H,31,38) KQZYQOJQXJGZMI-UHFFFAOYSA-N 413732 4-{[2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-2-fluorobenzamide (Racemate)::US10421742, Example 125::US11180471, Example 125 Coagulation factor XI Homo sapiens 2.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413732 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413732&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204823 433913835 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115709 CCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2N7O3/c1-3-4-23(27(38)32-17-6-7-20-21(12-17)31-10-9-30-20)35-14-24(39-2)19(13-26(35)37)18-11-16(28)5-8-22(18)36-15-25(29)33-34-36/h5-15,23H,3-4H2,1-2H3,(H,32,38) AJXCDVGDMKCSJV-UHFFFAOYSA-N 413733 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanamide (Racemate)::US10421742, Example 126::US11180471, Example 126 Coagulation factor XI Homo sapiens 1.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413733 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413733&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204993 433913836 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115710 CCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H25Cl2N7O4/c1-4-5-21(26(38)31-16-7-8-19(30-12-16)25(37)29-2)34-13-22(39-3)18(11-24(34)36)17-10-15(27)6-9-20(17)35-14-23(28)32-33-35/h6-14,21H,4-5H2,1-3H3,(H,29,37)(H,31,38) RMNQUVGQJWBXRY-UHFFFAOYSA-N 413734 5-{[2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 127::US11180471, Example 127 Coagulation factor XI Homo sapiens 2.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413734 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413734&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205374 433913837 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115711 CCC[C@@H](C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H25Cl2N7O4/c1-4-5-21(26(38)31-16-7-8-19(30-12-16)25(37)29-2)34-13-22(39-3)18(11-24(34)36)17-10-15(27)6-9-20(17)35-14-23(28)32-33-35/h6-14,21H,4-5H2,1-3H3,(H,29,37)(H,31,38)/t21-/m0/s1 RMNQUVGQJWBXRY-NRFANRHFSA-N 413735 5-{[(2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-N-methylpyridine-2-carboxamide (Enantiomer 2)::US10421742, Example 128::US11180471, Example 128 Coagulation factor XI Homo sapiens 1.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413735 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413735&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205795 433913838 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115712 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O3/c1-4-5-23(27(38)30-18-7-8-21-16(10-18)13-34(2)32-21)35-14-24(39-3)20(12-26(35)37)19-11-17(28)6-9-22(19)36-15-25(29)31-33-36/h6-15,23H,4-5H2,1-3H3,(H,30,38) XMGACJAVDNSYFS-UHFFFAOYSA-N 413736 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 129::US11180471, Example 129 Coagulation factor XI Homo sapiens 2.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413736 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413736&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205483 433913839 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115713 CCC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O3/c1-4-5-23(27(38)30-18-7-8-21-16(10-18)13-34(2)32-21)35-14-24(39-3)20(12-26(35)37)19-11-17(28)6-9-22(19)36-15-25(29)31-33-36/h6-15,23H,4-5H2,1-3H3,(H,30,38)/t23-/m0/s1 XMGACJAVDNSYFS-QHCPKHFHSA-N 413737 (2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Enantiomer 2)::US10421742, Example 130::US11180471, Example 130 Coagulation factor XI Homo sapiens 0.840 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413737 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413737&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205651 433913840 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115714 CCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C27H28ClN5O5/c1-4-5-23(27(36)31-17-7-9-22(30-14-17)26(35)29-2)33-15-24(37-3)20(13-25(33)34)19-12-16(28)6-8-18(19)21-10-11-38-32-21/h6-9,12-15,23H,4-5,10-11H2,1-3H3,(H,29,35)(H,31,36) FVMMOGSUTBHAJT-UHFFFAOYSA-N 413738 5-{[2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 131::US11180471, Example 131 Coagulation factor XI Homo sapiens 33.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413738 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413738&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205781 433913841 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115715 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C28H28ClN5O4/c1-4-5-25(28(36)30-19-7-9-23-17(12-19)15-33(2)31-23)34-16-26(37-3)22(14-27(34)35)21-13-18(29)6-8-20(21)24-10-11-38-32-24/h6-9,12-16,25H,4-5,10-11H2,1-3H3,(H,30,36) GGCCNKNGPKYJET-UHFFFAOYSA-N 413739 2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 132::US11180471, Example 132 Coagulation factor XI Homo sapiens 15.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413739 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413739&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205590 433913842 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115716 CCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C27H26ClFN4O5/c1-3-4-23(27(36)31-16-6-8-18(26(30)35)21(29)12-16)33-14-24(37-2)20(13-25(33)34)19-11-15(28)5-7-17(19)22-9-10-38-32-22/h5-8,11-14,23H,3-4,9-10H2,1-2H3,(H2,30,35)(H,31,36) CACLNVKPTHLQAL-UHFFFAOYSA-N 413740 4-{[2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-2-fluorobenzamide (Racemate)::US10421742, Example 133::US11180471, Example 133 Coagulation factor XI Homo sapiens 38.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413740 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413740&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211499 433913843 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115717 CCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C28H26ClN5O4/c1-3-4-25(28(36)32-18-6-8-23-24(14-18)31-11-10-30-23)34-16-26(37-2)21(15-27(34)35)20-13-17(29)5-7-19(20)22-9-12-38-33-22/h5-8,10-11,13-16,25H,3-4,9,12H2,1-2H3,(H,32,36) QYYKJTWIVWXLBD-UHFFFAOYSA-N 413741 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanamide (Racemate)::US10421742, Example 134::US11180471, Example 134 Coagulation factor XI Homo sapiens 18.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413741 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413741&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204822 433913844 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115718 CCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C26H26ClN5O5/c1-3-4-22(26(35)30-16-6-8-21(25(28)34)29-13-16)32-14-23(36-2)19(12-24(32)33)18-11-15(27)5-7-17(18)20-9-10-37-31-20/h5-8,11-14,22H,3-4,9-10H2,1-2H3,(H2,28,34)(H,30,35) WRJUZVZDXJUFIS-UHFFFAOYSA-N 413742 5-{[2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}pyridine-2-carboxamide (Racemate)::US10421742, Example 135::US11180471, Example 135 Coagulation factor XI Homo sapiens 30.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413742 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413742&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205806 433913845 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115719 CCCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H25ClN8O4/c1-3-4-5-21(25(37)30-16-7-8-19(24(27)36)28-12-16)33-13-22(38-2)18(11-23(33)35)17-10-15(26)6-9-20(17)34-14-29-31-32-34/h6-14,21H,3-5H2,1-2H3,(H2,27,36)(H,30,37) ZIAUCGPBMPJNBL-UHFFFAOYSA-N 413743 5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}hexanoyl]amino}pyridine-2-carboxamide (Racemate)::US10421742, Example 136::US11180471, Example 136 Coagulation factor XI Homo sapiens 0.720 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413743 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413743&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205668 433913846 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115720 CCCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H25ClFN7O4/c1-3-4-5-22(26(38)31-16-7-8-17(25(29)37)20(28)11-16)34-13-23(39-2)19(12-24(34)36)18-10-15(27)6-9-21(18)35-14-30-32-33-35/h6-14,22H,3-5H2,1-2H3,(H2,29,37)(H,31,38) VQBUYPWHWZACJN-UHFFFAOYSA-N 413744 4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}hexanoyl]amino}-2-fluorobenzamide (Racemate)::US10421742, Example 137::US11180471, Example 137 Coagulation factor XI Homo sapiens 0.840 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413744 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413744&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205878 433913847 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115721 CCCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H25ClN6O5/c1-3-4-5-22(25(35)29-18-9-6-16(7-10-18)26(36)37)32-14-23(38-2)20(13-24(32)34)19-12-17(27)8-11-21(19)33-15-28-30-31-33/h6-15,22H,3-5H2,1-2H3,(H,29,35)(H,36,37) FCSAYDZPMDLFSN-UHFFFAOYSA-N 413745 4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}hexanoyl]amino}benzoic acid (Racemate)::US10421742, Example 138::US11180471, Example 138 Coagulation factor XI Homo sapiens 0.360 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413745 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413745&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205666 433913848 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115722 CCCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C27H27ClN8O3/c1-4-5-6-24(27(38)30-19-8-9-22-17(11-19)14-34(2)31-22)35-15-25(39-3)21(13-26(35)37)20-12-18(28)7-10-23(20)36-16-29-32-33-36/h7-16,24H,4-6H2,1-3H3,(H,30,38) GTVFMNZALGQANW-UHFFFAOYSA-N 413746 2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)hexanamide (Racemate)::US10421742, Example 139::US11180471, Example 139 Coagulation factor XI Homo sapiens 0.590 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413746 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413746&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205025 433913849 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115723 CCCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C27H25ClN8O3/c1-3-4-5-24(27(38)32-18-7-8-21-22(13-18)30-11-10-29-21)35-15-25(39-2)20(14-26(35)37)19-12-17(28)6-9-23(19)36-16-31-33-34-36/h6-16,24H,3-5H2,1-2H3,(H,32,38) DVTLDIPPLKDTBX-UHFFFAOYSA-N 413747 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}hexanamide (Racemate)::US10421742, Example 140::US11180471, Example 140 Coagulation factor XI Homo sapiens 0.760 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413747 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413747&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205988 433913850 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115724 CCCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H27ClN8O4/c1-4-5-6-22(26(38)31-17-8-9-20(29-13-17)25(37)28-2)34-14-23(39-3)19(12-24(34)36)18-11-16(27)7-10-21(18)35-15-30-32-33-35/h7-15,22H,4-6H2,1-3H3,(H,28,37)(H,31,38) ORRIMSVBDDRCMC-UHFFFAOYSA-N 413748 5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}hexanoyl]amino}-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 141::US11180471, Example 141 Coagulation factor XI Homo sapiens 0.710 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413748 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413748&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205579 433913851 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115725 CCCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H26ClF2N5O5/c1-3-4-5-23(27(38)32-18-9-6-16(7-10-18)28(39)40)35-15-24(41-2)20(13-25(35)37)19-12-17(29)8-11-22(19)36-14-21(26(30)31)33-34-36/h6-15,23,26H,3-5H2,1-2H3,(H,32,38)(H,39,40) PSPFOZLTTSZDFP-UHFFFAOYSA-N 413749 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]hexanoyl}amino)benzoic acid (Racemate)::US10421742, Example 142::US11180471, Example 142 Coagulation factor XI Homo sapiens 0.710 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413749 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413749&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204833 433913852 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115726 CCCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H26ClF2N7O4/c1-3-4-5-22(27(40)33-16-7-8-19(26(31)39)32-12-16)36-14-23(41-2)18(11-24(36)38)17-10-15(28)6-9-21(17)37-13-20(25(29)30)34-35-37/h6-14,22,25H,3-5H2,1-2H3,(H2,31,39)(H,33,40) JSHWYUYKRGKALM-UHFFFAOYSA-N 413750 5-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]hexanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 143::US11180471, Example 143 Coagulation factor XI Homo sapiens 3.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413750 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413750&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205512 433913853 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115727 CCCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H26ClF3N6O4/c1-3-4-5-23(28(41)34-16-7-8-17(27(33)40)20(30)11-16)37-14-24(42-2)19(12-25(37)39)18-10-15(29)6-9-22(18)38-13-21(26(31)32)35-36-38/h6-14,23,26H,3-5H2,1-2H3,(H2,33,40)(H,34,41) HGCFEYDNSXOVOU-UHFFFAOYSA-N 413751 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]hexanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 144::US11180471, Example 144 Coagulation factor XI Homo sapiens 4.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413751 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413751&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205069 433913854 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115728 CCCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H28ClF2N7O3/c1-4-5-6-25(29(41)33-19-8-9-22-17(11-19)14-37(2)35-22)38-16-26(42-3)21(13-27(38)40)20-12-18(30)7-10-24(20)39-15-23(28(31)32)34-36-39/h7-16,25,28H,4-6H2,1-3H3,(H,33,41) OUOIBTWZEMQDJD-UHFFFAOYSA-N 413752 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)hexanamide (Racemate)::US10421742, Example 145::US11180471, Example 145 Coagulation factor XI Homo sapiens 2.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413752 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413752&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205547 433913855 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115729 CCCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H26ClF2N7O3/c1-3-4-5-25(29(41)35-18-7-8-21-22(13-18)34-11-10-33-21)38-16-26(42-2)20(14-27(38)40)19-12-17(30)6-9-24(19)39-15-23(28(31)32)36-37-39/h6-16,25,28H,3-5H2,1-2H3,(H,35,41) YGFSDBVKNXCHFA-UHFFFAOYSA-N 413753 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]hexanamide (Racemate)::US10421742, Example 146::US11180471, Example 146 Coagulation factor XI Homo sapiens 2.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413753 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413753&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205951 433913856 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115730 CCCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H28ClF2N7O4/c1-4-5-6-23(28(41)34-17-8-9-20(33-13-17)27(40)32-2)37-15-24(42-3)19(12-25(37)39)18-11-16(29)7-10-22(18)38-14-21(26(30)31)35-36-38/h7-15,23,26H,4-6H2,1-3H3,(H,32,40)(H,34,41) LATWNRFJRFBWAT-UHFFFAOYSA-N 413754 5-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]hexanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 147::US11180471, Example 147 Coagulation factor XI Homo sapiens 2.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413754 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413754&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206088 433913857 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115731 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C26H20ClF3N4O6/c1-3-19(22(36)31-15-7-4-13(5-8-15)24(37)38)34-12-20(39-2)18(11-21(34)35)17-10-14(27)6-9-16(17)23-32-33-25(40-23)26(28,29)30/h4-12,19H,3H2,1-2H3,(H,31,36)(H,37,38) QIVMZHNMVQBPGT-UHFFFAOYSA-N 413755 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)benzoic acid (Racemate)::US10421742, Example 148::US11180471, Example 148 Coagulation factor XI Homo sapiens 2.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413755 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413755&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205817 433913858 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115732 CCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C25H20ClF3N6O5/c1-3-18(22(38)32-13-5-7-17(21(30)37)31-10-13)35-11-19(39-2)16(9-20(35)36)15-8-12(26)4-6-14(15)23-33-34-24(40-23)25(27,28)29/h4-11,18H,3H2,1-2H3,(H2,30,37)(H,32,38) IQJSIJCMDLKBFX-UHFFFAOYSA-N 413756 5-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 149::US11180471, Example 149 Coagulation factor XI Homo sapiens 13.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413756 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413756&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206048 433913859 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115733 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C26H20ClF4N5O5/c1-3-19(23(39)33-13-5-7-15(22(32)38)18(28)9-13)36-11-20(40-2)17(10-21(36)37)16-8-12(27)4-6-14(16)24-34-35-25(41-24)26(29,30)31/h4-11,19H,3H2,1-2H3,(H2,32,38)(H,33,39) UHOHRXOOGVHYED-UHFFFAOYSA-N 413757 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 150::US11180471, Example 150 Coagulation factor XI Homo sapiens 12.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413757 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413757&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205709 433913860 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115734 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C27H22ClF3N6O4/c1-4-21(24(39)32-16-6-8-20-14(9-16)12-36(2)35-20)37-13-22(40-3)19(11-23(37)38)18-10-15(28)5-7-17(18)25-33-34-26(41-25)27(29,30)31/h5-13,21H,4H2,1-3H3,(H,32,39) HHSBQKYCPNEOQX-UHFFFAOYSA-N 413758 2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 151::US11180471, Example 151 Coagulation factor XI Homo sapiens 6.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413758 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413758&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205384 433913861 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115735 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C27H20ClF3N6O4/c1-3-21(24(39)34-15-5-7-19-20(11-15)33-9-8-32-19)37-13-22(40-2)18(12-23(37)38)17-10-14(28)4-6-16(17)25-35-36-26(41-25)27(29,30)31/h4-13,21H,3H2,1-2H3,(H,34,39) OLLLLNYOIWPNPJ-UHFFFAOYSA-N 413759 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanamide (Racemate)::US10421742, Example 152::US11180471, Example 152 Coagulation factor XI Homo sapiens 6.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413759 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413759&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205969 433913862 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115736 CCC(C(=O)Nc1ccc(C(=O)NC)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C27H22ClF4N5O5/c1-4-20(24(40)34-14-6-8-16(19(29)10-14)23(39)33-2)37-12-21(41-3)18(11-22(37)38)17-9-13(28)5-7-15(17)25-35-36-26(42-25)27(30,31)32/h5-12,20H,4H2,1-3H3,(H,33,39)(H,34,40) DLRRJLUTWALOOR-UHFFFAOYSA-N 413760 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluoro-N-methylbenzamide (Racemate)::US10421742, Example 153::US11180471, Example 153 Coagulation factor XI Homo sapiens 16.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413760 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413760&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204746 433913863 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115737 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C26H21ClF2N4O6/c1-3-19(23(35)30-15-7-4-13(5-8-15)26(36)37)33-12-20(38-2)18(11-21(33)34)17-10-14(27)6-9-16(17)24-31-32-25(39-24)22(28)29/h4-12,19,22H,3H2,1-2H3,(H,30,35)(H,36,37) ARBVSWGIQYWRFI-UHFFFAOYSA-N 413761 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)benzoic acid (Racemate)::US10421742, Example 154::US11180471, Example 154 Coagulation factor XI Homo sapiens 2.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413761 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413761&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205186 433913864 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115738 CCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C25H21ClF2N6O5/c1-3-18(23(37)31-13-5-7-17(22(29)36)30-10-13)34-11-19(38-2)16(9-20(34)35)15-8-12(26)4-6-14(15)24-32-33-25(39-24)21(27)28/h4-11,18,21H,3H2,1-2H3,(H2,29,36)(H,31,37) MXCXAGMMMBQTPS-UHFFFAOYSA-N 413762 5-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 155::US11180471, Example 155 Coagulation factor XI Homo sapiens 9.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413762 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413762&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205309 433913865 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115739 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C26H21ClF3N5O5/c1-3-19(24(38)32-13-5-7-15(23(31)37)18(28)9-13)35-11-20(39-2)17(10-21(35)36)16-8-12(27)4-6-14(16)25-33-34-26(40-25)22(29)30/h4-11,19,22H,3H2,1-2H3,(H2,31,37)(H,32,38) GELPZCSNZJPUPR-UHFFFAOYSA-N 413763 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 156::US11180471, Example 160 Coagulation factor XI Homo sapiens 15.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413763 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413763&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205925 433913866 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115740 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C27H23ClF2N6O4/c1-4-21(25(38)31-16-6-8-20-14(9-16)12-35(2)34-20)36-13-22(39-3)19(11-23(36)37)18-10-15(28)5-7-17(18)26-32-33-27(40-26)24(29)30/h5-13,21,24H,4H2,1-3H3,(H,31,38) HUAFIQJRZLYLOU-UHFFFAOYSA-N 413764 2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 157::US11180471, Example 157 Coagulation factor XI Homo sapiens 8.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413764 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413764&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205941 433913867 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115741 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C27H21ClF2N6O4/c1-3-21(25(38)33-15-5-7-19-20(11-15)32-9-8-31-19)36-13-22(39-2)18(12-23(36)37)17-10-14(28)4-6-16(17)26-34-35-27(40-26)24(29)30/h4-13,21,24H,3H2,1-2H3,(H,33,38) ZXOWUCFZXVCGPI-UHFFFAOYSA-N 413765 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanamide (Racemate)::US10421742, Example 158::US11180471, Example 158 Coagulation factor XI Homo sapiens 7.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413765 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413765&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205104 433913868 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115742 CCC(C(=O)Nc1ccc(C(=O)NC)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C27H23ClF3N5O5/c1-4-20(25(39)33-14-6-8-16(19(29)10-14)24(38)32-2)36-12-21(40-3)18(11-22(36)37)17-9-13(28)5-7-15(17)26-34-35-27(41-26)23(30)31/h5-12,20,23H,4H2,1-3H3,(H,32,38)(H,33,39) XEUUKFFBCFEEHJ-UHFFFAOYSA-N 413766 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluoro-N-methylbenzamide (Racemate)::US10421742, Example 159::US11180471, Example 159 Coagulation factor XI Homo sapiens 24.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413766 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413766&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205157 433913869 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115743 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C26H21ClF3N5O5/c1-3-19(24(38)32-13-5-7-15(23(31)37)18(28)9-13)35-11-20(39-2)17(10-21(35)36)16-8-12(27)4-6-14(16)25-33-34-26(40-25)22(29)30/h4-11,19,22H,3H2,1-2H3,(H2,31,37)(H,32,38) GELPZCSNZJPUPR-UHFFFAOYSA-N 413763 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 156::US11180471, Example 160 Coagulation factor XI Homo sapiens 2.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413763 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413763&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205925 433913866 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115744 CC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C26H22ClF3N6O4/c1-3-20(26(39)32-14-5-6-15(25(31)38)18(28)9-14)35-12-22(40-2)17(10-23(35)37)16-8-13(27)4-7-21(16)36-11-19(24(29)30)33-34-36/h4-12,20,24H,3H2,1-2H3,(H2,31,38)(H,32,39)/t20-/m0/s1 OETZVLILMHLZTG-FQEVSTJZSA-N 413768 4-({(2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 161::US11180471, Example 161 Coagulation factor XI Homo sapiens 2.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413768 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413768&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205281 433913871 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115745 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H22ClF2N7O3/c1-3-22(27(39)33-16-5-6-19-20(11-16)32-9-8-31-19)36-14-24(40-2)18(12-25(36)38)17-10-15(28)4-7-23(17)37-13-21(26(29)30)34-35-37/h4-14,22,26H,3H2,1-2H3,(H,33,39) OEMBYSUFEIJUEQ-UHFFFAOYSA-N 413769 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanamide (Racemate)::US10421742, Example 162::US11180471, Example 162 Coagulation factor XI Homo sapiens 1.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413769 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413769&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205522 433913872 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115746 CC[C@@H](C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H22ClF2N7O3/c1-3-22(27(39)33-16-5-6-19-20(11-16)32-9-8-31-19)36-14-24(40-2)18(12-25(36)38)17-10-15(28)4-7-23(17)37-13-21(26(29)30)34-35-37/h4-14,22,26H,3H2,1-2H3,(H,33,39)/t22-/m0/s1 OEMBYSUFEIJUEQ-QFIPXVFZSA-N 413770 N-(Quinoxalin-6-yl)-(2S)-2-[4-{5-chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanamide (Enantiomer 2)::US10421742, Example 163::US11180471, Example 163 Coagulation factor XI Homo sapiens 0.700 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413770 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413770&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205521 433913873 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115747 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H24ClF2N7O3/c1-4-22(27(39)31-17-6-7-20-15(9-17)12-35(2)33-20)36-14-24(40-3)19(11-25(36)38)18-10-16(28)5-8-23(18)37-13-21(26(29)30)32-34-37/h5-14,22,26H,4H2,1-3H3,(H,31,39) UAHXABWWDRJQRK-UHFFFAOYSA-N 413771 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 164::US11180471, Example 164 Coagulation factor XI Homo sapiens 1.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413771 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413771&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205536 433913874 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115748 CC[C@@H](C(=O)Nc1ccc2cn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H25ClF2N6O3/c1-4-23(28(39)32-19-7-5-16-12-35(2)13-17(16)9-19)36-15-25(40-3)21(11-26(36)38)20-10-18(29)6-8-24(20)37-14-22(27(30)31)33-34-37/h5-15,23,27H,4H2,1-3H3,(H,32,39)/t23-/m0/s1 VFCPFXPPJSVUEB-QHCPKHFHSA-N 528187 (2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (enantiomer 2)::US11180471, Example 165 Coagulation factor XI Homo sapiens 0.860 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528187 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528187&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 163200077 463791736 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115749 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C26H22ClF2N5O5/c1-3-20(25(36)30-16-7-4-14(5-8-16)26(37)38)33-13-22(39-2)18(11-23(33)35)17-10-15(27)6-9-21(17)34-12-19(24(28)29)31-32-34/h4-13,20,24H,3H2,1-2H3,(H,30,36)(H,37,38) NNJGQRMOKIHSCI-UHFFFAOYSA-N 413773 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)benzoic acid (Racemate)::US10421742, Example 166::US11180471, Example 166 Coagulation factor XI Homo sapiens 0.620 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413773 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413773&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205919 433913876 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115750 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2N7O3/c1-4-21(26(37)29-17-6-7-20-15(9-17)12-33(2)31-20)34-13-23(38-3)19(11-25(34)36)18-10-16(27)5-8-22(18)35-14-24(28)30-32-35/h5-14,21H,4H2,1-3H3,(H,29,37) QBWXHIMIUSZAOP-UHFFFAOYSA-N 413774 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 167::US10421742, Example 225::US11180471, Example 225 Coagulation factor XI Homo sapiens 1.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413774 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413774&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205467 433913877 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115751 CC[C@@H](C(=O)Nc1ccc2cn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H24Cl2N6O3/c1-4-22(27(37)30-19-7-5-16-12-33(2)13-17(16)9-19)34-14-24(38-3)21(11-26(34)36)20-10-18(28)6-8-23(20)35-15-25(29)31-32-35/h5-15,22H,4H2,1-3H3,(H,30,37)/t22-/m0/s1 HNHBZVLOAXVGOW-QFIPXVFZSA-N 528190 (2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (enantiomer 2)::US11180471, Example 168 Coagulation factor XI Homo sapiens 0.780 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528190 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528190&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 163200078 463791738 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115752 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2N7O3/c1-3-21(26(37)31-16-5-6-19-20(11-16)30-9-8-29-19)34-13-23(38-2)18(12-25(34)36)17-10-15(27)4-7-22(17)35-14-24(28)32-33-35/h4-14,21H,3H2,1-2H3,(H,31,37) QWJAHBCIMJSNPO-UHFFFAOYSA-N 413776 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanamide (Racemate)::US10421742, Example 169::US11180471, Example 169 Coagulation factor XI Homo sapiens 1.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413776 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413776&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205827 433913879 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115753 CC[C@@H](C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2N7O3/c1-3-21(26(37)31-16-5-6-19-20(11-16)30-9-8-29-19)34-13-23(38-2)18(12-25(34)36)17-10-15(27)4-7-22(17)35-14-24(28)32-33-35/h4-14,21H,3H2,1-2H3,(H,31,37)/t21-/m0/s1 QWJAHBCIMJSNPO-NRFANRHFSA-N 413777 N-(Quinoxalin-6-yl)-(2S)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanamide (Enantiomer 2)::US10421742, Example 170::US11180471, Example 170 Coagulation factor XI Homo sapiens 0.550 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413777 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413777&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206028 433913880 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115754 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H21Cl2FN6O4/c1-3-19(25(37)30-14-5-6-15(24(29)36)18(28)9-14)33-11-21(38-2)17(10-23(33)35)16-8-13(26)4-7-20(16)34-12-22(27)31-32-34/h4-12,19H,3H2,1-2H3,(H2,29,36)(H,30,37) FPAKZDLGEHHCTC-UHFFFAOYSA-N 413778 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 171::US11180471, Example 171 Coagulation factor XI Homo sapiens 1.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413778 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413778&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205799 433913881 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115755 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H23ClN8O3/c1-4-21(25(36)28-17-6-7-20-15(9-17)12-32(2)29-20)33-13-23(37-3)19(11-24(33)35)18-10-16(26)5-8-22(18)34-14-27-30-31-34/h5-14,21H,4H2,1-3H3,(H,28,36) IQNORUMXNDXEIL-UHFFFAOYSA-N 528194 2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (racemate)::US11180471, Example 172 Coagulation factor XI Homo sapiens 0.820 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528194 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528194&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 142742732 463791741 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115756 COc1cn(C(CC2CCC2)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C29H25Cl2N7O3/c1-41-26-15-37(28(39)14-21(26)20-12-18(30)5-8-24(20)38-16-27(31)35-36-38)25(11-17-3-2-4-17)29(40)34-19-6-7-22-23(13-19)33-10-9-32-22/h5-10,12-17,25H,2-4,11H2,1H3,(H,34,40) MZJDBIVMBJLQSX-UHFFFAOYSA-N 413780 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-cyclobutylpropanamide (Racemate)::US10421742, Example 173::US11180471, Example 173 Coagulation factor XI Homo sapiens 3.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413780 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413780&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206019 433913883 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115757 CCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)F InChI=1S/C26H22ClF2N5O5/c1-3-20(26(37)32-14-5-7-18(25(30)36)31-11-14)34-12-22(38-2)17(9-23(34)35)16-8-13(27)4-6-15(16)19-10-21(24(28)29)39-33-19/h4-12,20,24H,3H2,1-2H3,(H2,30,36)(H,32,37) CFZRHXMVQOAQBA-UHFFFAOYSA-N 413781 5-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 174::US11180471, Example 174 Coagulation factor XI Homo sapiens 2.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413781 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413781&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205546 433913884 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115758 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)F InChI=1S/C27H22ClF3N4O5/c1-3-21(27(38)33-14-5-7-16(26(32)37)19(29)9-14)35-12-23(39-2)18(10-24(35)36)17-8-13(28)4-6-15(17)20-11-22(25(30)31)40-34-20/h4-12,21,25H,3H2,1-2H3,(H2,32,37)(H,33,38) WJQZEXDXRMYEAJ-UHFFFAOYSA-N 413782 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 175::US11180471, Example 175 Coagulation factor XI Homo sapiens 6.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413782 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413782&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205744 433913885 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115759 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)F InChI=1S/C28H24ClF2N5O4/c1-4-23(28(38)32-17-6-8-21-15(9-17)13-35(2)33-21)36-14-25(39-3)20(11-26(36)37)19-10-16(29)5-7-18(19)22-12-24(27(30)31)40-34-22/h5-14,23,27H,4H2,1-3H3,(H,32,38) YPTNTTHZSPASJM-UHFFFAOYSA-N 413783 2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 176::US11180471, Example 176 Coagulation factor XI Homo sapiens 4.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413783 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413783&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205796 433913886 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115760 CCC(C(=O)Nc1ccc(C(=O)NC)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)F InChI=1S/C28H24ClF3N4O5/c1-4-22(28(39)34-15-6-8-17(20(30)10-15)27(38)33-2)36-13-24(40-3)19(11-25(36)37)18-9-14(29)5-7-16(18)21-12-23(26(31)32)41-35-21/h5-13,22,26H,4H2,1-3H3,(H,33,38)(H,34,39) GWQBOPAUXMQWRD-UHFFFAOYSA-N 413784 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluoro-N-methylbenzamide (Racemate)::US10421742, Example 177::US11180471, Example 177 Coagulation factor XI Homo sapiens 7.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413784 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413784&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205630 433913887 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115761 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)F InChI=1S/C28H22ClF2N5O4/c1-3-23(28(38)34-16-5-7-20-22(11-16)33-9-8-32-20)36-14-25(39-2)19(12-26(36)37)18-10-15(29)4-6-17(18)21-13-24(27(30)31)40-35-21/h4-14,23,27H,3H2,1-2H3,(H,34,38) VCYPQGRHNOEINV-UHFFFAOYSA-N 413785 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[5-(difluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanamide (Racemate)::US10421742, Example 178::US11180471, Example 178 Coagulation factor XI Homo sapiens 9.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413785 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413785&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205450 433913888 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115762 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H32ClN3O7/c1-30(2,3)40-13-12-25(28(36)32-20-8-5-18(6-9-20)29(37)38)34-17-26(39-4)23(16-27(34)35)22-15-19(31)7-10-21(22)24-11-14-41-33-24/h5-10,15-17,25H,11-14H2,1-4H3,(H,32,36)(H,37,38) IZEONOSVIATBHE-UHFFFAOYSA-N 413786 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 179::US11180471, Example 179 Coagulation factor XI Homo sapiens 5.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413786 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413786&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205653 433913889 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115763 COCC[C@@H](C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(c1)C(F)F InChI=1S/C28H25ClF2N4O6/c1-40-10-9-23(26(37)33-19-6-3-16(4-7-19)27(38)39)34-15-24(41-2)22(12-25(34)36)21-11-18(29)5-8-20(21)17-13-32-35(14-17)28(30)31/h3-8,11-15,23,28H,9-10H2,1-2H3,(H,33,37)(H,38,39)/t23-/m0/s1 KPDQGYYQHYCMAC-QHCPKHFHSA-N 413787 4-({(2S)-2-[4-{5-Chloro-2-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Enantiomer 2)::US10421742, Example 180::US11180471, Example 180 Coagulation factor XI Homo sapiens 1.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413787 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413787&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205723 433913890 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115764 COCC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C27H22ClF4N5O6/c1-41-8-7-20(24(40)34-14-4-6-16(23(33)39)19(29)10-14)37-12-21(42-2)18(11-22(37)38)17-9-13(28)3-5-15(17)25-35-36-26(43-25)27(30,31)32/h3-6,9-12,20H,7-8H2,1-2H3,(H2,33,39)(H,34,40)/t20-/m0/s1 FGIRAZNDJOPUAW-FQEVSTJZSA-N 413788 4-({(2S)-2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 181::US11180471, Example 181 Coagulation factor XI Homo sapiens 1.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413788 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413788&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205816 433913891 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115765 CCC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H24ClF3N6O4/c1-3-4-22(27(40)33-15-6-7-16(26(32)39)19(29)10-15)36-13-23(41-2)18(11-24(36)38)17-9-14(28)5-8-21(17)37-12-20(25(30)31)34-35-37/h5-13,22,25H,3-4H2,1-2H3,(H2,32,39)(H,33,40)/t22-/m0/s1 WZUXJAUBKKDABN-QFIPXVFZSA-N 413789 4-({(2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 182::US11180471, Example 182 Coagulation factor XI Homo sapiens 3.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413789 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413789&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205866 433913892 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115766 CCC[C@@H](C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H26ClF2N7O4/c1-4-5-22(27(40)33-16-7-8-19(32-12-16)26(39)31-2)36-14-23(41-3)18(11-24(36)38)17-10-15(28)6-9-21(17)37-13-20(25(29)30)34-35-37/h6-14,22,25H,4-5H2,1-3H3,(H,31,39)(H,33,40)/t22-/m0/s1 ZZXQOEFXCPENDW-QFIPXVFZSA-N 413790 5-({(2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanoyl}amino)-N-methylpyridine-2-carboxamide (Enantiomer 2)::US10421742, Example 183::US11180471, Example 183 Coagulation factor XI Homo sapiens 2.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413790 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413790&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205807 433913893 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115767 COc1cn(C(C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C24H19Cl2FN6O4/c1-12(24(36)29-14-4-5-15(23(28)35)18(27)8-14)32-10-20(37-2)17(9-22(32)34)16-7-13(25)3-6-19(16)33-11-21(26)30-31-33/h3-12H,1-2H3,(H2,28,35)(H,29,36) QGNJMTPKSKWTBQ-UHFFFAOYSA-N 413791 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}propanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 184::US11180471, Example 184 Coagulation factor XI Homo sapiens 1.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413791 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413791&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205405 433913894 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115768 COc1cn(C(C)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H19Cl2N7O3/c1-14(25(36)30-16-4-5-19-20(10-16)29-8-7-28-19)33-12-22(37-2)18(11-24(33)35)17-9-15(26)3-6-21(17)34-13-23(27)31-32-34/h3-14H,1-2H3,(H,30,36) BJLPPNMAKGCMOT-UHFFFAOYSA-N 413792 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}propanamide (Racemate)::US10421742, Example 185::US11180471, Example 185 Coagulation factor XI Homo sapiens 0.750 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413792 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413792&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205724 433913895 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115769 COc1cn(C(C)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H21Cl2N7O3/c1-14(25(36)28-17-5-6-20-15(8-17)11-32(2)30-20)33-12-22(37-3)19(10-24(33)35)18-9-16(26)4-7-21(18)34-13-23(27)29-31-34/h4-14H,1-3H3,(H,28,36) GBMNOBITEYOELC-UHFFFAOYSA-N 413793 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)propanamide (Racemate)::US10421742, Example 186::US11180471, Example 186 Coagulation factor XI Homo sapiens 0.650 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413793 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413793&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205501 433913896 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115770 COc1cn(CC(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C23H19ClN8O3/c1-30-10-14-7-16(4-5-19(14)27-30)26-22(33)12-31-11-21(35-2)18(9-23(31)34)17-8-15(24)3-6-20(17)32-13-25-28-29-32/h3-11,13H,12H2,1-2H3,(H,26,33) OGFVUXQMVAVOQF-UHFFFAOYSA-N 413794 2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)acetamide::US10421742, Example 187::US11180471, Example 187 Coagulation factor XI Homo sapiens 1.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413794 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413794&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205510 433913897 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115771 CNC(=O)c1ccc(NC(=O)Cn2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-n2cnnn2)cn1 InChI=1S/C22H19ClN8O4/c1-24-22(34)17-5-4-14(9-25-17)27-20(32)11-30-10-19(35-2)16(8-21(30)33)15-7-13(23)3-6-18(15)31-12-26-28-29-31/h3-10,12H,11H2,1-2H3,(H,24,34)(H,27,32) MPORBPNHVULGJP-UHFFFAOYSA-N 413795 5-[({4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}acetyl)amino]-N-methylpyridine-2-carboxamide::US10421742, Example 188::US11180471, Example 188 Coagulation factor XI Homo sapiens 1.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413795 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413795&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205086 433913898 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115772 COc1cn(CC(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C23H17ClN8O3/c1-35-21-11-31(12-22(33)28-15-3-4-18-19(9-15)26-7-6-25-18)23(34)10-17(21)16-8-14(24)2-5-20(16)32-13-27-29-30-32/h2-11,13H,12H2,1H3,(H,28,33) GOCDCIBQPRFDPL-UHFFFAOYSA-N 413796 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}acetamide::US10421742, Example 189::US11180471, Example 189 Coagulation factor XI Homo sapiens 0.730 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413796 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413796&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205044 433913899 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115773 COc1cn(CC(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C22H17ClN6O5/c1-34-19-10-28(11-20(30)25-15-5-2-13(3-6-15)22(32)33)21(31)9-17(19)16-8-14(23)4-7-18(16)29-12-24-26-27-29/h2-10,12H,11H2,1H3,(H,25,30)(H,32,33) KWIOAPQMNXFJOI-UHFFFAOYSA-N 413797 4-[({4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}acetyl)amino]benzoic acid::US10421742, Example 190::US11180471, Example 190 Coagulation factor XI Homo sapiens 0.650 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413797 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413797&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205876 433913900 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115774 COc1cn(CC(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C22H17ClFN7O4/c1-35-19-9-30(10-20(32)27-13-3-4-14(22(25)34)17(24)7-13)21(33)8-16(19)15-6-12(23)2-5-18(15)31-11-26-28-29-31/h2-9,11H,10H2,1H3,(H2,25,34)(H,27,32) NEENJQHZEIXZHZ-UHFFFAOYSA-N 413798 4-[({4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}acetyl)amino]-2-fluorobenzamide::US10421742, Example 191::US11180471, Example 191 Coagulation factor XI Homo sapiens 1.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413798 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413798&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205431 433913901 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115775 CCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)F InChI=1S/C25H21ClF2N6O4S/c1-3-18(23(37)31-13-5-7-17(22(29)36)30-10-13)34-11-19(38-2)16(9-20(34)35)15-8-12(26)4-6-14(15)24-32-33-25(39-24)21(27)28/h4-11,18,21H,3H2,1-2H3,(H2,29,36)(H,31,37) UMNQYPPSVMIHGW-UHFFFAOYSA-N 413799 5-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 192::US11180471, Example 192 Coagulation factor XI Homo sapiens 4.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413799 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413799&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205370 433913902 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115776 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)F InChI=1S/C26H21ClF3N5O4S/c1-3-19(24(38)32-13-5-7-15(23(31)37)18(28)9-13)35-11-20(39-2)17(10-21(35)36)16-8-12(27)4-6-14(16)25-33-34-26(40-25)22(29)30/h4-11,19,22H,3H2,1-2H3,(H2,31,37)(H,32,38) CTFVRNUYERRNLZ-UHFFFAOYSA-N 413800 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 193::US11180471, Example 193 Coagulation factor XI Homo sapiens 10.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413800 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413800&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205721 433913903 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115777 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)F InChI=1S/C27H23ClF2N6O3S/c1-4-21(25(38)31-16-6-8-20-14(9-16)12-35(2)34-20)36-13-22(39-3)19(11-23(36)37)18-10-15(28)5-7-17(18)26-32-33-27(40-26)24(29)30/h5-13,21,24H,4H2,1-3H3,(H,31,38) DFCBCYSQFOUFPJ-UHFFFAOYSA-N 413801 2-[4-{5-Chloro-2-[5-(difluoroethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 194::US11180471, Example 194 Coagulation factor XI Homo sapiens 5.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413801 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413801&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211537 433913904 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115778 CCC(C(=O)Nc1ccc(C(=O)NC)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)F InChI=1S/C27H23ClF3N5O4S/c1-4-20(25(39)33-14-6-8-16(19(29)10-14)24(38)32-2)36-12-21(40-3)18(11-22(36)37)17-9-13(28)5-7-15(17)26-34-35-27(41-26)23(30)31/h5-12,20,23H,4H2,1-3H3,(H,32,38)(H,33,39) DPAIONDPIWYBAL-UHFFFAOYSA-N 413802 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluoro-N-methylbenzamide (Racemate)::US10421742, Example 195::US11180471, Example 195 Coagulation factor XI Homo sapiens 10.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413802 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413802&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205747 433913905 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115779 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)F InChI=1S/C27H21ClF2N6O3S/c1-3-21(25(38)33-15-5-7-19-20(11-15)32-9-8-31-19)36-13-22(39-2)18(12-23(36)37)17-10-14(28)4-6-16(17)26-34-35-27(40-26)24(29)30/h4-13,21,24H,3H2,1-2H3,(H,33,38) CVGKJPRJDXNZKV-UHFFFAOYSA-N 413803 2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(quinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 196::US11180471, Example 196 Coagulation factor XI Homo sapiens 3.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413803 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413803&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211531 433913906 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115780 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)(F)F InChI=1S/C27H21ClF4N4O5/c1-3-21(26(39)34-14-5-7-16(25(33)38)19(29)9-14)36-12-22(40-2)18(10-24(36)37)17-8-13(28)4-6-15(17)20-11-23(41-35-20)27(30,31)32/h4-12,21H,3H2,1-2H3,(H2,33,38)(H,34,39) VMJCKYNXJRHMKZ-UHFFFAOYSA-N 413804 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 197::US11180471, Example 197 Coagulation factor XI Homo sapiens 6.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413804 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413804&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206067 433913907 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115781 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)(F)F InChI=1S/C28H23ClF3N5O4/c1-4-23(27(39)33-17-6-8-21-15(9-17)13-36(2)34-21)37-14-24(40-3)20(11-26(37)38)19-10-16(29)5-7-18(19)22-12-25(41-35-22)28(30,31)32/h5-14,23H,4H2,1-3H3,(H,33,39) KLVMLPOMRPNVJU-UHFFFAOYSA-N 413805 2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 198::US11180471, Example 198 Coagulation factor XI Homo sapiens 4.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413805 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413805&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205719 433913908 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115782 CCC(C(=O)Nc1ccc2nc([NH3+])ccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2N7O3/c1-3-21(27(38)31-17-6-7-20-15(10-17)4-9-25(30)32-20)35-13-23(39-2)19(12-26(35)37)18-11-16(28)5-8-22(18)36-14-24(29)33-34-36/h4-14,21H,3H2,1-2H3,(H2,30,32)(H,31,38)/p+1 UOFFBMYRFFCNLY-UHFFFAOYSA-O 413806 6-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]quinolin-2-aminium formate (Racemate)::US10421742, Example 199::US11180471, Example 199 Coagulation factor XI Homo sapiens 1.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413806 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413806&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 152948432 433913909 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115783 CCC(C(=O)Nc1ccc2ncc(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2N7O3/c1-4-22(27(38)32-17-6-7-20-21(10-17)31-15(2)12-30-20)35-13-24(39-3)19(11-26(35)37)18-9-16(28)5-8-23(18)36-14-25(29)33-34-36/h5-14,22H,4H2,1-3H3,(H,32,38) SADGBXCCQGIXDH-UHFFFAOYSA-N 413807 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(3-methylquinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 200::US11180471, Example 200 Coagulation factor XI Homo sapiens 1.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413807 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413807&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205297 433913910 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115784 CC[C@@H](C(=O)Nc1ccc2ncc(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2N7O3/c1-4-22(27(38)32-17-6-7-20-21(10-17)31-15(2)12-30-20)35-13-24(39-3)19(11-26(35)37)18-9-16(28)5-8-23(18)36-14-25(29)33-34-36/h5-14,22H,4H2,1-3H3,(H,32,38)/t22-/m0/s1 SADGBXCCQGIXDH-QFIPXVFZSA-N 413808 (S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(3-methylquinoxalin-6-yl)butanamide (Enantiomer 2)::US10421742, Example 201::US11180471, Example 201 Coagulation factor XI Homo sapiens 1.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413808 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413808&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205797 433913911 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115785 CCC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2FN6O4/c1-3-4-21(26(38)31-15-6-7-16(25(30)37)19(29)10-15)34-12-22(39-2)18(11-24(34)36)17-9-14(27)5-8-20(17)35-13-23(28)32-33-35/h5-13,21H,3-4H2,1-2H3,(H2,30,37)(H,31,38)/t21-/m0/s1 KQZYQOJQXJGZMI-NRFANRHFSA-N 413809 4-{[(2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 202::US11180471, Example 202 Coagulation factor XI Homo sapiens 1.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413809 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413809&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205777 433913912 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115786 CCC(C(=O)Nc1ccc2ncc(nc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H20Cl2F3N7O3/c1-3-20(26(41)34-15-5-6-18-19(9-15)35-23(11-33-18)27(30,31)32)38-12-22(42-2)17(10-25(38)40)16-8-14(28)4-7-21(16)39-13-24(29)36-37-39/h4-13,20H,3H2,1-2H3,(H,34,41) ZIDSWWLSQTUOIZ-UHFFFAOYSA-N 413810 2-{4-[5-Chloro-2-(4-chloro-1H-H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[3-(trifluoromethyl)quinoxalin-6-yl]butanamide (Racemate)::US10421742, Example 203::US10421742, Example 205::US11180471, Example 203 Coagulation factor XI Homo sapiens 11.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413810 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413810&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211523 433913913 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115787 CCC(C(=O)Nc1ccc2nc(cnc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H20Cl2F3N7O3/c1-3-20(26(41)34-15-5-6-18-19(9-15)33-11-23(35-18)27(30,31)32)38-12-22(42-2)17(10-25(38)40)16-8-14(28)4-7-21(16)39-13-24(29)36-37-39/h4-13,20H,3H2,1-2H3,(H,34,41) AGDBQILBKXGVMA-UHFFFAOYSA-N 413811 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(trifluoromethyl)quinoxalin-6-yl]butanamide (Racemate)::US10421742, Example 204::US10421742, Example 206::US11180471, Example 204 Coagulation factor XI Homo sapiens 3.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413811 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413811&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205251 433913914 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115788 CCC(C(=O)Nc1ccc2ncc(nc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C28H20ClF6N7O3/c1-3-20(26(44)37-15-5-6-18-19(9-15)38-23(11-36-18)27(30,31)32)41-12-22(45-2)17(10-25(41)43)16-8-14(29)4-7-21(16)42-13-24(39-40-42)28(33,34)35/h4-13,20H,3H2,1-2H3,(H,37,44) HFIYSVHJSLVEKM-UHFFFAOYSA-N 528227 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[3-(trifluoromethyl)quinoxalin-6-yl]butanamide (racemate)::US11180471, Example 205 Coagulation factor XI Homo sapiens 17.0 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528227 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528227&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205528 463791769 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115789 CCC(C(=O)Nc1ccc2nc(cnc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C28H20ClF6N7O3/c1-3-20(26(44)37-15-5-6-18-19(9-15)36-11-23(38-18)27(30,31)32)41-12-22(45-2)17(10-25(41)43)16-8-14(29)4-7-21(16)42-13-24(39-40-42)28(33,34)35/h4-13,20H,3H2,1-2H3,(H,37,44) NCZFXYVMXDGJAQ-UHFFFAOYSA-N 528228 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[2-(trifluoromethyl)quinoxalin-6-yl]butanamide (racemate)::US11180471, Example 206 Coagulation factor XI Homo sapiens 5.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528228 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528228&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205616 463791770 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115790 CCC(C(=O)Nc1ccc2cnncc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2N7O3/c1-3-21(26(37)31-18-6-4-15-11-29-30-12-16(15)8-18)34-13-23(38-2)20(10-25(34)36)19-9-17(27)5-7-22(19)35-14-24(28)32-33-35/h4-14,21H,3H2,1-2H3,(H,31,37) UENKHDMGQRVXOA-UHFFFAOYSA-N 413814 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(phthalazin-6-yl)butanamide (Racemate)::US10421742, Example 207::US10421742, Example 208::US11180471, Example 207 Coagulation factor XI Homo sapiens 2.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413814 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413814&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205592 433913915 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115791 CCC(C(=O)Nc1ccc2cnncc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C27H21ClF3N7O3/c1-3-21(26(40)34-18-6-4-15-11-32-33-12-16(15)8-18)37-13-23(41-2)20(10-25(37)39)19-9-17(28)5-7-22(19)38-14-24(35-36-38)27(29,30)31/h4-14,21H,3H2,1-2H3,(H,34,40) AWJUPCORVZXGJV-UHFFFAOYSA-N 528230 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(phthalazin-6-yl)butanamide (racemate)::US11180471, Example 208 Coagulation factor XI Homo sapiens 1.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528230 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528230&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206097 463791772 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115792 CCC(C(=O)Nc1ccc2nn(cc2c1)C(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H22ClF4N7O3/c1-3-21(26(41)33-16-5-6-19-14(8-16)11-39(35-19)27(31)32)37-13-23(42-2)18(10-24(37)40)17-9-15(28)4-7-22(17)38-12-20(25(29)30)34-36-38/h4-13,21,25,27H,3H2,1-2H3,(H,33,41) METWKYXLYOAEDA-UHFFFAOYSA-N 413816 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[2-(difluoromethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 209::US11180471, Example 209 Coagulation factor XI Homo sapiens 1.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413816 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413816&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205934 433913916 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115793 CC[C@@H](C(=O)Nc1ccc2nn(cc2c1)C(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H22ClF4N7O3/c1-3-21(26(41)33-16-5-6-19-14(8-16)11-39(35-19)27(31)32)37-13-23(42-2)18(10-24(37)40)17-9-15(28)4-7-22(17)38-12-20(25(29)30)34-36-38/h4-13,21,25,27H,3H2,1-2H3,(H,33,41)/t21-/m0/s1 METWKYXLYOAEDA-NRFANRHFSA-N 413817 (2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[2-(difluoromethyl)-2H-indazol-5-yl]butanamide (Enantiomer 2)::US10421742, Example 210::US11180471, Example 210 Coagulation factor XI Homo sapiens 0.780 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413817 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413817&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206066 433913917 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115794 CCC(C(=O)Nc1ccc2nn(cc2c1)C(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2F2N7O3/c1-3-20(25(39)31-16-5-6-19-14(8-16)11-37(33-19)26(29)30)35-12-22(40-2)18(10-24(35)38)17-9-15(27)4-7-21(17)36-13-23(28)32-34-36/h4-13,20,26H,3H2,1-2H3,(H,31,39) ZXSDTWYIYKNDSR-UHFFFAOYSA-N 413818 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(difluoromethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 211::US11180471, Example 211 Coagulation factor XI Homo sapiens 1.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413818 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413818&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204866 433913918 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115795 CC[C@@H](C(=O)Nc1ccc2nn(cc2c1)C(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2F2N7O3/c1-3-20(25(39)31-16-5-6-19-14(8-16)11-37(33-19)26(29)30)35-12-22(40-2)18(10-24(35)38)17-9-15(27)4-7-21(17)36-13-23(28)32-34-36/h4-13,20,26H,3H2,1-2H3,(H,31,39)/t20-/m0/s1 ZXSDTWYIYKNDSR-FQEVSTJZSA-N 413819 (2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(difluoromethyl)-2H-indazol-5-yl]butanamide (Enantiomer 2)::US10421742, Example 212::US11180471, Example 212 Coagulation factor XI Homo sapiens 0.980 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413819 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413819&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206089 433913919 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115796 CCC(C(=O)Nc1ccc2nn(CC3CC3)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C29H27Cl2N7O3/c1-3-24(29(40)32-20-7-8-23-18(10-20)14-36(34-23)13-17-4-5-17)37-15-26(41-2)22(12-28(37)39)21-11-19(30)6-9-25(21)38-16-27(31)33-35-38/h6-12,14-17,24H,3-5,13H2,1-2H3,(H,32,40) TXLDRSXSUKQIEC-UHFFFAOYSA-N 413820 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(cyclopropylmethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 213::US11180471, Example 213 Coagulation factor XI Homo sapiens 3.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413820 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413820&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206022 433913920 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115797 COc1cn(C(CC(F)F)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H19Cl2F3N6O4/c1-40-20-10-35(19(9-22(29)30)25(39)32-13-3-4-14(24(31)38)17(28)7-13)23(37)8-16(20)15-6-12(26)2-5-18(15)36-11-21(27)33-34-36/h2-8,10-11,19,22H,9H2,1H3,(H2,31,38)(H,32,39) VICLFWRBPGESJU-UHFFFAOYSA-N 413821 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4,4-difluorobutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 214::US11180471, Example 214 Coagulation factor XI Homo sapiens 2.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413821 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413821&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206005 433913921 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115798 CCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)(F)F InChI=1S/C26H22ClF3N6O4S/c1-4-19(23(39)33-14-6-8-18(32-11-14)22(38)31-2)36-12-20(40-3)17(10-21(36)37)16-9-13(27)5-7-15(16)24-34-35-25(41-24)26(28,29)30/h5-12,19H,4H2,1-3H3,(H,31,38)(H,33,39) MTUVSPCBSRPPFH-UHFFFAOYSA-N 413822 5-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 215::US11180471, Example 215 Coagulation factor XI Homo sapiens 4.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413822 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413822&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205910 433913922 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115799 COc1cn(C(CC(F)F)C(=O)Nc2ccc3nn(cc3c2)C(F)F)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H19Cl2F4N7O3/c1-42-21-11-37(24(40)8-17(21)16-7-14(27)2-5-19(16)38-12-22(28)34-36-38)20(9-23(29)30)25(41)33-15-3-4-18-13(6-15)10-39(35-18)26(31)32/h2-8,10-12,20,23,26H,9H2,1H3,(H,33,41) RTIMPDQMXMBUMW-UHFFFAOYSA-N 413823 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(difluoromethyl)-2H-indazol-5-yl]-4,4-difluorobutanamide (Racemate)::US10421742, Example 216::US11180471, Example 216 Coagulation factor XI Homo sapiens 7.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413823 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413823&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204789 433913923 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115800 COc1cn(C(CC(F)F)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H19Cl2F2N7O3/c1-40-22-12-36(21(11-24(29)30)26(39)33-15-3-4-18-19(9-15)32-7-6-31-18)25(38)10-17(22)16-8-14(27)2-5-20(16)37-13-23(28)34-35-37/h2-10,12-13,21,24H,11H2,1H3,(H,33,39) SATGRGDFTKEDOC-UHFFFAOYSA-N 413824 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4,4-difluoro-N-(quinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 217::US11180471, Example 217 Coagulation factor XI Homo sapiens 1.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413824 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413824&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205462 433913924 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115801 COc1cn(C(CC(F)F)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2F2N7O3/c1-35-11-14-7-16(4-5-19(14)33-35)31-26(39)21(10-24(29)30)36-12-22(40-2)18(9-25(36)38)17-8-15(27)3-6-20(17)37-13-23(28)32-34-37/h3-9,11-13,21,24H,10H2,1-2H3,(H,31,39) SVTFEVREYQHXOM-UHFFFAOYSA-N 413825 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4,4-difluoro-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 218::US11180471, Example 218 Coagulation factor XI Homo sapiens 2.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413825 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413825&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205201 433913925 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115802 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)(F)F InChI=1S/C26H20ClF4N5O4S/c1-3-19(23(39)33-13-5-7-15(22(32)38)18(28)9-13)36-11-20(40-2)17(10-21(36)37)16-8-12(27)4-6-14(16)24-34-35-25(41-24)26(29,30)31/h4-11,19H,3H2,1-2H3,(H2,32,38)(H,33,39) XRCANQJWEYJRNE-UHFFFAOYSA-N 413826 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 219::US11180471, Example 219 Coagulation factor XI Homo sapiens 6.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413826 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413826&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205452 433913926 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115803 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)(F)F InChI=1S/C27H22ClF3N6O3S/c1-4-21(24(39)32-16-6-8-20-14(9-16)12-36(2)35-20)37-13-22(40-3)19(11-23(37)38)18-10-15(28)5-7-17(18)25-33-34-26(41-25)27(29,30)31/h5-13,21H,4H2,1-3H3,(H,32,39) HCRLZPHBOLGRPG-UHFFFAOYSA-N 413827 2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 220::US11180471, Example 220 Coagulation factor XI Homo sapiens 3.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413827 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413827&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206083 433913927 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115804 CCC(C(=O)Nc1ccc2nc(C)cnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2N7O3/c1-4-22(27(38)32-17-6-7-20-21(10-17)30-12-15(2)31-20)35-13-24(39-3)19(11-26(35)37)18-9-16(28)5-8-23(18)36-14-25(29)33-34-36/h5-14,22H,4H2,1-3H3,(H,32,38) NINJGBVHUFUANQ-UHFFFAOYSA-N 413828 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methylquinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 221::US11180471, Example 221 Coagulation factor XI Homo sapiens 1.000 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413828 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413828&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205262 433913928 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115805 CCC(C(=O)Nc1ccc2nc(C)c(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C28H25Cl2N7O3/c1-5-23(28(39)33-18-7-8-21-22(11-18)32-16(3)15(2)31-21)36-13-25(40-4)20(12-27(36)38)19-10-17(29)6-9-24(19)37-14-26(30)34-35-37/h6-14,23H,5H2,1-4H3,(H,33,39) PQLJHTCQQFICKU-UHFFFAOYSA-N 413829 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2,3-dimethylquinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 222::US11180471, Example 222 Coagulation factor XI Homo sapiens 1.20 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413829 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413829&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205457 433913929 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115806 CCC(C(=O)Nc1ccc2ncccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H22Cl2N6O3/c1-3-22(27(37)31-18-7-8-21-16(11-18)5-4-10-30-21)34-14-24(38-2)20(13-26(34)36)19-12-17(28)6-9-23(19)35-15-25(29)32-33-35/h4-15,22H,3H2,1-2H3,(H,31,37) FTLCKEYXULODRH-UHFFFAOYSA-N 413830 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(quinolin-6-yl)butanamide (Racemate)::US10421742, Example 223::US11180471, Example 223 Coagulation factor XI Homo sapiens 1.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413830 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413830&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211524 433913930 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115807 CCC(C(=O)Nc1ccc2cccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H22Cl2N6O3/c1-3-22(27(37)31-18-8-6-16-5-4-10-30-21(16)12-18)34-14-24(38-2)20(13-26(34)36)19-11-17(28)7-9-23(19)35-15-25(29)32-33-35/h4-15,22H,3H2,1-2H3,(H,31,37) FQMWRNFRVKBREN-UHFFFAOYSA-N 413831 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(quinolin-7-yl)butanamide (Racemate)::US10421742, Example 224::US11180471, Example 224 Coagulation factor XI Homo sapiens 3.40 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413831 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413831&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205567 433913931 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115808 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2N7O3/c1-4-21(26(37)29-17-6-7-20-15(9-17)12-33(2)31-20)34-13-23(38-3)19(11-25(34)36)18-10-16(27)5-8-22(18)35-14-24(28)30-32-35/h5-14,21H,4H2,1-3H3,(H,29,37) QBWXHIMIUSZAOP-UHFFFAOYSA-N 413774 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 167::US10421742, Example 225::US11180471, Example 225 Coagulation factor XI Homo sapiens 1.000 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413774 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413774&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205467 433913877 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115809 CCC(C(=O)Nc1ccc2nn(CC(F)F)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2F2N7O3/c1-3-21(27(40)32-17-5-6-20-15(8-17)11-36(34-20)14-25(30)31)37-12-23(41-2)19(10-26(37)39)18-9-16(28)4-7-22(18)38-13-24(29)33-35-38/h4-13,21,25H,3,14H2,1-2H3,(H,32,40) GTOBEZUWBRGMLK-UHFFFAOYSA-N 413833 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(2,2-difluoroethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 226::US11180471, Example 226 Coagulation factor XI Homo sapiens 1.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413833 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413833&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205643 433913932 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115810 CCC(C(=O)Nc1ccc2nn(CC(F)(F)F)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H22Cl2F3N7O3/c1-3-21(26(41)33-17-5-6-20-15(8-17)11-37(35-20)14-27(30,31)32)38-12-23(42-2)19(10-25(38)40)18-9-16(28)4-7-22(18)39-13-24(29)34-36-39/h4-13,21H,3,14H2,1-2H3,(H,33,41) DBBPDYZRKMIZOJ-UHFFFAOYSA-N 413834 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(2,2,2-trifluoroethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 227::US11180471, Example 227 Coagulation factor XI Homo sapiens 1.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413834 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413834&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204990 433913933 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115811 CCC(C(=O)Nc1ccc2nc(C)ccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C28H24Cl2N6O3/c1-4-23(28(38)32-19-8-9-22-17(11-19)6-5-16(2)31-22)35-14-25(39-3)21(13-27(35)37)20-12-18(29)7-10-24(20)36-15-26(30)33-34-36/h5-15,23H,4H2,1-3H3,(H,32,38) AZYMEDAZJNOBLR-UHFFFAOYSA-N 413835 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methylquinolin-6-yl)butanamide (Racemate)::US10421742, Example 228::US11180471, Example 228 Coagulation factor XI Homo sapiens 1.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413835 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413835&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205176 433913934 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115812 CCC(C(=O)Nc1ccc2nc(C)ccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H25ClF2N6O3/c1-4-24(29(40)34-19-8-9-22-17(11-19)6-5-16(2)33-22)37-15-26(41-3)21(13-27(37)39)20-12-18(30)7-10-25(20)38-14-23(28(31)32)35-36-38/h5-15,24,28H,4H2,1-3H3,(H,34,40) FVOIRKKFLDCVKH-UHFFFAOYSA-N 413836 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methylquinolin-6-yl)butanamide (Racemate)::US10421742, Example 229::US11180471, Example 229 Coagulation factor XI Homo sapiens 1.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413836 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413836&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205284 433913935 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115813 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C26H22ClF3N6O4/c1-3-20(26(39)32-14-5-6-15(25(31)38)18(28)9-14)35-12-22(40-2)17(10-23(35)37)16-8-13(27)4-7-21(16)36-11-19(24(29)30)33-34-36/h4-12,20,24H,3H2,1-2H3,(H2,31,38)(H,32,39) OETZVLILMHLZTG-UHFFFAOYSA-N 413767 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 160::US11180471, Example 230 Coagulation factor XI Homo sapiens 2.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413767 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413767&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205282 433913870 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115814 CCC[C@@H](C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H24ClF2N7O3/c1-3-4-24(28(40)34-17-6-7-20-21(12-17)33-10-9-32-20)37-15-25(41-2)19(13-26(37)39)18-11-16(29)5-8-23(18)38-14-22(27(30)31)35-36-38/h5-15,24,27H,3-4H2,1-2H3,(H,34,40)/t24-/m0/s1 NKCIMLZZOJBOGZ-DEOSSOPVSA-N 413838 (2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(quinoxalin-6-yl)pentanamide (Enantiomer 2)::US10421742, Example 231::US11180471, Example 231 Coagulation factor XI Homo sapiens 1.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413838 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413838&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135204967 433913937 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115815 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C27H23ClF3N7O3/c1-4-21(26(40)32-17-6-7-20-15(9-17)12-36(2)34-20)37-13-23(41-3)19(11-25(37)39)18-10-16(28)5-8-22(18)38-14-24(33-35-38)27(29,30)31/h5-14,21H,4H2,1-3H3,(H,32,40) YXQQDNTZJAXMNL-UHFFFAOYSA-N 413839 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 232::US11180471, Example 232 Coagulation factor XI Homo sapiens 1.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413839 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413839&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205554 433913938 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115816 CC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C27H23ClF3N7O3/c1-4-21(26(40)32-17-6-7-20-15(9-17)12-36(2)34-20)37-13-23(41-3)19(11-25(37)39)18-10-16(28)5-8-22(18)38-14-24(33-35-38)27(29,30)31/h5-14,21H,4H2,1-3H3,(H,32,40)/t21-/m0/s1 YXQQDNTZJAXMNL-NRFANRHFSA-N 413840 (2S)-2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Enantiomer 2)::US10421742, Example 233::US11180471, Example 233 Coagulation factor XI Homo sapiens 0.790 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413840 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413840&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205553 433913939 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115817 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C26H21ClF4N6O4/c1-3-19(25(40)33-14-5-6-15(24(32)39)18(28)9-14)36-11-21(41-2)17(10-23(36)38)16-8-13(27)4-7-20(16)37-12-22(34-35-37)26(29,30)31/h4-12,19H,3H2,1-2H3,(H2,32,39)(H,33,40) XYWIPYBIIRTJMM-UHFFFAOYSA-N 413841 4-({2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 234::US11180471, Example 234 Coagulation factor XI Homo sapiens 1.50 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413841 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413841&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205380 433913940 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115818 CC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C26H21ClF4N6O4/c1-3-19(25(40)33-14-5-6-15(24(32)39)18(28)9-14)36-11-21(41-2)17(10-23(36)38)16-8-13(27)4-7-20(16)37-12-22(34-35-37)26(29,30)31/h4-12,19H,3H2,1-2H3,(H2,32,39)(H,33,40)/t19-/m0/s1 XYWIPYBIIRTJMM-IBGZPJMESA-N 413842 4-({(2S)-2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 235::US11180471, Example 235 Coagulation factor XI Homo sapiens 0.920 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413842 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413842&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206011 433913941 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115819 CCC(C(=O)Nc1ccc2nc(C)c(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C29H25ClF3N7O3/c1-5-23(28(42)36-18-7-8-21-22(11-18)35-16(3)15(2)34-21)39-13-25(43-4)20(12-27(39)41)19-10-17(30)6-9-24(19)40-14-26(37-38-40)29(31,32)33/h6-14,23H,5H2,1-4H3,(H,36,42) UDQDURKQOJZYOA-UHFFFAOYSA-N 413843 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2,3-dimethylquinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 236::US11180471, Example 236 Coagulation factor XI Homo sapiens 1.80 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413843 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413843&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205535 433913942 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115820 CC[C@@H](C(=O)Nc1ccc2nc(C)c(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C29H25ClF3N7O3/c1-5-23(28(42)36-18-7-8-21-22(11-18)35-16(3)15(2)34-21)39-13-25(43-4)20(12-27(39)41)19-10-17(30)6-9-24(19)40-14-26(37-38-40)29(31,32)33/h6-14,23H,5H2,1-4H3,(H,36,42)/t23-/m0/s1 UDQDURKQOJZYOA-QHCPKHFHSA-N 413844 (2S)-2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2,3-dimethylquinoxalin-6-yl)butanamide (Enantiomer 2)::US10421742, Example 237::US11180471, Example 237 Coagulation factor XI Homo sapiens 0.890 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413844 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413844&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205533 433913943 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115821 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnc(o1)C(F)F InChI=1S/C27H22ClF2N3O6/c1-3-20(25(35)32-16-7-4-14(5-8-16)27(36)37)33-13-22(38-2)19(11-23(33)34)18-10-15(28)6-9-17(18)21-12-31-26(39-21)24(29)30/h4-13,20,24H,3H2,1-2H3,(H,32,35)(H,36,37) QFFBKCKFGNVYBW-UHFFFAOYSA-N 413845 4-({2-[4-{5-Chloro-2-[2-(difluoromethyl)-1,3-oxazol-5-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)benzoic acid (Racemate)::US10421742, Example 238::US11180471, Example 238 Coagulation factor XI Homo sapiens 10.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413845 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413845&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205970 433913944 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115822 COc1cn(C(C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C25H19ClF4N6O4/c1-12(24(39)32-14-4-5-15(23(31)38)18(27)8-14)35-10-20(40-2)17(9-22(35)37)16-7-13(26)3-6-19(16)36-11-21(33-34-36)25(28,29)30/h3-12H,1-2H3,(H2,31,38)(H,32,39) SNUMNATTXKTJQD-UHFFFAOYSA-N 413846 4-({2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]propanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 239::US11180471, Example 239 Coagulation factor XI Homo sapiens 0.890 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413846 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413846&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205033 433913945 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115823 COc1cn([C@@H](C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C24H19Cl2FN6O4/c1-12(24(36)29-14-4-5-15(23(28)35)18(27)8-14)32-10-20(37-2)17(9-22(32)34)16-7-13(25)3-6-19(16)33-11-21(26)30-31-33/h3-12H,1-2H3,(H2,28,35)(H,29,36)/t12-/m0/s1 QGNJMTPKSKWTBQ-LBPRGKRZSA-N 413847 4-{[(2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}propanoyl]amino}-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 240::US11180471, Example 240 Coagulation factor XI Homo sapiens 0.640 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413847 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413847&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205642 433913946 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115824 COc1cn([C@@H](C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C25H20ClF3N6O4/c1-12(25(38)31-14-4-5-15(24(30)37)18(27)8-14)34-11-21(39-2)17(9-22(34)36)16-7-13(26)3-6-20(16)35-10-19(23(28)29)32-33-35/h3-12,23H,1-2H3,(H2,30,37)(H,31,38)/t12-/m0/s1 JVCAULOQATWKKF-LBPRGKRZSA-N 413848 4-({(2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]propanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 241::US11180471, Example 241 Coagulation factor XI Homo sapiens 0.980 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413848 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413848&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205975 433913947 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115825 CC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H21Cl2FN6O4/c1-3-19(25(37)30-14-5-6-15(24(29)36)18(28)9-14)33-11-21(38-2)17(10-23(33)35)16-8-13(26)4-7-20(16)34-12-22(27)31-32-34/h4-12,19H,3H2,1-2H3,(H2,29,36)(H,30,37)/t19-/m0/s1 FPAKZDLGEHHCTC-IBGZPJMESA-N 413849 4-{[(2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl]amino}-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 242::US11180471, Example 242 Coagulation factor XI Homo sapiens 0.890 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413849 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413849&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205798 433913948 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115826 CC[C@@H](C(=O)Nc1ccc2nc(C)ccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H25ClF2N6O3/c1-4-24(29(40)34-19-8-9-22-17(11-19)6-5-16(2)33-22)37-15-26(41-3)21(13-27(37)39)20-12-18(30)7-10-25(20)38-14-23(28(31)32)35-36-38/h5-15,24,28H,4H2,1-3H3,(H,34,40)/t24-/m0/s1 FVOIRKKFLDCVKH-DEOSSOPVSA-N 413850 (2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methylquinolin-6-yl)butanamide (Enantiomer 2)::US10421742, Example 243::US11180471, Example 243 Coagulation factor XI Homo sapiens 0.870 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413850 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413850&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205377 433913949 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115827 CC[C@@H](C(=O)Nc1ccc2nc(C)ccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C28H24Cl2N6O3/c1-4-23(28(38)32-19-8-9-22-17(11-19)6-5-16(2)31-22)35-14-25(39-3)21(13-27(35)37)20-12-18(29)7-10-24(20)36-15-26(30)33-34-36/h5-15,23H,4H2,1-3H3,(H,32,38)/t23-/m0/s1 AZYMEDAZJNOBLR-QHCPKHFHSA-N 413851 (2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methylquinolin-6-yl)butanamide (Enantiomer 2)::US10421742, Example 244::US11180471, Example 244 Coagulation factor XI Homo sapiens 0.650 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413851 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413851&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205851 433913950 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115828 CCC(C(=O)Nc1ccc2nn(C)c(C)c2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O3/c1-5-22(27(38)30-17-7-8-21-18(11-17)15(2)34(3)32-21)35-13-24(39-4)20(12-26(35)37)19-10-16(28)6-9-23(19)36-14-25(29)31-33-36/h6-14,22H,5H2,1-4H3,(H,30,38) SBXOMGIKOINZME-UHFFFAOYSA-N 413852 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2,3-dimethyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 245::US11180471, Example 245 Coagulation factor XI Homo sapiens 2.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413852 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413852&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205409 433913951 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115829 CCC(C(=O)Nc1ccc2nn(C)c(C)c2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C28H25ClF3N7O3/c1-5-22(27(41)33-17-7-8-21-18(11-17)15(2)37(3)35-21)38-13-24(42-4)20(12-26(38)40)19-10-16(29)6-9-23(19)39-14-25(34-36-39)28(30,31)32/h6-14,22H,5H2,1-4H3,(H,33,41) MKSVLCRJUVAEQS-UHFFFAOYSA-N 413853 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2,3-dimethyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 246::US11180471, Example 246 Coagulation factor XI Homo sapiens 1.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413853 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413853&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205407 433913952 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115830 CCC(C(=O)Nc1ccc2nc(ccc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C28H21Cl2F3N6O3/c1-3-21(27(41)34-17-6-7-20-15(10-17)4-9-24(35-20)28(31,32)33)38-13-23(42-2)19(12-26(38)40)18-11-16(29)5-8-22(18)39-14-25(30)36-37-39/h4-14,21H,3H2,1-2H3,(H,34,41) SEVBXRKORJAERT-UHFFFAOYSA-N 413854 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(trifluoromethyl)quinolin-6-yl]butanamide (Racemate)::US10421742, Example 247::US11180471, Example 247 Coagulation factor XI Homo sapiens 6.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413854 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413854&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205363 433913953 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115831 CCC(C(=O)Nc1ccc2nc(ccc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H22ClF5N6O3/c1-3-22(28(43)36-17-6-7-20-15(10-17)4-9-25(37-20)29(33,34)35)40-14-24(44-2)19(12-26(40)42)18-11-16(30)5-8-23(18)41-13-21(27(31)32)38-39-41/h4-14,22,27H,3H2,1-2H3,(H,36,43) SDQAOZYYHXEPNT-UHFFFAOYSA-N 413855 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[2-(trifluoromethyl)quinolin-6-yl]butanamide (Racemate)::US10421742, Example 248::US11180471, Example 248 Coagulation factor XI Homo sapiens 7.90 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413855 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413855&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205958 433913954 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115832 CCC(C(=O)Nc1ccc2nn(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H22Cl2N8O3/c1-4-20(25(37)28-15-6-7-18-19(10-15)31-33(2)30-18)34-12-22(38-3)17(11-24(34)36)16-9-14(26)5-8-21(16)35-13-23(27)29-32-35/h5-13,20H,4H2,1-3H3,(H,28,37) LZHGUODYTWJFHC-UHFFFAOYSA-N 413856 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-benzotriazol-5-yl)butanamide (Racemate)::US10421742, Example 249::US11180471, Example 249 Coagulation factor XI Homo sapiens 4.10 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413856 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413856&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205352 433913955 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115833 CCC(C(=O)Nc1ccc2nn(CC)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O3/c1-4-22(27(38)30-18-7-8-21-16(10-18)13-34(5-2)32-21)35-14-24(39-3)20(12-26(35)37)19-11-17(28)6-9-23(19)36-15-25(29)31-33-36/h6-15,22H,4-5H2,1-3H3,(H,30,38) MSUOXKMCLUJSJC-UHFFFAOYSA-N 528272 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-ethyl-2H-indazol-5-yl)butanamide (racemate)::US11180471, Example 250 Coagulation factor XI Homo sapiens 1.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528272 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528272&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135206108 463791812 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115834 COc1cn([C@@H](C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C25H19ClF4N6O4/c1-12(24(39)32-14-4-5-15(23(31)38)18(27)8-14)35-10-20(40-2)17(9-22(35)37)16-7-13(26)3-6-19(16)36-11-21(33-34-36)25(28,29)30/h3-12H,1-2H3,(H2,31,38)(H,32,39)/t12-/m0/s1 SNUMNATTXKTJQD-LBPRGKRZSA-N 413858 4-({(2S)-2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]propanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 251::US11180471, Example 251 Coagulation factor XI Homo sapiens 0.740 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413858 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413858&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205940 433913957 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115835 CCC(C(=O)Nc1ccc2nc(ccc2c1)C#N)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H22ClF2N7O3/c1-3-24(29(41)35-18-7-8-22-16(10-18)4-6-19(13-33)34-22)38-15-26(42-2)21(12-27(38)40)20-11-17(30)5-9-25(20)39-14-23(28(31)32)36-37-39/h4-12,14-15,24,28H,3H2,1-2H3,(H,35,41) DERODARCDQXYDI-UHFFFAOYSA-N 413859 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-cyanoquinolin-6-yl)butanamide (Racemate)::US10421742, Example 252::US11180471, Example 252 Coagulation factor XI Homo sapiens 3.00 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413859 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413859&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205841 433913958 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115836 CCC(C(=O)Nc1ccc2nc(ccc2c1)C#N)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C28H21Cl2N7O3/c1-3-23(28(39)33-18-7-8-22-16(10-18)4-6-19(13-31)32-22)36-14-25(40-2)21(12-27(36)38)20-11-17(29)5-9-24(20)37-15-26(30)34-35-37/h4-12,14-15,23H,3H2,1-2H3,(H,33,39) QCAYWCRUVAGYIH-UHFFFAOYSA-N 413860 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-cyanoquinolin-6-yl)butanamide (Racemate)::US10421742, Example 253::US11180471, Example 253 Coagulation factor XI Homo sapiens 2.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413860 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413860&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135211506 433913959 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115837 CCC(C(=O)Nc1ccc2nn(CCO)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O4/c1-3-22(27(39)30-18-5-6-21-16(10-18)13-34(32-21)8-9-37)35-14-24(40-2)20(12-26(35)38)19-11-17(28)4-7-23(19)36-15-25(29)31-33-36/h4-7,10-15,22,37H,3,8-9H2,1-2H3,(H,30,39) CJLPNFNSEYZOKO-UHFFFAOYSA-N 413861 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(2-hydroxyethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 254::US11180471, Example 254 Coagulation factor XI Homo sapiens 0.810 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413861 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413861&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205337 433913960 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115838 CCC(C(=O)Nc1ccc2nn(CCO)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H26ClF2N7O4/c1-3-23(28(41)32-18-5-6-21-16(10-18)13-36(34-21)8-9-39)37-15-25(42-2)20(12-26(37)40)19-11-17(29)4-7-24(19)38-14-22(27(30)31)33-35-38/h4-7,10-15,23,27,39H,3,8-9H2,1-2H3,(H,32,41) ZWZWZPJQIZBWFH-UHFFFAOYSA-N 413862 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[2-(2-hydroxyethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 255::US11180471, Example 255 Coagulation factor XI Homo sapiens 1.70 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413862 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413862&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205193 433913961 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115839 CCC(C(=O)Nc1ccc2[nH]nc(c2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 413863 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[3-(trifluoromethyl)-1H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 256::US11180471, Example 256 Coagulation factor XI Homo sapiens 6.30 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413863 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413863&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205900 433913962 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115840 COc1cn([C@@H](CC(F)F)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H19Cl2F2N7O3/c1-40-22-12-36(21(11-24(29)30)26(39)33-15-3-4-18-19(9-15)32-7-6-31-18)25(38)10-17(22)16-8-14(27)2-5-20(16)37-13-23(28)34-35-37/h2-10,12-13,21,24H,11H2,1H3,(H,33,39)/t21-/m0/s1 SATGRGDFTKEDOC-NRFANRHFSA-N 413864 (2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4,4-difluoro-N-(quinoxalin-6-yl)butanamide (Enantiomer 2)::US10421742, Example 257::US11180471, Example 257 Coagulation factor XI Homo sapiens 0.850 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413864 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413864&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205541 433913963 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115841 CCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C27H23ClF4N6O4/c1-3-4-21(26(41)34-15-6-7-16(25(33)40)19(29)10-15)37-12-22(42-2)18(11-24(37)39)17-9-14(28)5-8-20(17)38-13-23(35-36-38)27(30,31)32/h5-13,21H,3-4H2,1-2H3,(H2,33,40)(H,34,41) FQRNHVWJUMYDQS-UHFFFAOYSA-N 413865 4-({2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 258::US11180471, Example 258 Coagulation factor XI Homo sapiens 4.60 US Patent 10.7270/Q2W09935 aid1806148 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413865 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413865&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 135205430 433913964 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 1XX9,2F83,2J8J,2J8L,4NA7,4NA8,5EOD,5EOK,5I25,6I58,7QOT Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 1115842 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C30H30ClN3O7/c1-30(2,3)41-12-11-24(28(36)33-20-8-5-18(6-9-20)29(37)38)34-16-26(39-4)23(14-27(34)35)22-13-19(31)7-10-21(22)25-15-32-17-40-25/h5-10,13-17,24H,11-12H2,1-4H3,(H,33,36)(H,37,38) WPCCHOKPWHOVEL-UHFFFAOYSA-N 413602 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 1::US11180471, Example 1 Plasma kallikrein Human 41.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413602 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413602&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205829 433913710 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115843 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C31H32ClN5O5/c1-31(2,3)42-11-10-26(30(39)34-21-7-9-25-19(12-21)16-36(4)35-25)37-17-28(40-5)24(14-29(37)38)23-13-20(32)6-8-22(23)27-15-33-18-41-27/h6-9,12-18,26H,10-11H2,1-5H3,(H,34,39) XCQGMIZGIJYINH-UHFFFAOYSA-N 413603 4-tert-Butoxy-2-{4-[5-chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 2::US11180471, Example 2 Plasma kallikrein Human 29.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413603 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413603&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205678 433913711 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115844 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C26H22ClN3O6/c1-3-21(25(32)29-17-7-4-15(5-8-17)26(33)34)30-13-23(35-2)20(11-24(30)31)19-10-16(27)6-9-18(19)22-12-28-14-36-22/h4-14,21H,3H2,1-2H3,(H,29,32)(H,33,34) IXCUXZHAJIAIIU-UHFFFAOYSA-N 413604 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 3::US11180471, Example 3 Plasma kallikrein Human 110 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413604 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413604&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205676 433913712 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115845 COc1cn(C(CCOC(F)(F)F)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C27H21ClF3N3O7/c1-39-23-13-34(24(35)11-20(23)19-10-16(28)4-7-18(19)22-12-32-14-40-22)21(8-9-41-27(29,30)31)25(36)33-17-5-2-15(3-6-17)26(37)38/h2-7,10-14,21H,8-9H2,1H3,(H,33,36)(H,37,38) BNAZVDSXUSMSQR-UHFFFAOYSA-N 413605 4-{[2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-(trifluoromethoxy)butanoyl]amino}benzoic acid (Racemate)::US10421742, Example 4::US11180471, Example 4 Plasma kallikrein Human 53.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413605 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413605&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204648 433913713 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115846 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C30H28ClN3O7/c1-39-27-16-34(28(35)14-24(27)23-12-19(31)7-10-22(23)26-15-32-17-41-26)25(13-21-4-2-3-11-40-21)29(36)33-20-8-5-18(6-9-20)30(37)38/h5-10,12,14-17,21,25H,2-4,11,13H2,1H3,(H,33,36)(H,37,38)/t21-,25?/m0/s1 DIXCLZVJKSCYHJ-BWDMCYIDSA-N 413608 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Mixture of Enantiomerically Pure Diastereomers)::US10421742, Example 5::US11180471, Example 5 Plasma kallikrein Human 53.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413608 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413608&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205983 433913716 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115847 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C27H24ClN3O7/c1-36-10-9-22(26(33)30-18-6-3-16(4-7-18)27(34)35)31-14-24(37-2)21(12-25(31)32)20-11-17(28)5-8-19(20)23-13-29-15-38-23/h3-8,11-15,22H,9-10H2,1-2H3,(H,30,33)(H,34,35) SEWAOULYQTXIQF-UHFFFAOYSA-N 413609 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 6::US11180471, Example 6 Plasma kallikrein Human 31.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413609 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413609&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204684 433913717 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115848 COCC[C@@H](C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C27H24ClN3O7/c1-36-10-9-22(26(33)30-18-6-3-16(4-7-18)27(34)35)31-14-24(37-2)21(12-25(31)32)20-11-17(28)5-8-19(20)23-13-29-15-38-23/h3-8,11-15,22H,9-10H2,1-2H3,(H,30,33)(H,34,35)/t22-/m0/s1 SEWAOULYQTXIQF-QFIPXVFZSA-N 413610 4-{[(2S)-2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl]amino}benzoic acid (Enantiomer 2)::US10421742, Example 7::US11180471, Example 7 Plasma kallikrein Human 13.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413610 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413610&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205514 433913718 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115849 COCCC(C(=O)Nc1ccc(s1)C(=O)NC1CC1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C28H27ClN4O6S/c1-37-10-9-21(27(35)32-25-8-7-24(40-25)28(36)31-17-4-5-17)33-14-23(38-2)20(12-26(33)34)19-11-16(29)3-6-18(19)22-13-30-15-39-22/h3,6-8,11-15,17,21H,4-5,9-10H2,1-2H3,(H,31,36)(H,32,35) QJNOMWVCKLXXGM-UHFFFAOYSA-N 413612 5-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-N-cyclopropylthiophen-2-carboxamide (Racemate)::US10421742, Example 8::US11180471, Example 8 Plasma kallikrein Human 21.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413612 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413612&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205789 433913720 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115850 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C28H26ClN5O5/c1-33-14-17-10-19(5-7-23(17)32-33)31-28(36)24(8-9-37-2)34-15-26(38-3)22(12-27(34)35)21-11-18(29)4-6-20(21)25-13-30-16-39-25/h4-7,10-16,24H,8-9H2,1-3H3,(H,31,36) NAFNAAZYCZFUNR-UHFFFAOYSA-N 413613 2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 9::US11180471, Example 9 Plasma kallikrein Human 11.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413613 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413613&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205704 433913721 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115851 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2cnco2)cn1 InChI=1S/C27H26ClN5O6/c1-29-26(35)21-7-5-17(12-31-21)32-27(36)22(8-9-37-2)33-14-24(38-3)20(11-25(33)34)19-10-16(28)4-6-18(19)23-13-30-15-39-23/h4-7,10-15,22H,8-9H2,1-3H3,(H,29,35)(H,32,36) BVTWDIIYCUBXNG-UHFFFAOYSA-N 413614 5-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 10::US11180471, Example 10 Plasma kallikrein Human 21.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413614 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413614&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205982 433913722 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115852 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnco1 InChI=1S/C27H24ClFN4O6/c1-37-8-7-22(27(36)32-16-4-6-18(26(30)35)21(29)10-16)33-13-24(38-2)20(11-25(33)34)19-9-15(28)3-5-17(19)23-12-31-14-39-23/h3-6,9-14,22H,7-8H2,1-2H3,(H2,30,35)(H,32,36) IQJRZUBQZPMNPH-UHFFFAOYSA-N 413615 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 11::US11180471, Example 11 Plasma kallikrein Human 19.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413615 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413615&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205451 433913723 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115853 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C28H28ClN5O5/c1-33-15-17-12-19(5-7-23(17)31-33)30-28(36)25(9-10-37-2)34-16-26(38-3)22(14-27(34)35)21-13-18(29)4-6-20(21)24-8-11-39-32-24/h4-7,12-16,25H,8-11H2,1-3H3,(H,30,36) NMQHQLHZXFJBKV-UHFFFAOYSA-N 413616 2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 12::US11180471, Example 12 Plasma kallikrein Human 34.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413616 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413616&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204747 433913724 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115854 COCC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C28H28ClN5O5/c1-33-15-17-12-19(5-7-23(17)31-33)30-28(36)25(9-10-37-2)34-16-26(38-3)22(14-27(34)35)21-13-18(29)4-6-20(21)24-8-11-39-32-24/h4-7,12-16,25H,8-11H2,1-3H3,(H,30,36)/t25-/m0/s1 NMQHQLHZXFJBKV-VWLOTQADSA-N 413617 (2S)-2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Enantiomer 2)::US10421742, Example 13::US11180471, Example 13 Plasma kallikrein Human 34.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413617 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413617&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205289 433913725 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115855 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C27H26ClFN4O6/c1-37-9-8-23(27(36)31-16-4-6-18(26(30)35)21(29)12-16)33-14-24(38-2)20(13-25(33)34)19-11-15(28)3-5-17(19)22-7-10-39-32-22/h3-6,11-14,23H,7-10H2,1-2H3,(H2,30,35)(H,31,36) DABAFGKGZQBJDK-UHFFFAOYSA-N 413618 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 14::US11180471, Example 14 Plasma kallikrein Human 85.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413618 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413618&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205928 433913726 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115856 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C27H26ClN3O7/c1-36-11-10-23(26(33)29-18-6-3-16(4-7-18)27(34)35)31-15-24(37-2)21(14-25(31)32)20-13-17(28)5-8-19(20)22-9-12-38-30-22/h3-8,13-15,23H,9-12H2,1-2H3,(H,29,33)(H,34,35) LOUUMSPZPZILMW-UHFFFAOYSA-N 413620 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 15::US11180471, Example 15 Plasma kallikrein Human 85.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413620 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413620&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205416 433913727 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115857 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2C2=NOCC2)cc1F InChI=1S/C28H28ClFN4O6/c1-31-27(36)19-7-5-17(13-22(19)30)32-28(37)24(9-10-38-2)34-15-25(39-3)21(14-26(34)35)20-12-16(29)4-6-18(20)23-8-11-40-33-23/h4-7,12-15,24H,8-11H2,1-3H3,(H,31,36)(H,32,37) JFECOVHUSFKCIW-UHFFFAOYSA-N 413622 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluoro-N-methylbenzamide (Racemate)::US10421742, Example 16::US11180471, Example 16 Plasma kallikrein Human 99.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413622 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413622&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205842 433913728 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115858 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCCO1 InChI=1S/C26H26ClN5O7/c1-36-8-7-21(25(35)30-16-4-6-20(24(28)34)29-13-16)32-14-22(37-2)19(12-23(32)33)18-11-15(27)3-5-17(18)26-31-39-10-9-38-26/h3-6,11-14,21H,7-10H2,1-2H3,(H2,28,34)(H,30,35) KGGJSEUIYZFMSZ-UHFFFAOYSA-N 413623 5-[(2-{4-[5-Chloro-2-(5,6-dihydro-1,4,2-dioxazin-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]pyridine-2-carboxamide (Racemate)::US10421742, Example 17::US11180471, Example 17 Plasma kallikrein Human 500 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413623 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413623&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205954 433913729 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115859 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCCO1 InChI=1S/C28H28ClN5O6/c1-33-15-17-12-19(5-7-23(17)31-33)30-27(36)24(8-9-37-2)34-16-25(38-3)22(14-26(34)35)21-13-18(29)4-6-20(21)28-32-40-11-10-39-28/h4-7,12-16,24H,8-11H2,1-3H3,(H,30,36) RGUMZXDJADTTSV-UHFFFAOYSA-N 413624 2-{4-[5-Chloro-2-(5,6-dihydro-1,4,2-dioxazin-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 18::US11180471, Example 18 Plasma kallikrein Human 150 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413624 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413624&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205290 433913730 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115860 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H25ClN8O4/c1-33-13-16-10-18(5-6-21(16)30-33)29-26(37)23(8-9-38-2)34-14-24(39-3)20(12-25(34)36)19-11-17(27)4-7-22(19)35-15-28-31-32-35/h4-7,10-15,23H,8-9H2,1-3H3,(H,29,37) UUIHUWPHJJSKFX-UHFFFAOYSA-N 413625 2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 19::US11180471, Example 19 Plasma kallikrein Human 1.10 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413625 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413625&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205820 433913731 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115861 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H23ClFN7O5/c1-38-8-7-21(25(37)30-15-4-5-16(24(28)36)19(27)10-15)33-12-22(39-2)18(11-23(33)35)17-9-14(26)3-6-20(17)34-13-29-31-32-34/h3-6,9-13,21H,7-8H2,1-2H3,(H2,28,36)(H,30,37) IICMIKXBIINPOO-UHFFFAOYSA-N 413626 4-[(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-butanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 20::US11180471, Example 20 Plasma kallikrein Human 1.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413626 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413626&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205703 433913732 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115862 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1ccnc1 InChI=1S/C27H25ClN4O6/c1-37-12-9-23(26(34)30-19-6-3-17(4-7-19)27(35)36)32-15-24(38-2)21(14-25(32)33)20-13-18(28)5-8-22(20)31-11-10-29-16-31/h3-8,10-11,13-16,23H,9,12H2,1-2H3,(H,30,34)(H,35,36) QAOJLVDDEDCBPJ-UHFFFAOYSA-N 413627 4-[(2-{4-[5-Chloro-2-(1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 21::US11180471, Example 21 Plasma kallikrein Human 69.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413627 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413627&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205879 433913733 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115863 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1ccnc1 InChI=1S/C27H25ClFN5O5/c1-38-10-7-23(27(37)32-17-4-5-18(26(30)36)21(29)12-17)34-14-24(39-2)20(13-25(34)35)19-11-16(28)3-6-22(19)33-9-8-31-15-33/h3-6,8-9,11-15,23H,7,10H2,1-2H3,(H2,30,36)(H,32,37) NHVDXTRNBLJMKL-UHFFFAOYSA-N 413628 4-[(2-{4-[5-Chloro-2-(1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-butanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 22::US11180471, Example 22 Plasma kallikrein Human 31.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413628 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413628&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205815 433913734 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115864 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1ccnc1 InChI=1S/C28H27ClN6O4/c1-33-15-18-12-20(5-6-23(18)32-33)31-28(37)25(8-11-38-2)35-16-26(39-3)22(14-27(35)36)21-13-19(29)4-7-24(21)34-10-9-30-17-34/h4-7,9-10,12-17,25H,8,11H2,1-3H3,(H,31,37) HEMONLHVVQNSEO-UHFFFAOYSA-N 413629 2-{4-[5-Chloro-2-(1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1 (2f)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 23::US11180471, Example 23 Plasma kallikrein Human 12.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413629 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413629&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205442 433913735 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115865 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cocn1 InChI=1S/C27H24ClFN4O6/c1-37-8-7-23(27(36)32-16-4-6-18(26(30)35)21(29)10-16)33-12-24(38-2)20(11-25(33)34)19-9-15(28)3-5-17(19)22-13-39-14-31-22/h3-6,9-14,23H,7-8H2,1-2H3,(H2,30,35)(H,32,36) WWYXXZQZSPIQLH-UHFFFAOYSA-N 413630 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1 (2N)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 24::US11180471, Example 24 Plasma kallikrein Human 360 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413630 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413630&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211514 433913736 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115866 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cocn1 InChI=1S/C28H26ClN5O5/c1-33-13-17-10-19(5-7-23(17)32-33)31-28(36)25(8-9-37-2)34-14-26(38-3)22(12-27(34)35)21-11-18(29)4-6-20(21)24-15-39-16-30-24/h4-7,10-16,25H,8-9H2,1-3H3,(H,31,36) LMABFZNOSCTFBL-UHFFFAOYSA-N 413631 2-{4-[5-Chloro-2-(1,3-oxazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 25::US11180471, Example 25 Plasma kallikrein Human 170 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413631 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413631&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206017 433913737 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115867 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cocn1 InChI=1S/C27H24ClN3O7/c1-36-10-9-23(26(33)30-18-6-3-16(4-7-18)27(34)35)31-13-24(37-2)21(12-25(31)32)20-11-17(28)5-8-19(20)22-14-38-15-29-22/h3-8,11-15,23H,9-10H2,1-2H3,(H,30,33)(H,34,35) DDOXVBZTTPBKNS-UHFFFAOYSA-N 413632 4-[(2-{4-[5-Chloro-2-(1,3-oxazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 26::US11180471, Example 26 Plasma kallikrein Human 510 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413632 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413632&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205923 433913738 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115868 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnco1 InChI=1S/C26H23ClN4O7/c1-36-10-9-21(24(33)29-17-6-3-15(4-7-17)26(34)35)31-13-22(37-2)20(12-23(31)32)19-11-16(27)5-8-18(19)25-30-28-14-38-25/h3-8,11-14,21H,9-10H2,1-2H3,(H,29,33)(H,34,35) QIURUUZJCMOSSC-UHFFFAOYSA-N 413633 4-[(2-{4-[5-Chloro-2-(1,3,4-oxadiazol-2-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 27::US11180471, Example 27 Plasma kallikrein Human 18.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413633 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413633&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205873 433913739 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115869 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnco1 InChI=1S/C26H23ClFN5O6/c1-37-8-7-21(25(36)31-15-4-6-17(24(29)35)20(28)10-15)33-12-22(38-2)19(11-23(33)34)18-9-14(27)3-5-16(18)26-32-30-13-39-26/h3-6,9-13,21H,7-8H2,1-2H3,(H2,29,35)(H,31,36) UISHCWSATBUTQA-UHFFFAOYSA-N 413634 4-[(2-{4-[5-Chloro-2-(1,3,4-oxadiazol-2-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 28::US11180471, Example 28 Plasma kallikrein Human 20.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413634 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413634&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205855 433913740 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115870 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-n2cc(F)cn2)cn1 InChI=1S/C27H26ClFN6O5/c1-30-26(37)21-6-5-18(13-31-21)33-27(38)23(8-9-39-2)34-15-24(40-3)20(11-25(34)36)19-10-16(28)4-7-22(19)35-14-17(29)12-32-35/h4-7,10-15,23H,8-9H2,1-3H3,(H,30,37)(H,33,38) VTZPJMDYPXOBMS-UHFFFAOYSA-N 413635 5-[(2-{4-[5-Chloro-2-(4-fluoro-1H-pyrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2N)-yl}-4-methoxybutanoyl)amino]-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 29::US11180471, Example 29 Plasma kallikrein Human 870 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413635 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413635&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211518 433913741 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115871 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnco1 InChI=1S/C27H25ClN6O5/c1-33-13-16-10-18(5-7-22(16)32-33)30-26(36)23(8-9-37-2)34-14-24(38-3)21(12-25(34)35)20-11-17(28)4-6-19(20)27-31-29-15-39-27/h4-7,10-15,23H,8-9H2,1-3H3,(H,30,36) VWKPWXZBFLVGCL-UHFFFAOYSA-N 413636 2-{4-[5-Chloro-2-(1,3,4-oxadiazol-2-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 30::US11180471, Example 30 Plasma kallikrein Human 11.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413636 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413636&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205971 433913742 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115872 COc1cn(C(CC2COCCO2)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H28ClN5O6/c1-39-28-16-36(29(37)15-23(28)22-12-18(31)2-4-21(22)24-6-9-42-35-24)27(14-20-17-40-10-11-41-20)30(38)34-19-3-5-25-26(13-19)33-8-7-32-25/h2-5,7-8,12-13,15-16,20,27H,6,9-11,14,17H2,1H3,(H,34,38) GRVRMTKUMARYRR-UHFFFAOYSA-N 413637 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-(1,4-dioxan-2-yl)propanamide (Diastereomer Mixture)::US10421742, Example 31::US11180471, Example 31 Plasma kallikrein Human 21.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413637 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413637&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205330 433913743 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115873 COc1cn(C(CC2COCCO2)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H30ClN5O6/c1-35-15-18-11-20(4-6-25(18)33-35)32-30(38)27(13-21-17-40-9-10-41-21)36-16-28(39-2)24(14-29(36)37)23-12-19(31)3-5-22(23)26-7-8-42-34-26/h3-6,11-12,14-16,21,27H,7-10,13,17H2,1-2H3,(H,32,38) NOYWIPLIXQSLPY-UHFFFAOYSA-N 413638 2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-(1,4-dioxan-2-yl)-N-(2-methyl-2H-indazol-5-yl)propanamide (Diastereomer Mixture)::US10421742, Example 32::US11180471, Example 32 Plasma kallikrein Human 51.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413638 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413638&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205291 433913744 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115874 COc1cn(C(CC2COCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C29H28ClN3O8/c1-38-26-15-33(27(34)14-23(26)22-12-18(30)4-7-21(22)24-8-9-41-32-24)25(13-20-16-39-10-11-40-20)28(35)31-19-5-2-17(3-6-19)29(36)37/h2-7,12,14-15,20,25H,8-11,13,16H2,1H3,(H,31,35)(H,36,37) DVWWRIVKJVUPDO-UHFFFAOYSA-N 413639 4-{[2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-(1,4-dioxan-2-yl)propanoyl]amino}benzoic acid (Diastereomer Mixture)::US10421742, Example 33::US11180471, Example 33 Plasma kallikrein Human 170 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413639 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413639&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205538 433913745 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115875 CNC(=O)c1ccc(NC(=O)C(CC2COCCO2)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2C2=NOCC2)cn1 InChI=1S/C29H30ClN5O7/c1-31-28(37)24-6-4-18(14-32-24)33-29(38)25(12-19-16-40-9-10-41-19)35-15-26(39-2)22(13-27(35)36)21-11-17(30)3-5-20(21)23-7-8-42-34-23/h3-6,11,13-15,19,25H,7-10,12,16H2,1-2H3,(H,31,37)(H,33,38) DEFNAUKAAWHGKT-UHFFFAOYSA-N 413640 5-{[2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-(1,4-dioxan-2-yl)propanoyl]amino}-N-methylpyridine-2-carboxamide (Diastereomer Mixture)::US10421742, Example 34::US11180471, Example 34 Plasma kallikrein Human 140 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413640 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413640&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205531 433913746 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115876 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H30ClN3O7/c1-39-27-17-34(28(35)16-24(27)23-14-19(31)7-10-22(23)25-11-13-41-33-25)26(15-21-4-2-3-12-40-21)29(36)32-20-8-5-18(6-9-20)30(37)38/h5-10,14,16-17,21,26H,2-4,11-13,15H2,1H3,(H,32,36)(H,37,38)/t21-,26?/m0/s1 DSSYHGODIQPLGT-GVNKFJBHSA-N 413641 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 35::US10421742, Example 36::US11180471, Example 36 Plasma kallikrein Human 83.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413641 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413641&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205730 433913747 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115877 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H30ClN3O7/c1-39-27-17-34(28(35)16-24(27)23-14-19(31)7-10-22(23)25-11-13-41-33-25)26(15-21-4-2-3-12-40-21)29(36)32-20-8-5-18(6-9-20)30(37)38/h5-10,14,16-17,21,26H,2-4,11-13,15H2,1H3,(H,32,36)(H,37,38)/t21-,26?/m0/s1 DSSYHGODIQPLGT-GVNKFJBHSA-N 413641 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 35::US10421742, Example 36::US11180471, Example 36 Plasma kallikrein Human 96.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413641 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413641&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205730 433913747 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115878 CNC(=O)c1ccc(NC(=O)C(C[C@@H]2CCCCO2)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2C2=NOCC2)cn1 InChI=1S/C30H32ClN5O6/c1-32-29(38)25-9-7-19(16-33-25)34-30(39)26(14-20-5-3-4-11-41-20)36-17-27(40-2)23(15-28(36)37)22-13-18(31)6-8-21(22)24-10-12-42-35-24/h6-9,13,15-17,20,26H,3-5,10-12,14H2,1-2H3,(H,32,38)(H,34,39)/t20-,26?/m0/s1 YJLNILRUWJVMCG-DQUNLGLBSA-N 413643 5-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]-N-methylpyridine-2-carboxamide (Diastereomer Mixture)::US10421742, Example 37::US11180471, Example 37 Plasma kallikrein Human 100.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413643 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413643&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205449 433913748 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115879 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C31H32ClN5O5/c1-36-17-19-13-21(7-9-26(19)34-36)33-31(39)28(15-22-5-3-4-11-41-22)37-18-29(40-2)25(16-30(37)38)24-14-20(32)6-8-23(24)27-10-12-42-35-27/h6-9,13-14,16-18,22,28H,3-5,10-12,15H2,1-2H3,(H,33,39)/t22-,28?/m0/s1 LNIZEAPOEAZWLH-XYXHBKGXSA-N 413644 2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanamide (Diastereomer Mixture)::US10421742, Example 38::US11180471, Example 38 Plasma kallikrein Human 46.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413644 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413644&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205844 433913749 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115880 COc1cn(C(C[C@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H30ClN3O7/c1-39-27-17-34(28(35)16-24(27)23-14-19(31)7-10-22(23)25-11-13-41-33-25)26(15-21-4-2-3-12-40-21)29(36)32-20-8-5-18(6-9-20)30(37)38/h5-10,14,16-17,21,26H,2-4,11-13,15H2,1H3,(H,32,36)(H,37,38)/t21-,26?/m1/s1 DSSYHGODIQPLGT-OSMGYRLQSA-N 413645 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2R)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 39::US11180471, Example 39 Plasma kallikrein Human 570 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413645 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413645&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205996 433913750 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115881 COc1cn(C(C[C@H]2CCCCO2)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C31H32ClN5O5/c1-36-17-19-13-21(7-9-26(19)34-36)33-31(39)28(15-22-5-3-4-11-41-22)37-18-29(40-2)25(16-30(37)38)24-14-20(32)6-8-23(24)27-10-12-42-35-27/h6-9,13-14,16-18,22,28H,3-5,10-12,15H2,1-2H3,(H,33,39)/t22-,28?/m1/s1 LNIZEAPOEAZWLH-WZOMIXFGSA-N 413646 2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)-3-[(2R)-tetrahydro-2H-pyran-2-yl]propanamide (Diastereomer Mixture)::US10421742, Example 40::US11180471, Example 40 Plasma kallikrein Human 130 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413646 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413646&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205645 433913751 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115882 COc1cn(C(C[C@H]2CCCCO2)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H30ClFN4O6/c1-40-27-16-36(28(37)15-23(27)22-12-17(31)5-7-20(22)25-9-11-42-35-25)26(14-19-4-2-3-10-41-19)30(39)34-18-6-8-21(29(33)38)24(32)13-18/h5-8,12-13,15-16,19,26H,2-4,9-11,14H2,1H3,(H2,33,38)(H,34,39)/t19-,26?/m1/s1 BKMNWKMPOGYRQA-ICCFGIFFSA-N 413647 4-[(2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2R)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]-2-fluorobenzamide (Diastereomer Mixture)::US10421742, Example 41::US11180471, Example 41 Plasma kallikrein Human 220 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413647 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413647&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205771 433913752 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115883 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2ccon2)cn1 InChI=1S/C27H26ClN5O6/c1-29-26(35)22-7-5-17(14-30-22)31-27(36)23(9-10-37-2)33-15-24(38-3)20(13-25(33)34)19-12-16(28)4-6-18(19)21-8-11-39-32-21/h4-8,11-15,23H,9-10H2,1-3H3,(H,29,35)(H,31,36) DGUWRYFZSHPSRF-UHFFFAOYSA-N 413648 5-[(2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-N-methylpyridin-2-carboxamide (Racemate)::US10421742, Example 42::US11180471, Example 42 Plasma kallikrein Human 24.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413648 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413648&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206087 433913753 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115884 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C28H26ClN5O5/c1-33-15-17-12-19(5-7-23(17)31-33)30-28(36)25(9-10-37-2)34-16-26(38-3)22(14-27(34)35)21-13-18(29)4-6-20(21)24-8-11-39-32-24/h4-8,11-16,25H,9-10H2,1-3H3,(H,30,36) MQPMEUJFEVBLRJ-UHFFFAOYSA-N 413649 2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 43::US11180471, Example 43 Plasma kallikrein Human 18.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413649 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413649&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206020 433913754 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115885 CNC(=O)c1ccc(NC(=O)C(CCOC(C)(C)C)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2ccon2)cn1 InChI=1S/C30H32ClN5O6/c1-30(2,3)41-12-11-25(29(39)34-19-7-9-24(33-16-19)28(38)32-4)36-17-26(40-5)22(15-27(36)37)21-14-18(31)6-8-20(21)23-10-13-42-35-23/h6-10,13-17,25H,11-12H2,1-5H3,(H,32,38)(H,34,39) XQIJVKWEUWNLCF-UHFFFAOYSA-N 413650 5-[(4-tert-Butoxy-2-{4-[5-chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 44::US11180471, Example 44 Plasma kallikrein Human 18.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413650 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413650&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205942 433913755 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115886 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C30H30ClN3O7/c1-30(2,3)40-13-12-25(28(36)32-20-8-5-18(6-9-20)29(37)38)34-17-26(39-4)23(16-27(34)35)22-15-19(31)7-10-21(22)24-11-14-41-33-24/h5-11,14-17,25H,12-13H2,1-4H3,(H,32,36)(H,37,38) XVQJXIHGEMVIBL-UHFFFAOYSA-N 413651 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 45::US11180471, Example 45 Plasma kallikrein Human 28.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413651 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413651&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205454 433913756 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115887 COc1cn([C@@H](CCOC(C)(C)C)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C30H30ClN3O7/c1-30(2,3)40-13-12-25(28(36)32-20-8-5-18(6-9-20)29(37)38)34-17-26(39-4)23(16-27(34)35)22-15-19(31)7-10-21(22)24-11-14-41-33-24/h5-11,14-17,25H,12-13H2,1-4H3,(H,32,36)(H,37,38)/t25-/m0/s1 XVQJXIHGEMVIBL-VWLOTQADSA-N 413652 4-{[(2S)-4-tert-Butoxy-2-{4-[5-chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl]amino}benzoic acid (Enantiomer 2)::US10421742, Example 46::US11180471, Example 46 Plasma kallikrein Human 15.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413652 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413652&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205453 433913757 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115888 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C31H28ClN5O5/c1-40-29-18-37(30(38)17-24(29)23-14-19(32)5-7-22(23)25-9-13-42-36-25)28(16-21-4-2-3-12-41-21)31(39)35-20-6-8-26-27(15-20)34-11-10-33-26/h5-11,13-15,17-18,21,28H,2-4,12,16H2,1H3,(H,35,39)/t21-,28?/m0/s1 QHFRLRVXSRUUOC-QDLLFRBVSA-N 413653 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanamide (Diastereomer Mixture)::US10421742, Example 47::US11180471, Example 47 Plasma kallikrein Human 25.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413653 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413653&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205254 433913758 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115889 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C30H28ClN3O7/c1-39-27-17-34(28(35)16-24(27)23-14-19(31)7-10-22(23)25-11-13-41-33-25)26(15-21-4-2-3-12-40-21)29(36)32-20-8-5-18(6-9-20)30(37)38/h5-11,13-14,16-17,21,26H,2-4,12,15H2,1H3,(H,32,36)(H,37,38)/t21-,26?/m0/s1 RTTPBBKILQCFGH-GVNKFJBHSA-N 413654 4-[(2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 48::US10421742, Example 49::US11180471, Example 49 Plasma kallikrein Human 49.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413654 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413654&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205526 433913759 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115890 COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1 InChI=1S/C30H28ClN3O7/c1-39-27-17-34(28(35)16-24(27)23-14-19(31)7-10-22(23)25-11-13-41-33-25)26(15-21-4-2-3-12-40-21)29(36)32-20-8-5-18(6-9-20)30(37)38/h5-11,13-14,16-17,21,26H,2-4,12,15H2,1H3,(H,32,36)(H,37,38)/t21-,26?/m0/s1 RTTPBBKILQCFGH-GVNKFJBHSA-N 413654 4-[(2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 48::US10421742, Example 49::US11180471, Example 49 Plasma kallikrein Human 17.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413654 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413654&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205526 433913759 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115891 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(F)c1 InChI=1S/C28H26ClFN6O4/c1-34-13-17-10-19(5-6-22(17)33-34)32-28(38)24(8-9-39-2)36-14-25(40-3)21(12-27(36)37)20-11-18(29)4-7-23(20)35-15-26(30)31-16-35/h4-7,10-16,24H,8-9H2,1-3H3,(H,32,38) XXIIEASKYLNDLZ-UHFFFAOYSA-N 413656 2-{4-[5-Chloro-2-(4-fluoro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 50::US11180471, Example 50 Plasma kallikrein Human 95.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413656 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413656&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206014 433913760 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115892 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(F)c1 InChI=1S/C27H24ClFN4O6/c1-38-10-9-22(26(35)31-18-6-3-16(4-7-18)27(36)37)33-13-23(39-2)20(12-25(33)34)19-11-17(28)5-8-21(19)32-14-24(29)30-15-32/h3-8,11-15,22H,9-10H2,1-2H3,(H,31,35)(H,36,37) LQOPQTHAZLUPRF-UHFFFAOYSA-N 413657 4-[(2-{4-[5-Chloro-2-(4-fluoro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 51::US11180471, Example 51 Plasma kallikrein Human 56.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413657 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413657&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205822 433913761 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115893 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C28H26Cl2N6O4/c1-34-13-17-10-19(5-6-22(17)33-34)32-28(38)24(8-9-39-2)36-14-25(40-3)21(12-27(36)37)20-11-18(29)4-7-23(20)35-15-26(30)31-16-35/h4-7,10-16,24H,8-9H2,1-3H3,(H,32,38) VHDZGIZYASTKPK-UHFFFAOYSA-N 413658 2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 52::US11180471, Example 52 Plasma kallikrein Human 19.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413658 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413658&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205518 433913762 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115894 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C27H24Cl2N4O6/c1-38-10-9-22(26(35)31-18-6-3-16(4-7-18)27(36)37)33-13-23(39-2)20(12-25(33)34)19-11-17(28)5-8-21(19)32-14-24(29)30-15-32/h3-8,11-15,22H,9-10H2,1-2H3,(H,31,35)(H,36,37) ATCFLROFGUZFNA-UHFFFAOYSA-N 413659 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 53::US11180471, Example 53 Plasma kallikrein Human 37.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413659 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413659&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206033 433913763 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115895 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-n2cnc(Cl)c2)cn1 InChI=1S/C27H26Cl2N6O5/c1-30-26(37)20-6-5-17(12-31-20)33-27(38)22(8-9-39-2)35-13-23(40-3)19(11-25(35)36)18-10-16(28)4-7-21(18)34-14-24(29)32-15-34/h4-7,10-15,22H,8-9H2,1-3H3,(H,30,37)(H,33,38) ILXCPIBUCWIAMK-UHFFFAOYSA-N 413660 5-[(2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 54::US11180471, Example 54 Plasma kallikrein Human 44.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413660 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413660&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206034 433913764 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115896 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C28H24Cl2N6O4/c1-39-10-7-24(28(38)34-18-4-5-21-22(12-18)32-9-8-31-21)36-14-25(40-2)20(13-27(36)37)19-11-17(29)3-6-23(19)35-15-26(30)33-16-35/h3-6,8-9,11-16,24H,7,10H2,1-2H3,(H,34,38) FCJJBIBALYUNQH-UHFFFAOYSA-N 413661 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanamide (Racemate)::US10421742, Example 55::US11180471, Example 55 Plasma kallikrein Human 12.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413661 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413661&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205710 433913765 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115897 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnc1 InChI=1S/C26H24ClFN6O5/c1-38-8-7-22(26(37)32-16-4-5-17(25(29)36)20(28)10-16)34-12-23(39-2)19(11-24(34)35)18-9-15(27)3-6-21(18)33-13-30-31-14-33/h3-6,9-14,22H,7-8H2,1-2H3,(H2,29,36)(H,32,37) YIFQLPJMHMOWFU-UHFFFAOYSA-N 413662 4-[(2-{4-[5-Chloro-2-(4H-1,2,4-triazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 56::US11180471, Example 56 Plasma kallikrein Human 26.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413662 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413662&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205108 433913766 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115898 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnc1 InChI=1S/C27H24ClN7O4/c1-38-10-7-24(27(37)33-18-4-5-21-22(12-18)30-9-8-29-21)35-14-25(39-2)20(13-26(35)36)19-11-17(28)3-6-23(19)34-15-31-32-16-34/h3-6,8-9,11-16,24H,7,10H2,1-2H3,(H,33,37) QEUZUPMZRYSKJR-UHFFFAOYSA-N 413663 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4H-1,2,4-triazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanamide (Racemate)::US10421742, Example 57::US11180471, Example 57 Plasma kallikrein Human 8.70 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413663 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413663&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205805 433913767 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115899 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnc1 InChI=1S/C26H24ClN5O6/c1-37-10-9-22(25(34)30-18-6-3-16(4-7-18)26(35)36)32-13-23(38-2)20(12-24(32)33)19-11-17(27)5-8-21(19)31-14-28-29-15-31/h3-8,11-15,22H,9-10H2,1-2H3,(H,30,34)(H,35,36) BABSEGOQVMFTTL-UHFFFAOYSA-N 413664 4-[(2-{4-[5-Chloro-2-(4H-1,2,4-triazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 58::US11180471, Example 58 Plasma kallikrein Human 47.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413664 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413664&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205192 433913768 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115900 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnc1 InChI=1S/C27H26ClN7O4/c1-33-13-17-10-19(5-6-22(17)32-33)31-27(37)24(8-9-38-2)35-14-25(39-3)21(12-26(35)36)20-11-18(28)4-7-23(20)34-15-29-30-16-34/h4-7,10-16,24H,8-9H2,1-3H3,(H,31,37) FGCCTMXHTZVEGP-UHFFFAOYSA-N 413665 2-{4-[5-Chloro-2-(4H-1,2,4-triazol-4-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 59::US11180471, Example 59 Plasma kallikrein Human 15.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413665 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413665&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206021 433913769 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115901 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H24ClF2N7O4/c1-41-10-7-24(28(40)34-17-4-5-20-21(12-17)33-9-8-32-20)37-15-25(42-2)19(13-26(37)39)18-11-16(29)3-6-23(18)38-14-22(27(30)31)35-36-38/h3-6,8-9,11-15,24,27H,7,10H2,1-2H3,(H,34,40) SSZTYGHNKCZYAF-UHFFFAOYSA-N 528079 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanamide (racemate)::US11180471, Example 60 Plasma kallikrein Human 6.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528079 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528079&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 163200076 463791634 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115902 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)F InChI=1S/C29H25ClF2N6O4/c1-41-10-7-25(29(40)36-18-4-5-21-22(12-18)34-9-8-33-21)38-15-26(42-2)20(13-27(38)39)19-11-17(30)3-6-24(19)37-14-23(28(31)32)35-16-37/h3-6,8-9,11-16,25,28H,7,10H2,1-2H3,(H,36,40) JXACRAOKHLGFCC-UHFFFAOYSA-N 413667 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanamide (Racemate)::US10421742, Example 61::US11180471, Example 61 Plasma kallikrein Human 15.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413667 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413667&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205843 433913771 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115903 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)F InChI=1S/C28H25ClF2N4O6/c1-40-10-9-23(27(37)33-18-6-3-16(4-7-18)28(38)39)35-14-24(41-2)20(12-25(35)36)19-11-17(29)5-8-22(19)34-13-21(26(30)31)32-15-34/h3-8,11-15,23,26H,9-10H2,1-2H3,(H,33,37)(H,38,39) RXURALNQBFWKQS-UHFFFAOYSA-N 413668 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Racemate)::US10421742, Example 62::US11180471, Example 62 Plasma kallikrein Human 140 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413668 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413668&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205732 433913772 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115904 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)F InChI=1S/C28H25ClF3N5O5/c1-41-8-7-23(28(40)35-16-4-5-17(27(33)39)20(30)10-16)37-13-24(42-2)19(11-25(37)38)18-9-15(29)3-6-22(18)36-12-21(26(31)32)34-14-36/h3-6,9-14,23,26H,7-8H2,1-2H3,(H2,33,39)(H,35,40) LOOFPSIULDNXTC-UHFFFAOYSA-N 413669 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 63::US11180471, Example 63 Plasma kallikrein Human 170 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413669 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413669&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205511 433913773 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115905 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)F InChI=1S/C27H25ClF2N6O5/c1-40-8-7-22(27(39)34-16-4-5-19(26(31)38)32-11-16)36-13-23(41-2)18(10-24(36)37)17-9-15(28)3-6-21(17)35-12-20(25(29)30)33-14-35/h3-6,9-14,22,25H,7-8H2,1-2H3,(H2,31,38)(H,34,39) SRNOHCLEBDLQNM-UHFFFAOYSA-N 413670 5-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 64::US11180471, Example 64 Plasma kallikrein Human 180 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413670 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413670&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205917 433913774 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115906 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-n2cnc(c2)C(F)F)cn1 InChI=1S/C28H27ClF2N6O5/c1-32-27(39)20-6-5-17(12-33-20)35-28(40)23(8-9-41-2)37-14-24(42-3)19(11-25(37)38)18-10-16(29)4-7-22(18)36-13-21(26(30)31)34-15-36/h4-7,10-15,23,26H,8-9H2,1-3H3,(H,32,39)(H,35,40) BZGWCVVHLRMNJS-UHFFFAOYSA-N 413671 5-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 65::US11180471, Example 65 Plasma kallikrein Human 93.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413671 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413671&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211501 433913775 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115907 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)F InChI=1S/C29H27ClF2N6O4/c1-36-13-17-10-19(5-6-22(17)35-36)34-29(40)25(8-9-41-2)38-15-26(42-3)21(12-27(38)39)20-11-18(30)4-7-24(20)37-14-23(28(31)32)33-16-37/h4-7,10-16,25,28H,8-9H2,1-3H3,(H,34,40) RVACDGDJWAWWGJ-UHFFFAOYSA-N 413672 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 66::US11180471, Example 66 Plasma kallikrein Human 43.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413672 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413672&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211559 433913776 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115908 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(C)no1 InChI=1S/C28H26ClN3O7/c1-16-12-24(39-31-16)20-9-6-18(29)13-21(20)22-14-26(33)32(15-25(22)38-3)23(10-11-37-2)27(34)30-19-7-4-17(5-8-19)28(35)36/h4-9,12-15,23H,10-11H2,1-3H3,(H,30,34)(H,35,36) KHIKDAHZRTYQLP-UHFFFAOYSA-N 413673 4-[(2-{4-[5-Chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 67::US11180471, Example 67 Plasma kallikrein Human 45.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413673 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413673&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205834 433913777 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115909 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(C)no1 InChI=1S/C27H26ClN5O6/c1-15-10-23(39-32-15)18-6-4-16(28)11-19(18)20-12-25(34)33(14-24(20)38-3)22(8-9-37-2)27(36)31-17-5-7-21(26(29)35)30-13-17/h4-7,10-14,22H,8-9H2,1-3H3,(H2,29,35)(H,31,36) MJTYRMTXTRTXFO-UHFFFAOYSA-N 413674 5-[(2-{4-[5-Chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]pyridine-2-carboxamide (Racemate)::US10421742, Example 68::US11180471, Example 68 Plasma kallikrein Human 51.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413674 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413674&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205583 433913778 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115910 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(C)no1 InChI=1S/C28H26ClFN4O6/c1-15-10-24(40-33-15)18-6-4-16(29)11-20(18)21-13-26(35)34(14-25(21)39-3)23(8-9-38-2)28(37)32-17-5-7-19(27(31)36)22(30)12-17/h4-7,10-14,23H,8-9H2,1-3H3,(H2,31,36)(H,32,37) IOKBSWHNAJFKBB-UHFFFAOYSA-N 413675 4-[(2-{4-[5-Chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 69::US11180471, Example 69 Plasma kallikrein Human 58.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413675 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413675&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205883 433913779 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115911 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(C)no1 InChI=1S/C29H28ClN5O5/c1-17-11-26(40-33-17)21-7-5-19(30)13-22(21)23-14-28(36)35(16-27(23)39-4)25(9-10-38-3)29(37)31-20-6-8-24-18(12-20)15-34(2)32-24/h5-8,11-16,25H,9-10H2,1-4H3,(H,31,37) YKKFWRCDYBEJHT-UHFFFAOYSA-N 528089 2-{4-[5-Chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (racemate)::US11180471, Example 70 Plasma kallikrein Human 21.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528089 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528089&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 140885364 463791643 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115912 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2cc(C)no2)cn1 InChI=1S/C28H28ClN5O6/c1-16-11-24(40-33-16)19-7-5-17(29)12-20(19)21-13-26(35)34(15-25(21)39-4)23(9-10-38-3)28(37)32-18-6-8-22(31-14-18)27(36)30-2/h5-8,11-15,23H,9-10H2,1-4H3,(H,30,36)(H,32,37) ROFGROGQJVVGAV-UHFFFAOYSA-N 413677 5-[(2-{4-[5-Chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 71::US11180471, Example 71 Plasma kallikrein Human 35.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413677 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413677&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205793 433913781 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115913 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(C)no1 InChI=1S/C29H26ClN5O5/c1-17-12-26(40-34-17)20-6-4-18(30)13-21(20)22-15-28(36)35(16-27(22)39-3)25(8-11-38-2)29(37)33-19-5-7-23-24(14-19)32-10-9-31-23/h4-7,9-10,12-16,25H,8,11H2,1-3H3,(H,33,37) BOMMICKHAGJNKQ-UHFFFAOYSA-N 413678 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanamide (Racemate)::US10421742, Example 72::US11180471, Example 72 Plasma kallikrein Human 18.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413678 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413678&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205700 433913782 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115914 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C26H22ClF3N6O6/c1-40-8-7-19(23(39)33-14-4-6-18(22(31)38)32-11-14)36-12-20(41-2)17(10-21(36)37)16-9-13(27)3-5-15(16)24-34-35-25(42-24)26(28,29)30/h3-6,9-12,19H,7-8H2,1-2H3,(H2,31,38)(H,33,39) LICUUHCNECQSQW-UHFFFAOYSA-N 413679 5-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 73::US11180471, Example 73 Plasma kallikrein Human 110 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413679 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413679&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205765 433913783 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115915 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C27H22ClF4N5O6/c1-41-8-7-20(24(40)34-14-4-6-16(23(33)39)19(29)10-14)37-12-21(42-2)18(11-22(37)38)17-9-13(28)3-5-15(17)25-35-36-26(43-25)27(30,31)32/h3-6,9-12,20H,7-8H2,1-2H3,(H2,33,39)(H,34,40) FGIRAZNDJOPUAW-UHFFFAOYSA-N 413680 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 74::US11180471, Example 74 Plasma kallikrein Human 98.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413680 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413680&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205473 433913784 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115916 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C28H24ClF3N6O5/c1-37-13-15-10-17(5-7-21(15)36-37)33-25(40)22(8-9-41-2)38-14-23(42-3)20(12-24(38)39)19-11-16(29)4-6-18(19)26-34-35-27(43-26)28(30,31)32/h4-7,10-14,22H,8-9H2,1-3H3,(H,33,40) YOTPLZPCUXHOMZ-UHFFFAOYSA-N 413681 2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 75::US11180471, Example 75 Plasma kallikrein Human 28.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413681 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413681&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205440 433913785 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115917 COCC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C28H24ClF3N6O5/c1-37-13-15-10-17(5-7-21(15)36-37)33-25(40)22(8-9-41-2)38-14-23(42-3)20(12-24(38)39)19-11-16(29)4-6-18(19)26-34-35-27(43-26)28(30,31)32/h4-7,10-14,22H,8-9H2,1-3H3,(H,33,40)/t22-/m0/s1 YOTPLZPCUXHOMZ-QFIPXVFZSA-N 413682 (2S)-2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Enantiomer 2)::US10421742, Example 76::US11180471, Example 76 Plasma kallikrein Human 23.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413682 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413682&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205552 433913786 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115918 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2nnc(o2)C(F)(F)F)cn1 InChI=1S/C27H24ClF3N6O6/c1-32-23(39)19-7-5-15(12-33-19)34-24(40)20(8-9-41-2)37-13-21(42-3)18(11-22(37)38)17-10-14(28)4-6-16(17)25-35-36-26(43-25)27(29,30)31/h4-7,10-13,20H,8-9H2,1-3H3,(H,32,39)(H,34,40) NUOFQPYZYCWJHB-UHFFFAOYSA-N 413683 5-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 77::US11180471, Example 77 Plasma kallikrein Human 47.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413683 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413683&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206080 433913787 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115919 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C28H22ClF3N6O5/c1-41-10-7-22(25(40)35-16-4-6-20-21(12-16)34-9-8-33-20)38-14-23(42-2)19(13-24(38)39)18-11-15(29)3-5-17(18)26-36-37-27(43-26)28(30,31)32/h3-6,8-9,11-14,22H,7,10H2,1-2H3,(H,35,40) RLFXIFOZOPMNCY-UHFFFAOYSA-N 413684 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanamide (Racemate)::US10421742, Example 78::US11180471, Example 78 Plasma kallikrein Human 14.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413684 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413684&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205675 433913788 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115920 COCC[C@@H](C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C28H22ClF3N6O5/c1-41-10-7-22(25(40)35-16-4-6-20-21(12-16)34-9-8-33-20)38-14-23(42-2)19(13-24(38)39)18-11-15(29)3-5-17(18)26-36-37-27(43-26)28(30,31)32/h3-6,8-9,11-14,22H,7,10H2,1-2H3,(H,35,40)/t22-/m0/s1 RLFXIFOZOPMNCY-QFIPXVFZSA-N 413685 N-(Quinoxalin-6-yl)-(2S)-2-[4-{5-chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanamide (Enantiomer 2)::US10421742, Example 79::US11180471, Example 79 Plasma kallikrein Human 9.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413685 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413685&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205803 433913789 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115921 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C27H23ClF2N4O7/c1-39-10-9-20(24(36)31-16-6-3-14(4-7-16)27(37)38)34-13-21(40-2)19(12-22(34)35)18-11-15(28)5-8-17(18)25-32-33-26(41-25)23(29)30/h3-8,11-13,20,23H,9-10H2,1-2H3,(H,31,36)(H,37,38) XNHWHTYAEJBBSE-UHFFFAOYSA-N 413686 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Racemate)::US10421742, Example 80::US11180471, Example 80 Plasma kallikrein Human 78.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413686 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413686&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205800 433913790 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115922 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C26H23ClF2N6O6/c1-39-8-7-19(24(38)32-14-4-6-18(23(30)37)31-11-14)35-12-20(40-2)17(10-21(35)36)16-9-13(27)3-5-15(16)25-33-34-26(41-25)22(28)29/h3-6,9-12,19,22H,7-8H2,1-2H3,(H2,30,37)(H,32,38) MDWVKPVBVQCTPE-UHFFFAOYSA-N 413687 5-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 81::US11180471, Example 81 Plasma kallikrein Human 100.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413687 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413687&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206035 433913791 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115923 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C27H23ClF3N5O6/c1-40-8-7-20(25(39)33-14-4-6-16(24(32)38)19(29)10-14)36-12-21(41-2)18(11-22(36)37)17-9-13(28)3-5-15(17)26-34-35-27(42-26)23(30)31/h3-6,9-12,20,23H,7-8H2,1-2H3,(H2,32,38)(H,33,39) ZFLRJTQBCYIFEA-UHFFFAOYSA-N 413688 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 82::US11180471, Example 82 Plasma kallikrein Human 67.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413688 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413688&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205342 433913792 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115924 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C28H25ClF2N6O5/c1-36-13-15-10-17(5-7-21(15)35-36)32-26(39)22(8-9-40-2)37-14-23(41-3)20(12-24(37)38)19-11-16(29)4-6-18(19)27-33-34-28(42-27)25(30)31/h4-7,10-14,22,25H,8-9H2,1-3H3,(H,32,39) OYMYFSRVCJZGAS-UHFFFAOYSA-N 413689 2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 83::US11180471, Example 83 Plasma kallikrein Human 21.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413689 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413689&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205398 433913793 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115925 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2nnc(o2)C(F)F)cn1 InChI=1S/C27H25ClF2N6O6/c1-31-24(38)19-7-5-15(12-32-19)33-25(39)20(8-9-40-2)36-13-21(41-3)18(11-22(36)37)17-10-14(28)4-6-16(17)26-34-35-27(42-26)23(29)30/h4-7,10-13,20,23H,8-9H2,1-3H3,(H,31,38)(H,33,39) HOPVUQHXIRDKQQ-UHFFFAOYSA-N 413690 5-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 84::US11180471, Example 84 Plasma kallikrein Human 49.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413690 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413690&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205828 433913794 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115926 COCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C28H23ClF2N6O5/c1-40-10-7-22(26(39)34-16-4-6-20-21(12-16)33-9-8-32-20)37-14-23(41-2)19(13-24(37)38)18-11-15(29)3-5-17(18)27-35-36-28(42-27)25(30)31/h3-6,8-9,11-14,22,25H,7,10H2,1-2H3,(H,34,39) XQGAAZGSIZFZJH-UHFFFAOYSA-N 413691 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanamide (Racemate)::US10421742, Example 85::US11180471, Example 85 Plasma kallikrein Human 9.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413691 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413691&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205474 433913795 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115927 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(c1)C(F)F InChI=1S/C28H25ClF2N4O6/c1-40-10-9-23(26(37)33-19-6-3-16(4-7-19)27(38)39)34-15-24(41-2)22(12-25(34)36)21-11-18(29)5-8-20(21)17-13-32-35(14-17)28(30)31/h3-8,11-15,23,28H,9-10H2,1-2H3,(H,33,37)(H,38,39) KPDQGYYQHYCMAC-UHFFFAOYSA-N 413692 4-({2-[4-{5-Chloro-2-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Racemate)::US10421742, Example 86::US11180471, Example 86 Plasma kallikrein Human 88.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413692 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413692&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205712 433913796 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115928 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(c1)C(F)F InChI=1S/C29H27ClF2N6O4/c1-36-14-17-10-20(5-7-24(17)35-36)34-28(40)25(8-9-41-2)37-16-26(42-3)23(12-27(37)39)22-11-19(30)4-6-21(22)18-13-33-38(15-18)29(31)32/h4-7,10-16,25,29H,8-9H2,1-3H3,(H,34,40) FLLYAGGTZNJKNW-UHFFFAOYSA-N 413693 2-[4-{5-Chloro-2-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 87::US11180471, Example 87 Plasma kallikrein Human 41.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413693 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413693&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205794 433913797 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115929 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(c1)C(F)F InChI=1S/C27H25ClF2N6O5/c1-40-8-7-22(26(39)34-17-4-6-21(25(31)38)32-12-17)35-14-23(41-2)20(10-24(35)37)19-9-16(28)3-5-18(19)15-11-33-36(13-15)27(29)30/h3-6,9-14,22,27H,7-8H2,1-2H3,(H2,31,38)(H,34,39) ZDGFODUVDKHNBN-UHFFFAOYSA-N 413694 5-({2-[4-{5-Chloro-2-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 88::US11180471, Example 88 Plasma kallikrein Human 110 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413694 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413694&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205957 433913798 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115930 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C27H25ClFN5O6/c1-14-31-27(40-33-14)17-6-4-15(28)10-19(17)20-12-24(35)34(13-23(20)39-3)22(8-9-38-2)26(37)32-16-5-7-18(25(30)36)21(29)11-16/h4-7,10-13,22H,8-9H2,1-3H3,(H2,30,36)(H,32,37) KXEKQPUKVUVDQB-UHFFFAOYSA-N 413695 4-[(2-{4-[5-Chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 89::US11180471, Example 89 Plasma kallikrein Human 58.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413695 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413695&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205626 433913799 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115931 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C27H25ClN4O7/c1-15-29-26(39-31-15)19-9-6-17(28)12-20(19)21-13-24(33)32(14-23(21)38-3)22(10-11-37-2)25(34)30-18-7-4-16(5-8-18)27(35)36/h4-9,12-14,22H,10-11H2,1-3H3,(H,30,34)(H,35,36) NOYZMHMPNZKENJ-UHFFFAOYSA-N 413696 4-[(2-{4-[5-Chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 90::US11180471, Example 90 Plasma kallikrein Human 54.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413696 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413696&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205964 433913800 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115932 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C28H27ClN6O5/c1-16-30-28(40-33-16)20-7-5-18(29)12-21(20)22-13-26(36)35(15-25(22)39-4)24(9-10-38-3)27(37)31-19-6-8-23-17(11-19)14-34(2)32-23/h5-8,11-15,24H,9-10H2,1-4H3,(H,31,37) AKPADQIFUKNACD-UHFFFAOYSA-N 413697 2-{4-[5-Chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 91::US11180471, Example 91 Plasma kallikrein Human 25.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413697 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413697&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204923 433913801 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115933 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C31H31ClN6O5/c1-18-35-30(43-37-18)21-8-6-19(32)14-22(21)23-16-28(39)38(17-27(23)41-5)26(10-13-42-31(2,3)4)29(40)36-20-7-9-24-25(15-20)34-12-11-33-24/h6-9,11-12,14-17,26H,10,13H2,1-5H3,(H,36,40) WHJFAHUWUMDVIH-UHFFFAOYSA-N 413699 4-tert-Butoxy-N-(quinoxalin-6-yl)-2-{4-[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanamide (Racemate)::US10421742, Example 92::US11180471, Example 92 Plasma kallikrein Human 24.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413699 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413699&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205417 433913802 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115934 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C30H31ClFN5O6/c1-16-34-29(43-36-16)19-8-6-17(31)12-21(19)22-14-26(38)37(15-25(22)41-5)24(10-11-42-30(2,3)4)28(40)35-18-7-9-20(27(33)39)23(32)13-18/h6-9,12-15,24H,10-11H2,1-5H3,(H2,33,39)(H,35,40) NZUPFRNOGBEVPO-UHFFFAOYSA-N 413700 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 93::US11180471, Example 93 Plasma kallikrein Human 87.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413700 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413700&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205738 433913803 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115935 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C30H31ClN4O7/c1-17-32-28(42-34-17)21-11-8-19(31)14-22(21)23-15-26(36)35(16-25(23)40-5)24(12-13-41-30(2,3)4)27(37)33-20-9-6-18(7-10-20)29(38)39/h6-11,14-16,24H,12-13H2,1-5H3,(H,33,37)(H,38,39) ZWRNKDXMIOGALM-UHFFFAOYSA-N 413701 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 94::US11180471, Example 94 Plasma kallikrein Human 40.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413701 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413701&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205935 433913804 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115936 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-c1nc(C)no1 InChI=1S/C31H33ClN6O5/c1-18-33-30(43-36-18)22-9-7-20(32)14-23(22)24-15-28(39)38(17-27(24)41-6)26(11-12-42-31(2,3)4)29(40)34-21-8-10-25-19(13-21)16-37(5)35-25/h7-10,13-17,26H,11-12H2,1-6H3,(H,34,40) QVRAHCXUFLLOFP-UHFFFAOYSA-N 413702 4-tert-Butoxy-2-{4-[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 95::US11180471, Example 95 Plasma kallikrein Human 51.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413702 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413702&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205986 433913805 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115937 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(CC(F)(F)F)c1 InChI=1S/C29H26ClF3N4O6/c1-42-10-9-24(27(39)35-20-6-3-17(4-7-20)28(40)41)37-15-25(43-2)23(12-26(37)38)22-11-19(30)5-8-21(22)18-13-34-36(14-18)16-29(31,32)33/h3-8,11-15,24H,9-10,16H2,1-2H3,(H,35,39)(H,40,41) RUCWELAAUNKPGR-UHFFFAOYSA-N 413703 4-({2-[4-{5-Chloro-2-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Racemate)::US10421742, Example 96::US11180471, Example 96 Plasma kallikrein Human 230 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413703 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413703&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211517 433913806 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115938 CNC(=O)c1ccc(NC(=O)C(CCOC)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-c2cnn(CC(F)(F)F)c2)cn1 InChI=1S/C29H28ClF3N6O5/c1-34-27(41)23-7-5-19(13-35-23)37-28(42)24(8-9-43-2)39-15-25(44-3)22(11-26(39)40)21-10-18(30)4-6-20(21)17-12-36-38(14-17)16-29(31,32)33/h4-7,10-15,24H,8-9,16H2,1-3H3,(H,34,41)(H,37,42) BSBZPHKWOOZTDV-UHFFFAOYSA-N 413704 5-({2-[4-{5-Chloro-2-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 97::US11180471, Example 97 Plasma kallikrein Human 190 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413704 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413704&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211552 433913807 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115939 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(CC(F)(F)F)c1 InChI=1S/C30H28ClF3N6O4/c1-38-14-18-10-21(5-7-25(18)37-38)36-29(42)26(8-9-43-2)40-16-27(44-3)24(12-28(40)41)23-11-20(31)4-6-22(23)19-13-35-39(15-19)17-30(32,33)34/h4-7,10-16,26H,8-9,17H2,1-3H3,(H,36,42) SSDUONDHEXQWQO-UHFFFAOYSA-N 413705 2-[4-{5-Chloro-2-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 98::US11180471, Example 98 Plasma kallikrein Human 100.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413705 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413705&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205464 433913808 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115940 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O4/c1-34-13-16-10-18(5-6-21(16)32-34)30-27(38)23(8-9-39-2)35-14-24(40-3)20(12-26(35)37)19-11-17(28)4-7-22(19)36-15-25(29)31-33-36/h4-7,10-15,23H,8-9H2,1-3H3,(H,30,38) HQFBMTXLTXVRAL-UHFFFAOYSA-N 413706 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 99::US11180471, Example 99 Plasma kallikrein Human 3.20 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413706 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413706&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205773 433913809 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115941 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2FN6O5/c1-39-8-7-21(26(38)31-15-4-5-16(25(30)37)19(29)10-15)34-12-22(40-2)18(11-24(34)36)17-9-14(27)3-6-20(17)35-13-23(28)32-33-35/h3-6,9-13,21H,7-8H2,1-2H3,(H2,30,37)(H,31,38) AITUBRIGGLTKMQ-UHFFFAOYSA-N 413707 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 100::US11180471, Example 100 Plasma kallikrein Human 5.00 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413707 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413707&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206029 433913810 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115942 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2N5O6/c1-38-10-9-21(25(35)29-17-6-3-15(4-7-17)26(36)37)32-13-22(39-2)19(12-24(32)34)18-11-16(27)5-8-20(18)33-14-23(28)30-31-33/h3-8,11-14,21H,9-10H2,1-2H3,(H,29,35)(H,36,37) WCANIIANZRELQI-UHFFFAOYSA-N 413708 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4-methoxybutanoyl)amino]benzoic acid (Racemate)::US10421742, Example 101::US11180471, Example 101 Plasma kallikrein Human 6.00 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413708 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413708&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205978 433913811 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115943 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C29H29Cl2FN6O5/c1-29(2,3)43-10-9-23(28(41)34-17-6-7-18(27(33)40)21(32)12-17)37-14-24(42-4)20(13-26(37)39)19-11-16(30)5-8-22(19)38-15-25(31)35-36-38/h5-8,11-15,23H,9-10H2,1-4H3,(H2,33,40)(H,34,41) JFTPUCJHGXFNAL-UHFFFAOYSA-N 413709 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 102::US11180471, Example 102 Plasma kallikrein Human 4.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413709 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413709&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205886 433913812 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115944 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C30H31Cl2N7O4/c1-30(2,3)43-11-10-25(29(41)33-20-7-8-23-18(12-20)15-37(4)35-23)38-16-26(42-5)22(14-28(38)40)21-13-19(31)6-9-24(21)39-17-27(32)34-36-39/h6-9,12-17,25H,10-11H2,1-5H3,(H,33,41) ZAKSQHPNZWUBFJ-UHFFFAOYSA-N 413710 4-tert-Butoxy-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 103::US11180471, Example 103 Plasma kallikrein Human 4.30 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413710 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413710&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205159 433913813 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115945 CCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(F)c1 InChI=1S/C27H24ClFN4O5/c1-3-4-22(26(35)31-18-8-5-16(6-9-18)27(36)37)33-13-23(38-2)20(12-25(33)34)19-11-17(28)7-10-21(19)32-14-24(29)30-15-32/h5-15,22H,3-4H2,1-2H3,(H,31,35)(H,36,37) UEDRHDRNPGYCFA-UHFFFAOYSA-N 413711 4-{[2-{4-[5-Chloro-2-(4-fluoro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}benzoic acid (Racemate)::US10421742, Example 104::US11180471, Example 104 Plasma kallikrein Human 250 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413711 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413711&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205818 433913814 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115946 CCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(F)c1 InChI=1S/C28H24ClFN6O3/c1-3-4-24(28(38)34-18-6-7-21-22(12-18)32-10-9-31-21)36-14-25(39-2)20(13-27(36)37)19-11-17(29)5-8-23(19)35-15-26(30)33-16-35/h5-16,24H,3-4H2,1-2H3,(H,34,38) ZJEBCRXBTDTSDY-UHFFFAOYSA-N 413712 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-fluoro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanamide (Racemate)::US10421742, Example 105::US11180471, Example 105 Plasma kallikrein Human 47.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413712 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413712&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205899 433913815 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115947 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(F)c1 InChI=1S/C28H26ClFN6O3/c1-4-5-24(28(38)32-19-7-8-22-17(10-19)13-34(2)33-22)36-14-25(39-3)21(12-27(36)37)20-11-18(29)6-9-23(20)35-15-26(30)31-16-35/h6-16,24H,4-5H2,1-3H3,(H,32,38) ZFHCCWVEIZPKIK-UHFFFAOYSA-N 413713 2-{4-[5-Chloro-2-(4-fluoro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 106::US11180471, Example 106 Plasma kallikrein Human 85.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413713 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413713&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205875 433913816 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115948 CCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C26H24Cl2N6O4/c1-3-4-21(26(37)32-16-6-7-19(25(29)36)30-11-16)34-12-22(38-2)18(10-24(34)35)17-9-15(27)5-8-20(17)33-13-23(28)31-14-33/h5-14,21H,3-4H2,1-2H3,(H2,29,36)(H,32,37) ZZSYBTPQPYGNKT-UHFFFAOYSA-N 413714 5-{[2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}pyridine-2-carboxamide (Racemate)::US10421742, Example 107::US11180471, Example 107 Plasma kallikrein Human 200 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413714 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413714&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205208 433913817 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115949 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C28H26Cl2N6O3/c1-4-5-24(28(38)32-19-7-8-22-17(10-19)13-34(2)33-22)36-14-25(39-3)21(12-27(36)37)20-11-18(29)6-9-23(20)35-15-26(30)31-16-35/h6-16,24H,4-5H2,1-3H3,(H,32,38) GJZFNUOEHXFLPK-UHFFFAOYSA-N 413715 2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 108::US11180471, Example 108 Plasma kallikrein Human 67.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413715 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413715&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205633 433913818 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115950 CCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(Cl)c1 InChI=1S/C27H24Cl2N4O5/c1-3-4-22(26(35)31-18-8-5-16(6-9-18)27(36)37)33-13-23(38-2)20(12-25(33)34)19-11-17(28)7-10-21(19)32-14-24(29)30-15-32/h5-15,22H,3-4H2,1-2H3,(H,31,35)(H,36,37) PYCOXKADFBYSOX-UHFFFAOYSA-N 413716 4-{[2-{4-[5-Chloro-2-(4-chloro-1H-imidazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}benzoic acid (Racemate)::US10421742, Example 109::US11180471, Example 109 Plasma kallikrein Human 180 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413716 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413716&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205936 433913819 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115951 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)(F)F InChI=1S/C28H24ClF4N5O5/c1-42-8-7-22(27(41)36-16-4-5-17(26(34)40)20(30)10-16)38-12-23(43-2)19(11-25(38)39)18-9-15(29)3-6-21(18)37-13-24(35-14-37)28(31,32)33/h3-6,9-14,22H,7-8H2,1-2H3,(H2,34,40)(H,36,41) NDZYZAAAWXQARZ-UHFFFAOYSA-N 413717 4-({2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 110::US11180471, Example 110 Plasma kallikrein Human 330 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413717 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413717&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205099 433913820 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115952 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnc(c1)C(F)(F)F InChI=1S/C29H26ClF3N6O4/c1-37-13-17-10-19(5-6-22(17)36-37)35-28(41)24(8-9-42-2)39-14-25(43-3)21(12-27(39)40)20-11-18(30)4-7-23(20)38-15-26(34-16-38)29(31,32)33/h4-7,10-16,24H,8-9H2,1-3H3,(H,35,41) MCUQCQLBAAKRPX-UHFFFAOYSA-N 413718 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 111::US11180471, Example 111 Plasma kallikrein Human 120 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413718 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413718&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205640 433913821 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115953 CCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H23ClN6O5/c1-3-4-21(24(34)28-17-8-5-15(6-9-17)25(35)36)31-13-22(37-2)19(12-23(31)33)18-11-16(26)7-10-20(18)32-14-27-29-30-32/h5-14,21H,3-4H2,1-2H3,(H,28,34)(H,35,36) KXLAWRVDSZAFKG-UHFFFAOYSA-N 413719 4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}benzoic acid (Racemate)::US10421742, Example 112::US11180471, Example 112 Plasma kallikrein Human 2.90 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413719 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413719&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205582 433913822 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115954 CCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H23ClFN7O4/c1-3-4-21(25(37)30-15-6-7-16(24(28)36)19(27)10-15)33-12-22(38-2)18(11-23(33)35)17-9-14(26)5-8-20(17)34-13-29-31-32-34/h5-13,21H,3-4H2,1-2H3,(H2,28,36)(H,30,37) CZWHJSKWMSOPRC-UHFFFAOYSA-N 413720 4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-2-fluorobenzamide (Racemate)::US10421742, Example 113::US11180471, Example 113 Plasma kallikrein Human 3.70 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413720 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413720&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205931 433913823 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115955 CCC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H23ClFN7O4/c1-3-4-21(25(37)30-15-6-7-16(24(28)36)19(27)10-15)33-12-22(38-2)18(11-23(33)35)17-9-14(26)5-8-20(17)34-13-29-31-32-34/h5-13,21H,3-4H2,1-2H3,(H2,28,36)(H,30,37)/t21-/m0/s1 CZWHJSKWMSOPRC-NRFANRHFSA-N 413721 4-{[(2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-2-fluorobenzamide (Enantiomer 1)::US10421742, Example 114::US11180471, Example 114 Plasma kallikrein Human 1.30 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413721 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413721&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205929 433913824 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115956 CCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C24H23ClN8O4/c1-3-4-20(24(36)29-15-6-7-18(23(26)35)27-11-15)32-12-21(37-2)17(10-22(32)34)16-9-14(25)5-8-19(16)33-13-28-30-31-33/h5-13,20H,3-4H2,1-2H3,(H2,26,35)(H,29,36) AWLPKPUSDZNVQR-UHFFFAOYSA-N 413722 5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}pyridine-2-carboxamide (Racemate)::US10421742, Example 115::US11180471, Example 115 Plasma kallikrein Human 1.90 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413722 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413722&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205390 433913825 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115957 CCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H25ClN8O4/c1-4-5-21(25(37)30-16-7-8-19(28-12-16)24(36)27-2)33-13-22(38-3)18(11-23(33)35)17-10-15(26)6-9-20(17)34-14-29-31-32-34/h6-14,21H,4-5H2,1-3H3,(H,27,36)(H,30,37) NZYSNSQHJHYDEI-UHFFFAOYSA-N 413723 5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]-amino}-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 116::US11180471, Example 116 Plasma kallikrein Human 1.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413723 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413723&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205823 433913826 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115958 CCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H23ClN8O3/c1-3-4-23(26(37)31-17-6-7-20-21(12-17)29-10-9-28-20)34-14-24(38-2)19(13-25(34)36)18-11-16(27)5-8-22(18)35-15-30-32-33-35/h5-15,23H,3-4H2,1-2H3,(H,31,37) BSNRZZUTVDCZAA-UHFFFAOYSA-N 413724 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanamide (Racemate)::US10421742, Example 117::US11180471, Example 117 Plasma kallikrein Human 0.970 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413724 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413724&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205052 433913827 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115959 CCC[C@@H](C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H23ClN8O3/c1-3-4-23(26(37)31-17-6-7-20-21(12-17)29-10-9-28-20)34-14-24(38-2)19(13-25(34)36)18-11-16(27)5-8-22(18)35-15-30-32-33-35/h5-15,23H,3-4H2,1-2H3,(H,31,37)/t23-/m0/s1 BSNRZZUTVDCZAA-QHCPKHFHSA-N 413725 N-(Quinoxalin-6-yl)-(2S)-2-{4-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanamide (Enantiomer 2)::US10421742, Example 118::US11180471, Example 118 Plasma kallikrein Human 0.570 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413725 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413725&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211528 433913828 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115960 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H25ClN8O3/c1-4-5-23(26(37)29-18-7-8-21-16(10-18)13-33(2)30-21)34-14-24(38-3)20(12-25(34)36)19-11-17(27)6-9-22(19)35-15-28-31-32-35/h6-15,23H,4-5H2,1-3H3,(H,29,37) DROSFHKHAAIBHD-UHFFFAOYSA-N 413726 2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 119::US11180471, Example 119 Plasma kallikrein Human 1.10 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413726 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413726&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204930 433913829 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115961 CCC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H25ClN8O3/c1-4-5-23(26(37)29-18-7-8-21-16(10-18)13-33(2)30-21)34-14-24(38-3)20(12-25(34)36)19-11-17(27)6-9-22(19)35-15-28-31-32-35/h6-15,23H,4-5H2,1-3H3,(H,29,37)/t23-/m0/s1 DROSFHKHAAIBHD-QHCPKHFHSA-N 413727 (2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Enantiomer 2)::US10421742, Example 120::US11180471, Example 120 Plasma kallikrein Human 0.780 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413727 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413727&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204928 433913830 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115962 CCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H24ClF3N6O4/c1-3-4-22(27(40)33-15-6-7-16(26(32)39)19(29)10-15)36-13-23(41-2)18(11-24(36)38)17-9-14(28)5-8-21(17)37-12-20(25(30)31)34-35-37/h5-13,22,25H,3-4H2,1-2H3,(H2,32,39)(H,33,40) WZUXJAUBKKDABN-UHFFFAOYSA-N 413728 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 121::US11180471, Example 121 Plasma kallikrein Human 39.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413728 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413728&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205311 433913831 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115963 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H26ClF2N7O3/c1-4-5-24(28(40)32-18-7-8-21-16(10-18)13-36(2)34-21)37-15-25(41-3)20(12-26(37)39)19-11-17(29)6-9-23(19)38-14-22(27(30)31)33-35-38/h6-15,24,27H,4-5H2,1-3H3,(H,32,40) TZKJUKFMINMKSP-UHFFFAOYSA-N 413729 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 122::US11180471, Example 122 Plasma kallikrein Human 16.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413729 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413729&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205690 433913832 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115964 CCC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H26ClF2N7O3/c1-4-5-24(28(40)32-18-7-8-21-16(10-18)13-36(2)34-21)37-15-25(41-3)20(12-26(37)39)19-11-17(29)6-9-23(19)38-14-22(27(30)31)33-35-38/h6-15,24,27H,4-5H2,1-3H3,(H,32,40)/t24-/m0/s1 TZKJUKFMINMKSP-DEOSSOPVSA-N 413730 (2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)pentanamide (Enantiomer 2)::US10421742, Example 123::US11180471, Example 123 Plasma kallikrein Human 4.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413730 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413730&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205688 433913833 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115965 CCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H26ClF2N7O4/c1-4-5-22(27(40)33-16-7-8-19(32-12-16)26(39)31-2)36-14-23(41-3)18(11-24(36)38)17-10-15(28)6-9-21(17)37-13-20(25(29)30)34-35-37/h6-14,22,25H,4-5H2,1-3H3,(H,31,39)(H,33,40) ZZXQOEFXCPENDW-UHFFFAOYSA-N 413731 5-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 124::US11180471, Example 124 Plasma kallikrein Human 24.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413731 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413731&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204627 433913834 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115966 CCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2FN6O4/c1-3-4-21(26(38)31-15-6-7-16(25(30)37)19(29)10-15)34-12-22(39-2)18(11-24(34)36)17-9-14(27)5-8-20(17)35-13-23(28)32-33-35/h5-13,21H,3-4H2,1-2H3,(H2,30,37)(H,31,38) KQZYQOJQXJGZMI-UHFFFAOYSA-N 413732 4-{[2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-2-fluorobenzamide (Racemate)::US10421742, Example 125::US11180471, Example 125 Plasma kallikrein Human 13.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413732 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413732&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204823 433913835 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115967 CCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2N7O3/c1-3-4-23(27(38)32-17-6-7-20-21(12-17)31-10-9-30-20)35-14-24(39-2)19(13-26(35)37)18-11-16(28)5-8-22(18)36-15-25(29)33-34-36/h5-15,23H,3-4H2,1-2H3,(H,32,38) AJXCDVGDMKCSJV-UHFFFAOYSA-N 413733 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanamide (Racemate)::US10421742, Example 126::US11180471, Example 126 Plasma kallikrein Human 3.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413733 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413733&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204993 433913836 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115968 CCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H25Cl2N7O4/c1-4-5-21(26(38)31-16-7-8-19(30-12-16)25(37)29-2)34-13-22(39-3)18(11-24(34)36)17-10-15(27)6-9-20(17)35-14-23(28)32-33-35/h6-14,21H,4-5H2,1-3H3,(H,29,37)(H,31,38) RMNQUVGQJWBXRY-UHFFFAOYSA-N 413734 5-{[2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 127::US11180471, Example 127 Plasma kallikrein Human 7.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413734 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413734&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205374 433913837 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115969 CCC[C@@H](C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H25Cl2N7O4/c1-4-5-21(26(38)31-16-7-8-19(30-12-16)25(37)29-2)34-13-22(39-3)18(11-24(34)36)17-10-15(27)6-9-20(17)35-14-23(28)32-33-35/h6-14,21H,4-5H2,1-3H3,(H,29,37)(H,31,38)/t21-/m0/s1 RMNQUVGQJWBXRY-NRFANRHFSA-N 413735 5-{[(2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-N-methylpyridine-2-carboxamide (Enantiomer 2)::US10421742, Example 128::US11180471, Example 128 Plasma kallikrein Human 4.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413735 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413735&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205795 433913838 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115970 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O3/c1-4-5-23(27(38)30-18-7-8-21-16(10-18)13-34(2)32-21)35-14-24(39-3)20(12-26(35)37)19-11-17(28)6-9-22(19)36-15-25(29)31-33-36/h6-15,23H,4-5H2,1-3H3,(H,30,38) XMGACJAVDNSYFS-UHFFFAOYSA-N 413736 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 129::US11180471, Example 129 Plasma kallikrein Human 6.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413736 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413736&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205483 433913839 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115971 CCC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O3/c1-4-5-23(27(38)30-18-7-8-21-16(10-18)13-34(2)32-21)35-14-24(39-3)20(12-26(35)37)19-11-17(28)6-9-22(19)36-15-25(29)31-33-36/h6-15,23H,4-5H2,1-3H3,(H,30,38)/t23-/m0/s1 XMGACJAVDNSYFS-QHCPKHFHSA-N 413737 (2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Enantiomer 2)::US10421742, Example 130::US11180471, Example 130 Plasma kallikrein Human 3.10 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413737 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413737&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205651 433913840 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115972 CCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C27H28ClN5O5/c1-4-5-23(27(36)31-17-7-9-22(30-14-17)26(35)29-2)33-15-24(37-3)20(13-25(33)34)19-12-16(28)6-8-18(19)21-10-11-38-32-21/h6-9,12-15,23H,4-5,10-11H2,1-3H3,(H,29,35)(H,31,36) FVMMOGSUTBHAJT-UHFFFAOYSA-N 413738 5-{[2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 131::US11180471, Example 131 Plasma kallikrein Human 250 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413738 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413738&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205781 433913841 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115973 CCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C28H28ClN5O4/c1-4-5-25(28(36)30-19-7-9-23-17(12-19)15-33(2)31-23)34-16-26(37-3)22(14-27(34)35)21-13-18(29)6-8-20(21)24-10-11-38-32-24/h6-9,12-16,25H,4-5,10-11H2,1-3H3,(H,30,36) GGCCNKNGPKYJET-UHFFFAOYSA-N 413739 2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)pentanamide (Racemate)::US10421742, Example 132::US11180471, Example 132 Plasma kallikrein Human 110 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413739 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413739&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205590 433913842 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115974 CCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C27H26ClFN4O5/c1-3-4-23(27(36)31-16-6-8-18(26(30)35)21(29)12-16)33-14-24(37-2)20(13-25(33)34)19-11-15(28)5-7-17(19)22-9-10-38-32-22/h5-8,11-14,23H,3-4,9-10H2,1-2H3,(H2,30,35)(H,31,36) CACLNVKPTHLQAL-UHFFFAOYSA-N 413740 4-{[2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-2-fluorobenzamide (Racemate)::US10421742, Example 133::US11180471, Example 133 Plasma kallikrein Human 460 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413740 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413740&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211499 433913843 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115975 CCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C28H26ClN5O4/c1-3-4-25(28(36)32-18-6-8-23-24(14-18)31-11-10-30-23)34-16-26(37-2)21(15-27(34)35)20-13-17(29)5-7-19(20)22-9-12-38-33-22/h5-8,10-11,13-16,25H,3-4,9,12H2,1-2H3,(H,32,36) QYYKJTWIVWXLBD-UHFFFAOYSA-N 413741 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanamide (Racemate)::US10421742, Example 134::US11180471, Example 134 Plasma kallikrein Human 45.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413741 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413741&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204822 433913844 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115976 CCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C26H26ClN5O5/c1-3-4-22(26(35)30-16-6-8-21(25(28)34)29-13-16)32-14-23(36-2)19(12-24(32)33)18-11-15(27)5-7-17(18)20-9-10-37-31-20/h5-8,11-14,22H,3-4,9-10H2,1-2H3,(H2,28,34)(H,30,35) WRJUZVZDXJUFIS-UHFFFAOYSA-N 413742 5-{[2-{4-[5-Chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}pyridine-2-carboxamide (Racemate)::US10421742, Example 135::US11180471, Example 135 Plasma kallikrein Human 380 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413742 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413742&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205806 433913845 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115977 CCCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H25ClN8O4/c1-3-4-5-21(25(37)30-16-7-8-19(24(27)36)28-12-16)33-13-22(38-2)18(11-23(33)35)17-10-15(26)6-9-20(17)34-14-29-31-32-34/h6-14,21H,3-5H2,1-2H3,(H2,27,36)(H,30,37) ZIAUCGPBMPJNBL-UHFFFAOYSA-N 413743 5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}hexanoyl]amino}pyridine-2-carboxamide (Racemate)::US10421742, Example 136::US11180471, Example 136 Plasma kallikrein Human 2.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413743 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413743&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205668 433913846 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115978 CCCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H25ClFN7O4/c1-3-4-5-22(26(38)31-16-7-8-17(25(29)37)20(28)11-16)34-13-23(39-2)19(12-24(34)36)18-10-15(27)6-9-21(18)35-14-30-32-33-35/h6-14,22H,3-5H2,1-2H3,(H2,29,37)(H,31,38) VQBUYPWHWZACJN-UHFFFAOYSA-N 413744 4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}hexanoyl]amino}-2-fluorobenzamide (Racemate)::US10421742, Example 137::US11180471, Example 137 Plasma kallikrein Human 2.10 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413744 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413744&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205878 433913847 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115979 CCCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H25ClN6O5/c1-3-4-5-22(25(35)29-18-9-6-16(7-10-18)26(36)37)32-14-23(38-2)20(13-24(32)34)19-12-17(27)8-11-21(19)33-15-28-30-31-33/h6-15,22H,3-5H2,1-2H3,(H,29,35)(H,36,37) FCSAYDZPMDLFSN-UHFFFAOYSA-N 413745 4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}hexanoyl]amino}benzoic acid (Racemate)::US10421742, Example 138::US11180471, Example 138 Plasma kallikrein Human 1.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413745 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413745&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205666 433913848 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115980 CCCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C27H27ClN8O3/c1-4-5-6-24(27(38)30-19-8-9-22-17(11-19)14-34(2)31-22)35-15-25(39-3)21(13-26(35)37)20-12-18(28)7-10-23(20)36-16-29-32-33-36/h7-16,24H,4-6H2,1-3H3,(H,30,38) GTVFMNZALGQANW-UHFFFAOYSA-N 413746 2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)hexanamide (Racemate)::US10421742, Example 139::US11180471, Example 139 Plasma kallikrein Human 1.000 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413746 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413746&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205025 433913849 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115981 CCCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C27H25ClN8O3/c1-3-4-5-24(27(38)32-18-7-8-21-22(13-18)30-11-10-29-21)35-15-25(39-2)20(14-26(35)37)19-12-17(28)6-9-23(19)36-16-31-33-34-36/h6-16,24H,3-5H2,1-2H3,(H,32,38) DVTLDIPPLKDTBX-UHFFFAOYSA-N 413747 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}hexanamide (Racemate)::US10421742, Example 140::US11180471, Example 140 Plasma kallikrein Human 1.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413747 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413747&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205988 433913850 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115982 CCCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C26H27ClN8O4/c1-4-5-6-22(26(38)31-17-8-9-20(29-13-17)25(37)28-2)34-14-23(39-3)19(12-24(34)36)18-11-16(27)7-10-21(18)35-15-30-32-33-35/h7-15,22H,4-6H2,1-3H3,(H,28,37)(H,31,38) ORRIMSVBDDRCMC-UHFFFAOYSA-N 413748 5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}hexanoyl]amino}-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 141::US11180471, Example 141 Plasma kallikrein Human 1.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413748 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413748&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205579 433913851 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115983 CCCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H26ClF2N5O5/c1-3-4-5-23(27(38)32-18-9-6-16(7-10-18)28(39)40)35-15-24(41-2)20(13-25(35)37)19-12-17(29)8-11-22(19)36-14-21(26(30)31)33-34-36/h6-15,23,26H,3-5H2,1-2H3,(H,32,38)(H,39,40) PSPFOZLTTSZDFP-UHFFFAOYSA-N 413749 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]hexanoyl}amino)benzoic acid (Racemate)::US10421742, Example 142::US11180471, Example 142 Plasma kallikrein Human 11.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413749 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413749&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204833 433913852 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115984 CCCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H26ClF2N7O4/c1-3-4-5-22(27(40)33-16-7-8-19(26(31)39)32-12-16)36-14-23(41-2)18(11-24(36)38)17-10-15(28)6-9-21(17)37-13-20(25(29)30)34-35-37/h6-14,22,25H,3-5H2,1-2H3,(H2,31,39)(H,33,40) JSHWYUYKRGKALM-UHFFFAOYSA-N 413750 5-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]hexanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 143::US11180471, Example 143 Plasma kallikrein Human 21.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413750 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413750&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205512 433913853 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115985 CCCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H26ClF3N6O4/c1-3-4-5-23(28(41)34-16-7-8-17(27(33)40)20(30)11-16)37-14-24(42-2)19(12-25(37)39)18-10-15(29)6-9-22(18)38-13-21(26(31)32)35-36-38/h6-14,23,26H,3-5H2,1-2H3,(H2,33,40)(H,34,41) HGCFEYDNSXOVOU-UHFFFAOYSA-N 413751 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]hexanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 144::US11180471, Example 144 Plasma kallikrein Human 30.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413751 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413751&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205069 433913854 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115986 CCCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H28ClF2N7O3/c1-4-5-6-25(29(41)33-19-8-9-22-17(11-19)14-37(2)35-22)38-16-26(42-3)21(13-27(38)40)20-12-18(30)7-10-24(20)39-15-23(28(31)32)34-36-39/h7-16,25,28H,4-6H2,1-3H3,(H,33,41) OUOIBTWZEMQDJD-UHFFFAOYSA-N 413752 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)hexanamide (Racemate)::US10421742, Example 145::US11180471, Example 145 Plasma kallikrein Human 7.30 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413752 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413752&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205547 433913855 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115987 CCCCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H26ClF2N7O3/c1-3-4-5-25(29(41)35-18-7-8-21-22(13-18)34-11-10-33-21)38-16-26(42-2)20(14-27(38)40)19-12-17(30)6-9-24(19)39-15-23(28(31)32)36-37-39/h6-16,25,28H,3-5H2,1-2H3,(H,35,41) YGFSDBVKNXCHFA-UHFFFAOYSA-N 413753 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]hexanamide (Racemate)::US10421742, Example 146::US11180471, Example 146 Plasma kallikrein Human 5.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413753 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413753&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205951 433913856 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115988 CCCCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H28ClF2N7O4/c1-4-5-6-23(28(41)34-17-8-9-20(33-13-17)27(40)32-2)37-15-24(42-3)19(12-25(37)39)18-11-16(29)7-10-22(18)38-14-21(26(30)31)35-36-38/h7-15,23,26H,4-6H2,1-3H3,(H,32,40)(H,34,41) LATWNRFJRFBWAT-UHFFFAOYSA-N 413754 5-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]hexanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 147::US11180471, Example 147 Plasma kallikrein Human 13.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413754 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413754&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206088 433913857 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115989 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C26H20ClF3N4O6/c1-3-19(22(36)31-15-7-4-13(5-8-15)24(37)38)34-12-20(39-2)18(11-21(34)35)17-10-14(27)6-9-16(17)23-32-33-25(40-23)26(28,29)30/h4-12,19H,3H2,1-2H3,(H,31,36)(H,37,38) QIVMZHNMVQBPGT-UHFFFAOYSA-N 413755 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)benzoic acid (Racemate)::US10421742, Example 148::US11180471, Example 148 Plasma kallikrein Human 200 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413755 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413755&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205817 433913858 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115990 CCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C25H20ClF3N6O5/c1-3-18(22(38)32-13-5-7-17(21(30)37)31-10-13)35-11-19(39-2)16(9-20(35)36)15-8-12(26)4-6-14(15)23-33-34-24(40-23)25(27,28)29/h4-11,18H,3H2,1-2H3,(H2,30,37)(H,32,38) IQJSIJCMDLKBFX-UHFFFAOYSA-N 413756 5-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 149::US11180471, Example 149 Plasma kallikrein Human 210 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413756 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413756&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206048 433913859 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115991 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C26H20ClF4N5O5/c1-3-19(23(39)33-13-5-7-15(22(32)38)18(28)9-13)36-11-20(40-2)17(10-21(36)37)16-8-12(27)4-6-14(16)24-34-35-25(41-24)26(29,30)31/h4-11,19H,3H2,1-2H3,(H2,32,38)(H,33,39) UHOHRXOOGVHYED-UHFFFAOYSA-N 413757 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 150::US11180471, Example 150 Plasma kallikrein Human 210 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413757 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413757&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205709 433913860 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115992 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C27H22ClF3N6O4/c1-4-21(24(39)32-16-6-8-20-14(9-16)12-36(2)35-20)37-13-22(40-3)19(11-23(37)38)18-10-15(28)5-7-17(18)25-33-34-26(41-25)27(29,30)31/h5-13,21H,4H2,1-3H3,(H,32,39) HHSBQKYCPNEOQX-UHFFFAOYSA-N 413758 2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 151::US11180471, Example 151 Plasma kallikrein Human 71.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413758 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413758&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205384 433913861 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115993 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C27H20ClF3N6O4/c1-3-21(24(39)34-15-5-7-19-20(11-15)33-9-8-32-19)37-13-22(40-2)18(12-23(37)38)17-10-14(28)4-6-16(17)25-35-36-26(41-25)27(29,30)31/h4-13,21H,3H2,1-2H3,(H,34,39) OLLLLNYOIWPNPJ-UHFFFAOYSA-N 413759 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanamide (Racemate)::US10421742, Example 152::US11180471, Example 152 Plasma kallikrein Human 40.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413759 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413759&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205969 433913862 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115994 CCC(C(=O)Nc1ccc(C(=O)NC)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C27H22ClF4N5O5/c1-4-20(24(40)34-14-6-8-16(19(29)10-14)23(39)33-2)37-12-21(41-3)18(11-22(37)38)17-9-13(28)5-7-15(17)25-35-36-26(42-25)27(30,31)32/h5-12,20H,4H2,1-3H3,(H,33,39)(H,34,40) DLRRJLUTWALOOR-UHFFFAOYSA-N 413760 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluoro-N-methylbenzamide (Racemate)::US10421742, Example 153::US11180471, Example 153 Plasma kallikrein Human 270 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413760 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413760&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204746 433913863 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115995 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C26H21ClF2N4O6/c1-3-19(23(35)30-15-7-4-13(5-8-15)26(36)37)33-12-20(38-2)18(11-21(33)34)17-10-14(27)6-9-16(17)24-31-32-25(39-24)22(28)29/h4-12,19,22H,3H2,1-2H3,(H,30,35)(H,36,37) ARBVSWGIQYWRFI-UHFFFAOYSA-N 413761 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)benzoic acid (Racemate)::US10421742, Example 154::US11180471, Example 154 Plasma kallikrein Human 170 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413761 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413761&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205186 433913864 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115996 CCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C25H21ClF2N6O5/c1-3-18(23(37)31-13-5-7-17(22(29)36)30-10-13)34-11-19(38-2)16(9-20(34)35)15-8-12(26)4-6-14(15)24-32-33-25(39-24)21(27)28/h4-11,18,21H,3H2,1-2H3,(H2,29,36)(H,31,37) MXCXAGMMMBQTPS-UHFFFAOYSA-N 413762 5-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 155::US11180471, Example 155 Plasma kallikrein Human 140 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413762 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413762&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205309 433913865 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115997 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C26H21ClF3N5O5/c1-3-19(24(38)32-13-5-7-15(23(31)37)18(28)9-13)35-11-20(39-2)17(10-21(35)36)16-8-12(27)4-6-14(16)25-33-34-26(40-25)22(29)30/h4-11,19,22H,3H2,1-2H3,(H2,31,37)(H,32,38) GELPZCSNZJPUPR-UHFFFAOYSA-N 413763 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 156::US11180471, Example 160 Plasma kallikrein Human 170 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413763 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413763&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205925 433913866 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115998 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C27H23ClF2N6O4/c1-4-21(25(38)31-16-6-8-20-14(9-16)12-35(2)34-20)36-13-22(39-3)19(11-23(36)37)18-10-15(28)5-7-17(18)26-32-33-27(40-26)24(29)30/h5-13,21,24H,4H2,1-3H3,(H,31,38) HUAFIQJRZLYLOU-UHFFFAOYSA-N 413764 2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 157::US11180471, Example 157 Plasma kallikrein Human 65.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413764 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413764&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205941 433913867 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1115999 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C27H21ClF2N6O4/c1-3-21(25(38)33-15-5-7-19-20(11-15)32-9-8-31-19)36-13-22(39-2)18(12-23(36)37)17-10-14(28)4-6-16(17)26-34-35-27(40-26)24(29)30/h4-13,21,24H,3H2,1-2H3,(H,33,38) ZXOWUCFZXVCGPI-UHFFFAOYSA-N 413765 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanamide (Racemate)::US10421742, Example 158::US11180471, Example 158 Plasma kallikrein Human 32.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413765 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413765&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205104 433913868 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116000 CCC(C(=O)Nc1ccc(C(=O)NC)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C27H23ClF3N5O5/c1-4-20(25(39)33-14-6-8-16(19(29)10-14)24(38)32-2)36-12-21(40-3)18(11-22(36)37)17-9-13(28)5-7-15(17)26-34-35-27(41-26)23(30)31/h5-12,20,23H,4H2,1-3H3,(H,32,38)(H,33,39) XEUUKFFBCFEEHJ-UHFFFAOYSA-N 413766 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluoro-N-methylbenzamide (Racemate)::US10421742, Example 159::US11180471, Example 159 Plasma kallikrein Human 230 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413766 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413766&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205157 433913869 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116001 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)F InChI=1S/C26H21ClF3N5O5/c1-3-19(24(38)32-13-5-7-15(23(31)37)18(28)9-13)35-11-20(39-2)17(10-21(35)36)16-8-12(27)4-6-14(16)25-33-34-26(40-25)22(29)30/h4-11,19,22H,3H2,1-2H3,(H2,31,37)(H,32,38) GELPZCSNZJPUPR-UHFFFAOYSA-N 413763 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 156::US11180471, Example 160 Plasma kallikrein Human 18.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413763 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413763&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205925 433913866 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116002 CC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C26H22ClF3N6O4/c1-3-20(26(39)32-14-5-6-15(25(31)38)18(28)9-14)35-12-22(40-2)17(10-23(35)37)16-8-13(27)4-7-21(16)36-11-19(24(29)30)33-34-36/h4-12,20,24H,3H2,1-2H3,(H2,31,38)(H,32,39)/t20-/m0/s1 OETZVLILMHLZTG-FQEVSTJZSA-N 413768 4-({(2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 161::US11180471, Example 161 Plasma kallikrein Human 14.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413768 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413768&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205281 433913871 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116003 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H22ClF2N7O3/c1-3-22(27(39)33-16-5-6-19-20(11-16)32-9-8-31-19)36-14-24(40-2)18(12-25(36)38)17-10-15(28)4-7-23(17)37-13-21(26(29)30)34-35-37/h4-14,22,26H,3H2,1-2H3,(H,33,39) OEMBYSUFEIJUEQ-UHFFFAOYSA-N 413769 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanamide (Racemate)::US10421742, Example 162::US11180471, Example 162 Plasma kallikrein Human 5.90 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413769 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413769&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205522 433913872 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116004 CC[C@@H](C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H22ClF2N7O3/c1-3-22(27(39)33-16-5-6-19-20(11-16)32-9-8-31-19)36-14-24(40-2)18(12-25(36)38)17-10-15(28)4-7-23(17)37-13-21(26(29)30)34-35-37/h4-14,22,26H,3H2,1-2H3,(H,33,39)/t22-/m0/s1 OEMBYSUFEIJUEQ-QFIPXVFZSA-N 413770 N-(Quinoxalin-6-yl)-(2S)-2-[4-{5-chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanamide (Enantiomer 2)::US10421742, Example 163::US11180471, Example 163 Plasma kallikrein Human 1.70 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413770 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413770&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205521 433913873 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116005 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H24ClF2N7O3/c1-4-22(27(39)31-17-6-7-20-15(9-17)12-35(2)33-20)36-14-24(40-3)19(11-25(36)38)18-10-16(28)5-8-23(18)37-13-21(26(29)30)32-34-37/h5-14,22,26H,4H2,1-3H3,(H,31,39) UAHXABWWDRJQRK-UHFFFAOYSA-N 413771 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 164::US11180471, Example 164 Plasma kallikrein Human 8.20 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413771 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413771&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205536 433913874 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116006 CC[C@@H](C(=O)Nc1ccc2cn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H25ClF2N6O3/c1-4-23(28(39)32-19-7-5-16-12-35(2)13-17(16)9-19)36-15-25(40-3)21(11-26(36)38)20-10-18(29)6-8-24(20)37-14-22(27(30)31)33-34-37/h5-15,23,27H,4H2,1-3H3,(H,32,39)/t23-/m0/s1 VFCPFXPPJSVUEB-QHCPKHFHSA-N 528187 (2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (enantiomer 2)::US11180471, Example 165 Plasma kallikrein Human 3.20 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528187 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528187&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 163200077 463791736 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116007 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C26H22ClF2N5O5/c1-3-20(25(36)30-16-7-4-14(5-8-16)26(37)38)33-13-22(39-2)18(11-23(33)35)17-10-15(27)6-9-21(17)34-12-19(24(28)29)31-32-34/h4-13,20,24H,3H2,1-2H3,(H,30,36)(H,37,38) NNJGQRMOKIHSCI-UHFFFAOYSA-N 413773 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)benzoic acid (Racemate)::US10421742, Example 166::US11180471, Example 166 Plasma kallikrein Human 20.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413773 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413773&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205919 433913876 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116008 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2N7O3/c1-4-21(26(37)29-17-6-7-20-15(9-17)12-33(2)31-20)34-13-23(38-3)19(11-25(34)36)18-10-16(27)5-8-22(18)35-14-24(28)30-32-35/h5-14,21H,4H2,1-3H3,(H,29,37) QBWXHIMIUSZAOP-UHFFFAOYSA-N 413774 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 167::US10421742, Example 225::US11180471, Example 225 Plasma kallikrein Human 6.30 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413774 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413774&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205467 433913877 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116009 CC[C@@H](C(=O)Nc1ccc2cn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H24Cl2N6O3/c1-4-22(27(37)30-19-7-5-16-12-33(2)13-17(16)9-19)34-14-24(38-3)21(11-26(34)36)20-10-18(28)6-8-23(20)35-15-25(29)31-32-35/h5-15,22H,4H2,1-3H3,(H,30,37)/t22-/m0/s1 HNHBZVLOAXVGOW-QFIPXVFZSA-N 528190 (2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (enantiomer 2)::US11180471, Example 168 Plasma kallikrein Human 2.10 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528190 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528190&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 163200078 463791738 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116010 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2N7O3/c1-3-21(26(37)31-16-5-6-19-20(11-16)30-9-8-29-19)34-13-23(38-2)18(12-25(34)36)17-10-15(27)4-7-22(17)35-14-24(28)32-33-35/h4-14,21H,3H2,1-2H3,(H,31,37) QWJAHBCIMJSNPO-UHFFFAOYSA-N 413776 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanamide (Racemate)::US10421742, Example 169::US11180471, Example 169 Plasma kallikrein Human 3.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413776 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413776&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205827 433913879 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116011 CC[C@@H](C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2N7O3/c1-3-21(26(37)31-16-5-6-19-20(11-16)30-9-8-29-19)34-13-23(38-2)18(12-25(34)36)17-10-15(27)4-7-22(17)35-14-24(28)32-33-35/h4-14,21H,3H2,1-2H3,(H,31,37)/t21-/m0/s1 QWJAHBCIMJSNPO-NRFANRHFSA-N 413777 N-(Quinoxalin-6-yl)-(2S)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanamide (Enantiomer 2)::US10421742, Example 170::US11180471, Example 170 Plasma kallikrein Human 1.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413777 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413777&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206028 433913880 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116012 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H21Cl2FN6O4/c1-3-19(25(37)30-14-5-6-15(24(29)36)18(28)9-14)33-11-21(38-2)17(10-23(33)35)16-8-13(26)4-7-20(16)34-12-22(27)31-32-34/h4-12,19H,3H2,1-2H3,(H2,29,36)(H,30,37) FPAKZDLGEHHCTC-UHFFFAOYSA-N 413778 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 171::US11180471, Example 171 Plasma kallikrein Human 9.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413778 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413778&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205799 433913881 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116013 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C25H23ClN8O3/c1-4-21(25(36)28-17-6-7-20-15(9-17)12-32(2)29-20)33-13-23(37-3)19(11-24(33)35)18-10-16(26)5-8-22(18)34-14-27-30-31-34/h5-14,21H,4H2,1-3H3,(H,28,36) IQNORUMXNDXEIL-UHFFFAOYSA-N 528194 2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (racemate)::US11180471, Example 172 Plasma kallikrein Human 1.70 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528194 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528194&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 142742732 463791741 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116014 COc1cn(C(CC2CCC2)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C29H25Cl2N7O3/c1-41-26-15-37(28(39)14-21(26)20-12-18(30)5-8-24(20)38-16-27(31)35-36-38)25(11-17-3-2-4-17)29(40)34-19-6-7-22-23(13-19)33-10-9-32-22/h5-10,12-17,25H,2-4,11H2,1H3,(H,34,40) MZJDBIVMBJLQSX-UHFFFAOYSA-N 413780 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-cyclobutylpropanamide (Racemate)::US10421742, Example 173::US11180471, Example 173 Plasma kallikrein Human 5.90 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413780 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413780&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206019 433913883 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116015 CCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)F InChI=1S/C26H22ClF2N5O5/c1-3-20(26(37)32-14-5-7-18(25(30)36)31-11-14)34-12-22(38-2)17(9-23(34)35)16-8-13(27)4-6-15(16)19-10-21(24(28)29)39-33-19/h4-12,20,24H,3H2,1-2H3,(H2,30,36)(H,32,37) CFZRHXMVQOAQBA-UHFFFAOYSA-N 413781 5-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 174::US11180471, Example 174 Plasma kallikrein Human 15.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413781 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413781&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205546 433913884 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116016 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)F InChI=1S/C27H22ClF3N4O5/c1-3-21(27(38)33-14-5-7-16(26(32)37)19(29)9-14)35-12-23(39-2)18(10-24(35)36)17-8-13(28)4-6-15(17)20-11-22(25(30)31)40-34-20/h4-12,21,25H,3H2,1-2H3,(H2,32,37)(H,33,38) WJQZEXDXRMYEAJ-UHFFFAOYSA-N 413782 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 175::US11180471, Example 175 Plasma kallikrein Human 38.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413782 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413782&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205744 433913885 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116017 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)F InChI=1S/C28H24ClF2N5O4/c1-4-23(28(38)32-17-6-8-21-15(9-17)13-35(2)33-21)36-14-25(39-3)20(11-26(36)37)19-10-16(29)5-7-18(19)22-12-24(27(30)31)40-34-22/h5-14,23,27H,4H2,1-3H3,(H,32,38) YPTNTTHZSPASJM-UHFFFAOYSA-N 413783 2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 176::US11180471, Example 176 Plasma kallikrein Human 14.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413783 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413783&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205796 433913886 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116018 CCC(C(=O)Nc1ccc(C(=O)NC)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)F InChI=1S/C28H24ClF3N4O5/c1-4-22(28(39)34-15-6-8-17(20(30)10-15)27(38)33-2)36-13-24(40-3)19(11-25(36)37)18-9-14(29)5-7-16(18)21-12-23(26(31)32)41-35-21/h5-13,22,26H,4H2,1-3H3,(H,33,38)(H,34,39) GWQBOPAUXMQWRD-UHFFFAOYSA-N 413784 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluoro-N-methylbenzamide (Racemate)::US10421742, Example 177::US11180471, Example 177 Plasma kallikrein Human 43.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413784 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413784&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205630 433913887 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116019 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)F InChI=1S/C28H22ClF2N5O4/c1-3-23(28(38)34-16-5-7-20-22(11-16)33-9-8-32-20)36-14-25(39-2)19(12-26(36)37)18-10-15(29)4-6-17(18)21-13-24(27(30)31)40-35-21/h4-14,23,27H,3H2,1-2H3,(H,34,38) VCYPQGRHNOEINV-UHFFFAOYSA-N 413785 N-(Quinoxalin-6-yl)-2-[4-{5-chloro-2-[5-(difluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanamide (Racemate)::US10421742, Example 178::US11180471, Example 178 Plasma kallikrein Human 24.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413785 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413785&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205450 433913888 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116020 COc1cn(C(CCOC(C)(C)C)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C1=NOCC1 InChI=1S/C30H32ClN3O7/c1-30(2,3)40-13-12-25(28(36)32-20-8-5-18(6-9-20)29(37)38)34-17-26(39-4)23(16-27(34)35)22-15-19(31)7-10-21(22)24-11-14-41-33-24/h5-10,15-17,25H,11-14H2,1-4H3,(H,32,36)(H,37,38) IZEONOSVIATBHE-UHFFFAOYSA-N 413786 4-[(4-tert-Butoxy-2-{4-[5-chloro-2-(4,5-dihydro-1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]benzoic acid (Racemate)::US10421742, Example 179::US11180471, Example 179 Plasma kallikrein Human 260 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413786 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413786&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205653 433913889 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116021 COCC[C@@H](C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnn(c1)C(F)F InChI=1S/C28H25ClF2N4O6/c1-40-10-9-23(26(37)33-19-6-3-16(4-7-19)27(38)39)34-15-24(41-2)22(12-25(34)36)21-11-18(29)5-8-20(21)17-13-32-35(14-17)28(30)31/h3-8,11-15,23,28H,9-10H2,1-2H3,(H,33,37)(H,38,39)/t23-/m0/s1 KPDQGYYQHYCMAC-QHCPKHFHSA-N 413787 4-({(2S)-2-[4-{5-Chloro-2-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Enantiomer 2)::US10421742, Example 180::US11180471, Example 180 Plasma kallikrein Human 71.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413787 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413787&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205723 433913890 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116022 COCC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(o1)C(F)(F)F InChI=1S/C27H22ClF4N5O6/c1-41-8-7-20(24(40)34-14-4-6-16(23(33)39)19(29)10-14)37-12-21(42-2)18(11-22(37)38)17-9-13(28)3-5-15(17)25-35-36-26(43-25)27(30,31)32/h3-6,9-12,20H,7-8H2,1-2H3,(H2,33,39)(H,34,40)/t20-/m0/s1 FGIRAZNDJOPUAW-FQEVSTJZSA-N 413788 4-({(2S)-2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 181::US11180471, Example 181 Plasma kallikrein Human 31.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413788 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413788&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205816 433913891 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116023 CCC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H24ClF3N6O4/c1-3-4-22(27(40)33-15-6-7-16(26(32)39)19(29)10-15)36-13-23(41-2)18(11-24(36)38)17-9-14(28)5-8-21(17)37-12-20(25(30)31)34-35-37/h5-13,22,25H,3-4H2,1-2H3,(H2,32,39)(H,33,40)/t22-/m0/s1 WZUXJAUBKKDABN-QFIPXVFZSA-N 413789 4-({(2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 182::US11180471, Example 182 Plasma kallikrein Human 19.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413789 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413789&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205866 433913892 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116024 CCC[C@@H](C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H26ClF2N7O4/c1-4-5-22(27(40)33-16-7-8-19(32-12-16)26(39)31-2)36-14-23(41-3)18(11-24(36)38)17-10-15(28)6-9-21(17)37-13-20(25(29)30)34-35-37/h6-14,22,25H,4-5H2,1-3H3,(H,31,39)(H,33,40)/t22-/m0/s1 ZZXQOEFXCPENDW-QFIPXVFZSA-N 413790 5-({(2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanoyl}amino)-N-methylpyridine-2-carboxamide (Enantiomer 2)::US10421742, Example 183::US11180471, Example 183 Plasma kallikrein Human 9.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413790 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413790&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205807 433913893 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116025 COc1cn(C(C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C24H19Cl2FN6O4/c1-12(24(36)29-14-4-5-15(23(28)35)18(27)8-14)32-10-20(37-2)17(9-22(32)34)16-7-13(25)3-6-19(16)33-11-21(26)30-31-33/h3-12H,1-2H3,(H2,28,35)(H,29,36) QGNJMTPKSKWTBQ-UHFFFAOYSA-N 413791 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}propanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 184::US11180471, Example 184 Plasma kallikrein Human 9.00 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413791 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413791&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205405 433913894 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116026 COc1cn(C(C)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H19Cl2N7O3/c1-14(25(36)30-16-4-5-19-20(10-16)29-8-7-28-19)33-12-22(37-2)18(11-24(33)35)17-9-15(26)3-6-21(17)34-13-23(27)31-32-34/h3-14H,1-2H3,(H,30,36) BJLPPNMAKGCMOT-UHFFFAOYSA-N 413792 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}propanamide (Racemate)::US10421742, Example 185::US11180471, Example 185 Plasma kallikrein Human 1.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413792 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413792&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205724 433913895 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116027 COc1cn(C(C)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H21Cl2N7O3/c1-14(25(36)28-17-5-6-20-15(8-17)11-32(2)30-20)33-12-22(37-3)19(10-24(33)35)18-9-16(26)4-7-21(18)34-13-23(27)29-31-34/h4-14H,1-3H3,(H,28,36) GBMNOBITEYOELC-UHFFFAOYSA-N 413793 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)propanamide (Racemate)::US10421742, Example 186::US11180471, Example 186 Plasma kallikrein Human 3.00 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413793 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413793&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205501 433913896 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116028 COc1cn(CC(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C23H19ClN8O3/c1-30-10-14-7-16(4-5-19(14)27-30)26-22(33)12-31-11-21(35-2)18(9-23(31)34)17-8-15(24)3-6-20(17)32-13-25-28-29-32/h3-11,13H,12H2,1-2H3,(H,26,33) OGFVUXQMVAVOQF-UHFFFAOYSA-N 413794 2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)acetamide::US10421742, Example 187::US11180471, Example 187 Plasma kallikrein Human 2.70 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413794 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413794&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205510 433913897 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116029 CNC(=O)c1ccc(NC(=O)Cn2cc(OC)c(cc2=O)-c2cc(Cl)ccc2-n2cnnn2)cn1 InChI=1S/C22H19ClN8O4/c1-24-22(34)17-5-4-14(9-25-17)27-20(32)11-30-10-19(35-2)16(8-21(30)33)15-7-13(23)3-6-18(15)31-12-26-28-29-31/h3-10,12H,11H2,1-2H3,(H,24,34)(H,27,32) MPORBPNHVULGJP-UHFFFAOYSA-N 413795 5-[({4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}acetyl)amino]-N-methylpyridine-2-carboxamide::US10421742, Example 188::US11180471, Example 188 Plasma kallikrein Human 5.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413795 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413795&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205086 433913898 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116030 COc1cn(CC(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C23H17ClN8O3/c1-35-21-11-31(12-22(33)28-15-3-4-18-19(9-15)26-7-6-25-18)23(34)10-17(21)16-8-14(24)2-5-20(16)32-13-27-29-30-32/h2-11,13H,12H2,1H3,(H,28,33) GOCDCIBQPRFDPL-UHFFFAOYSA-N 413796 N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}acetamide::US10421742, Example 189::US11180471, Example 189 Plasma kallikrein Human 1.000 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413796 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413796&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205044 433913899 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116031 COc1cn(CC(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C22H17ClN6O5/c1-34-19-10-28(11-20(30)25-15-5-2-13(3-6-15)22(32)33)21(31)9-17(19)16-8-14(23)4-7-18(16)29-12-24-26-27-29/h2-10,12H,11H2,1H3,(H,25,30)(H,32,33) KWIOAPQMNXFJOI-UHFFFAOYSA-N 413797 4-[({4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}acetyl)amino]benzoic acid::US10421742, Example 190::US11180471, Example 190 Plasma kallikrein Human 9.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413797 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413797&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205876 433913900 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116032 COc1cn(CC(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cnnn1 InChI=1S/C22H17ClFN7O4/c1-35-19-9-30(10-20(32)27-13-3-4-14(22(25)34)17(24)7-13)21(33)8-16(19)15-6-12(23)2-5-18(15)31-11-26-28-29-31/h2-9,11H,10H2,1H3,(H2,25,34)(H,27,32) NEENJQHZEIXZHZ-UHFFFAOYSA-N 413798 4-[({4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}acetyl)amino]-2-fluorobenzamide::US10421742, Example 191::US11180471, Example 191 Plasma kallikrein Human 7.90 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413798 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413798&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205431 433913901 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116033 CCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)F InChI=1S/C25H21ClF2N6O4S/c1-3-18(23(37)31-13-5-7-17(22(29)36)30-10-13)34-11-19(38-2)16(9-20(34)35)15-8-12(26)4-6-14(15)24-32-33-25(39-24)21(27)28/h4-11,18,21H,3H2,1-2H3,(H2,29,36)(H,31,37) UMNQYPPSVMIHGW-UHFFFAOYSA-N 413799 5-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)pyridine-2-carboxamide (Racemate)::US10421742, Example 192::US11180471, Example 192 Plasma kallikrein Human 32.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413799 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413799&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205370 433913902 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116034 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)F InChI=1S/C26H21ClF3N5O4S/c1-3-19(24(38)32-13-5-7-15(23(31)37)18(28)9-13)35-11-20(39-2)17(10-21(35)36)16-8-12(27)4-6-14(16)25-33-34-26(40-25)22(29)30/h4-11,19,22H,3H2,1-2H3,(H2,31,37)(H,32,38) CTFVRNUYERRNLZ-UHFFFAOYSA-N 413800 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 193::US11180471, Example 193 Plasma kallikrein Human 56.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413800 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413800&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205721 433913903 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116035 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)F InChI=1S/C27H23ClF2N6O3S/c1-4-21(25(38)31-16-6-8-20-14(9-16)12-35(2)34-20)36-13-22(39-3)19(11-23(36)37)18-10-15(28)5-7-17(18)26-32-33-27(40-26)24(29)30/h5-13,21,24H,4H2,1-3H3,(H,31,38) DFCBCYSQFOUFPJ-UHFFFAOYSA-N 413801 2-[4-{5-Chloro-2-[5-(difluoroethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 194::US11180471, Example 194 Plasma kallikrein Human 23.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413801 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413801&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211537 433913904 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116036 CCC(C(=O)Nc1ccc(C(=O)NC)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)F InChI=1S/C27H23ClF3N5O4S/c1-4-20(25(39)33-14-6-8-16(19(29)10-14)24(38)32-2)36-12-21(40-3)18(11-22(36)37)17-9-13(28)5-7-15(17)26-34-35-27(41-26)23(30)31/h5-12,20,23H,4H2,1-3H3,(H,32,38)(H,33,39) DPAIONDPIWYBAL-UHFFFAOYSA-N 413802 4-({2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluoro-N-methylbenzamide (Racemate)::US10421742, Example 195::US11180471, Example 195 Plasma kallikrein Human 72.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413802 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413802&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205747 433913905 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116037 CCC(C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)F InChI=1S/C27H21ClF2N6O3S/c1-3-21(25(38)33-15-5-7-19-20(11-15)32-9-8-31-19)36-13-22(39-2)18(12-23(36)37)17-10-14(28)4-6-16(17)26-34-35-27(40-26)24(29)30/h4-13,21,24H,3H2,1-2H3,(H,33,38) CVGKJPRJDXNZKV-UHFFFAOYSA-N 413803 2-[4-{5-Chloro-2-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(quinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 196::US11180471, Example 196 Plasma kallikrein Human 11.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413803 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413803&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211531 433913906 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116038 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)(F)F InChI=1S/C27H21ClF4N4O5/c1-3-21(26(39)34-14-5-7-16(25(33)38)19(29)9-14)36-12-22(40-2)18(10-24(36)37)17-8-13(28)4-6-15(17)20-11-23(41-35-20)27(30,31)32/h4-12,21H,3H2,1-2H3,(H2,33,38)(H,34,39) VMJCKYNXJRHMKZ-UHFFFAOYSA-N 413804 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 197::US11180471, Example 197 Plasma kallikrein Human 34.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413804 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413804&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206067 433913907 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116039 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cc(on1)C(F)(F)F InChI=1S/C28H23ClF3N5O4/c1-4-23(27(39)33-17-6-8-21-15(9-17)13-36(2)34-21)37-14-24(40-3)20(11-26(37)38)19-10-16(29)5-7-18(19)22-12-25(41-35-22)28(30,31)32/h5-14,23H,4H2,1-3H3,(H,33,39) KLVMLPOMRPNVJU-UHFFFAOYSA-N 413805 2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,2-oxazol-3-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 198::US11180471, Example 198 Plasma kallikrein Human 20.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413805 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413805&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205719 433913908 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116040 CCC(C(=O)Nc1ccc2nc([NH3+])ccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2N7O3/c1-3-21(27(38)31-17-6-7-20-15(10-17)4-9-25(30)32-20)35-13-23(39-2)19(12-26(35)37)18-11-16(28)5-8-22(18)36-14-24(29)33-34-36/h4-14,21H,3H2,1-2H3,(H2,30,32)(H,31,38)/p+1 UOFFBMYRFFCNLY-UHFFFAOYSA-O 413806 6-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl)amino]quinolin-2-aminium formate (Racemate)::US10421742, Example 199::US11180471, Example 199 Plasma kallikrein Human 3.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413806 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413806&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 152948432 433913909 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116041 CCC(C(=O)Nc1ccc2ncc(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2N7O3/c1-4-22(27(38)32-17-6-7-20-21(10-17)31-15(2)12-30-20)35-13-24(39-3)19(11-26(35)37)18-9-16(28)5-8-23(18)36-14-25(29)33-34-36/h5-14,22H,4H2,1-3H3,(H,32,38) SADGBXCCQGIXDH-UHFFFAOYSA-N 413807 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(3-methylquinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 200::US11180471, Example 200 Plasma kallikrein Human 2.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413807 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413807&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205297 433913910 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116042 CC[C@@H](C(=O)Nc1ccc2ncc(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2N7O3/c1-4-22(27(38)32-17-6-7-20-21(10-17)31-15(2)12-30-20)35-13-24(39-3)19(11-26(35)37)18-9-16(28)5-8-23(18)36-14-25(29)33-34-36/h5-14,22H,4H2,1-3H3,(H,32,38)/t22-/m0/s1 SADGBXCCQGIXDH-QFIPXVFZSA-N 413808 (S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(3-methylquinoxalin-6-yl)butanamide (Enantiomer 2)::US10421742, Example 201::US11180471, Example 201 Plasma kallikrein Human 2.20 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413808 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413808&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205797 433913911 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116043 CCC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2FN6O4/c1-3-4-21(26(38)31-15-6-7-16(25(30)37)19(29)10-15)34-12-22(39-2)18(11-24(34)36)17-9-14(27)5-8-20(17)35-13-23(28)32-33-35/h5-13,21H,3-4H2,1-2H3,(H2,30,37)(H,31,38)/t21-/m0/s1 KQZYQOJQXJGZMI-NRFANRHFSA-N 413809 4-{[(2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}pentanoyl]amino}-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 202::US11180471, Example 202 Plasma kallikrein Human 9.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413809 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413809&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205777 433913912 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116044 CCC(C(=O)Nc1ccc2ncc(nc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H20Cl2F3N7O3/c1-3-20(26(41)34-15-5-6-18-19(9-15)35-23(11-33-18)27(30,31)32)38-12-22(42-2)17(10-25(38)40)16-8-14(28)4-7-21(16)39-13-24(29)36-37-39/h4-13,20H,3H2,1-2H3,(H,34,41) ZIDSWWLSQTUOIZ-UHFFFAOYSA-N 413810 2-{4-[5-Chloro-2-(4-chloro-1H-H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[3-(trifluoromethyl)quinoxalin-6-yl]butanamide (Racemate)::US10421742, Example 203::US10421742, Example 205::US11180471, Example 203 Plasma kallikrein Human 29.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413810 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413810&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211523 433913913 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116045 CCC(C(=O)Nc1ccc2nc(cnc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H20Cl2F3N7O3/c1-3-20(26(41)34-15-5-6-18-19(9-15)33-11-23(35-18)27(30,31)32)38-12-22(42-2)17(10-25(38)40)16-8-14(28)4-7-21(16)39-13-24(29)36-37-39/h4-13,20H,3H2,1-2H3,(H,34,41) AGDBQILBKXGVMA-UHFFFAOYSA-N 413811 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(trifluoromethyl)quinoxalin-6-yl]butanamide (Racemate)::US10421742, Example 204::US10421742, Example 206::US11180471, Example 204 Plasma kallikrein Human 10.00 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413811 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413811&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205251 433913914 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116046 CCC(C(=O)Nc1ccc2ncc(nc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C28H20ClF6N7O3/c1-3-20(26(44)37-15-5-6-18-19(9-15)38-23(11-36-18)27(30,31)32)41-12-22(45-2)17(10-25(41)43)16-8-14(29)4-7-21(16)42-13-24(39-40-42)28(33,34)35/h4-13,20H,3H2,1-2H3,(H,37,44) HFIYSVHJSLVEKM-UHFFFAOYSA-N 528227 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[3-(trifluoromethyl)quinoxalin-6-yl]butanamide (racemate)::US11180471, Example 205 Plasma kallikrein Human 47.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528227 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528227&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205528 463791769 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116047 CCC(C(=O)Nc1ccc2nc(cnc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C28H20ClF6N7O3/c1-3-20(26(44)37-15-5-6-18-19(9-15)36-11-23(38-18)27(30,31)32)41-12-22(45-2)17(10-25(41)43)16-8-14(29)4-7-21(16)42-13-24(39-40-42)28(33,34)35/h4-13,20H,3H2,1-2H3,(H,37,44) NCZFXYVMXDGJAQ-UHFFFAOYSA-N 528228 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[2-(trifluoromethyl)quinoxalin-6-yl]butanamide (racemate)::US11180471, Example 206 Plasma kallikrein Human 24.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528228 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528228&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205616 463791770 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116048 CCC(C(=O)Nc1ccc2cnncc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2N7O3/c1-3-21(26(37)31-18-6-4-15-11-29-30-12-16(15)8-18)34-13-23(38-2)20(10-25(34)36)19-9-17(27)5-7-22(19)35-14-24(28)32-33-35/h4-14,21H,3H2,1-2H3,(H,31,37) UENKHDMGQRVXOA-UHFFFAOYSA-N 413814 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(phthalazin-6-yl)butanamide (Racemate)::US10421742, Example 207::US10421742, Example 208::US11180471, Example 207 Plasma kallikrein Human 3.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413814 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413814&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205592 433913915 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116049 CCC(C(=O)Nc1ccc2cnncc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C27H21ClF3N7O3/c1-3-21(26(40)34-18-6-4-15-11-32-33-12-16(15)8-18)37-13-23(41-2)20(10-25(37)39)19-9-17(28)5-7-22(19)38-14-24(35-36-38)27(29,30)31/h4-14,21H,3H2,1-2H3,(H,34,40) AWJUPCORVZXGJV-UHFFFAOYSA-N 528230 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(phthalazin-6-yl)butanamide (racemate)::US11180471, Example 208 Plasma kallikrein Human 4.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528230 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528230&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206097 463791772 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116050 CCC(C(=O)Nc1ccc2nn(cc2c1)C(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H22ClF4N7O3/c1-3-21(26(41)33-16-5-6-19-14(8-16)11-39(35-19)27(31)32)37-13-23(42-2)18(10-24(37)40)17-9-15(28)4-7-22(17)38-12-20(25(29)30)34-36-38/h4-13,21,25,27H,3H2,1-2H3,(H,33,41) METWKYXLYOAEDA-UHFFFAOYSA-N 413816 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[2-(difluoromethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 209::US11180471, Example 209 Plasma kallikrein Human 9.10 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413816 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413816&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205934 433913916 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116051 CC[C@@H](C(=O)Nc1ccc2nn(cc2c1)C(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C27H22ClF4N7O3/c1-3-21(26(41)33-16-5-6-19-14(8-16)11-39(35-19)27(31)32)37-13-23(42-2)18(10-24(37)40)17-9-15(28)4-7-22(17)38-12-20(25(29)30)34-36-38/h4-13,21,25,27H,3H2,1-2H3,(H,33,41)/t21-/m0/s1 METWKYXLYOAEDA-NRFANRHFSA-N 413817 (2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[2-(difluoromethyl)-2H-indazol-5-yl]butanamide (Enantiomer 2)::US10421742, Example 210::US11180471, Example 210 Plasma kallikrein Human 3.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413817 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413817&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206066 433913917 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116052 CCC(C(=O)Nc1ccc2nn(cc2c1)C(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2F2N7O3/c1-3-20(25(39)31-16-5-6-19-14(8-16)11-37(33-19)26(29)30)35-12-22(40-2)18(10-24(35)38)17-9-15(27)4-7-21(17)36-13-23(28)32-34-36/h4-13,20,26H,3H2,1-2H3,(H,31,39) ZXSDTWYIYKNDSR-UHFFFAOYSA-N 413818 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(difluoromethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 211::US11180471, Example 211 Plasma kallikrein Human 5.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413818 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413818&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204866 433913918 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116053 CC[C@@H](C(=O)Nc1ccc2nn(cc2c1)C(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2F2N7O3/c1-3-20(25(39)31-16-5-6-19-14(8-16)11-37(33-19)26(29)30)35-12-22(40-2)18(10-24(35)38)17-9-15(27)4-7-21(17)36-13-23(28)32-34-36/h4-13,20,26H,3H2,1-2H3,(H,31,39)/t20-/m0/s1 ZXSDTWYIYKNDSR-FQEVSTJZSA-N 413819 (2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(difluoromethyl)-2H-indazol-5-yl]butanamide (Enantiomer 2)::US10421742, Example 212::US11180471, Example 212 Plasma kallikrein Human 1.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413819 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413819&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206089 433913919 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116054 CCC(C(=O)Nc1ccc2nn(CC3CC3)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C29H27Cl2N7O3/c1-3-24(29(40)32-20-7-8-23-18(10-20)14-36(34-23)13-17-4-5-17)37-15-26(41-2)22(12-28(37)39)21-11-19(30)6-9-25(21)38-16-27(31)33-35-38/h6-12,14-17,24H,3-5,13H2,1-2H3,(H,32,40) TXLDRSXSUKQIEC-UHFFFAOYSA-N 413820 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(cyclopropylmethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 213::US11180471, Example 213 Plasma kallikrein Human 12.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413820 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413820&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206022 433913920 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116055 COc1cn(C(CC(F)F)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H19Cl2F3N6O4/c1-40-20-10-35(19(9-22(29)30)25(39)32-13-3-4-14(24(31)38)17(28)7-13)23(37)8-16(20)15-6-12(26)2-5-18(15)36-11-21(27)33-34-36/h2-8,10-11,19,22H,9H2,1H3,(H2,31,38)(H,32,39) VICLFWRBPGESJU-UHFFFAOYSA-N 413821 4-[(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4,4-difluorobutanoyl)amino]-2-fluorobenzamide (Racemate)::US10421742, Example 214::US11180471, Example 214 Plasma kallikrein Human 21.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413821 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413821&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206005 433913921 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116056 CCC(C(=O)Nc1ccc(nc1)C(=O)NC)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)(F)F InChI=1S/C26H22ClF3N6O4S/c1-4-19(23(39)33-14-6-8-18(32-11-14)22(38)31-2)36-12-20(40-3)17(10-21(36)37)16-9-13(27)5-7-15(16)24-34-35-25(41-24)26(28,29)30/h5-12,19H,4H2,1-3H3,(H,31,38)(H,33,39) MTUVSPCBSRPPFH-UHFFFAOYSA-N 413822 5-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-N-methylpyridine-2-carboxamide (Racemate)::US10421742, Example 215::US11180471, Example 215 Plasma kallikrein Human 20.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413822 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413822&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205910 433913922 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116057 COc1cn(C(CC(F)F)C(=O)Nc2ccc3nn(cc3c2)C(F)F)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H19Cl2F4N7O3/c1-42-21-11-37(24(40)8-17(21)16-7-14(27)2-5-19(16)38-12-22(28)34-36-38)20(9-23(29)30)25(41)33-15-3-4-18-13(6-15)10-39(35-18)26(31)32/h2-8,10-12,20,23,26H,9H2,1H3,(H,33,41) RTIMPDQMXMBUMW-UHFFFAOYSA-N 413823 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(difluoromethyl)-2H-indazol-5-yl]-4,4-difluorobutanamide (Racemate)::US10421742, Example 216::US11180471, Example 216 Plasma kallikrein Human 10.00 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413823 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413823&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204789 433913923 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116058 COc1cn(C(CC(F)F)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H19Cl2F2N7O3/c1-40-22-12-36(21(11-24(29)30)26(39)33-15-3-4-18-19(9-15)32-7-6-31-18)25(38)10-17(22)16-8-14(27)2-5-20(16)37-13-23(28)34-35-37/h2-10,12-13,21,24H,11H2,1H3,(H,33,39) SATGRGDFTKEDOC-UHFFFAOYSA-N 413824 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4,4-difluoro-N-(quinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 217::US11180471, Example 217 Plasma kallikrein Human 4.90 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413824 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413824&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205462 433913924 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116059 COc1cn(C(CC(F)F)C(=O)Nc2ccc3nn(C)cc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H21Cl2F2N7O3/c1-35-11-14-7-16(4-5-19(14)33-35)31-26(39)21(10-24(29)30)36-12-22(40-2)18(9-25(36)38)17-8-15(27)3-6-20(17)37-13-23(28)32-34-37/h3-9,11-13,21,24H,10H2,1-2H3,(H,31,39) SVTFEVREYQHXOM-UHFFFAOYSA-N 413825 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4,4-difluoro-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 218::US11180471, Example 218 Plasma kallikrein Human 10.00 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413825 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413825&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205201 433913925 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116060 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)(F)F InChI=1S/C26H20ClF4N5O4S/c1-3-19(23(39)33-13-5-7-15(22(32)38)18(28)9-13)36-11-20(40-2)17(10-21(36)37)16-8-12(27)4-6-14(16)24-34-35-25(41-24)26(29,30)31/h4-11,19H,3H2,1-2H3,(H2,32,38)(H,33,39) XRCANQJWEYJRNE-UHFFFAOYSA-N 413826 4-({2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 219::US11180471, Example 219 Plasma kallikrein Human 43.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413826 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413826&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205452 433913926 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116061 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1nnc(s1)C(F)(F)F InChI=1S/C27H22ClF3N6O3S/c1-4-21(24(39)32-16-6-8-20-14(9-16)12-36(2)35-20)37-13-22(40-3)19(11-23(37)38)18-10-15(28)5-7-17(18)25-33-34-26(41-25)27(29,30)31/h5-13,21H,4H2,1-3H3,(H,32,39) HCRLZPHBOLGRPG-UHFFFAOYSA-N 413827 2-[4-{5-Chloro-2-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 220::US11180471, Example 220 Plasma kallikrein Human 14.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413827 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413827&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206083 433913927 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116062 CCC(C(=O)Nc1ccc2nc(C)cnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2N7O3/c1-4-22(27(38)32-17-6-7-20-21(10-17)30-12-15(2)31-20)35-13-24(39-3)19(11-26(35)37)18-9-16(28)5-8-23(18)36-14-25(29)33-34-36/h5-14,22H,4H2,1-3H3,(H,32,38) NINJGBVHUFUANQ-UHFFFAOYSA-N 413828 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methylquinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 221::US11180471, Example 221 Plasma kallikrein Human 2.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413828 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413828&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205262 433913928 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116063 CCC(C(=O)Nc1ccc2nc(C)c(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C28H25Cl2N7O3/c1-5-23(28(39)33-18-7-8-21-22(11-18)32-16(3)15(2)31-21)36-13-25(40-4)20(12-27(36)38)19-10-17(29)6-9-24(19)37-14-26(30)34-35-37/h6-14,23H,5H2,1-4H3,(H,33,39) PQLJHTCQQFICKU-UHFFFAOYSA-N 413829 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2,3-dimethylquinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 222::US11180471, Example 222 Plasma kallikrein Human 2.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413829 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413829&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205457 433913929 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116064 CCC(C(=O)Nc1ccc2ncccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H22Cl2N6O3/c1-3-22(27(37)31-18-7-8-21-16(11-18)5-4-10-30-21)34-14-24(38-2)20(13-26(34)36)19-12-17(28)6-9-23(19)35-15-25(29)32-33-35/h4-15,22H,3H2,1-2H3,(H,31,37) FTLCKEYXULODRH-UHFFFAOYSA-N 413830 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(quinolin-6-yl)butanamide (Racemate)::US10421742, Example 223::US11180471, Example 223 Plasma kallikrein Human 3.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413830 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413830&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211524 433913930 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116065 CCC(C(=O)Nc1ccc2cccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H22Cl2N6O3/c1-3-22(27(37)31-18-8-6-16-5-4-10-30-21(16)12-18)34-14-24(38-2)20(13-26(34)36)19-11-17(28)7-9-23(19)35-15-25(29)32-33-35/h4-15,22H,3H2,1-2H3,(H,31,37) FQMWRNFRVKBREN-UHFFFAOYSA-N 413831 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(quinolin-7-yl)butanamide (Racemate)::US10421742, Example 224::US11180471, Example 224 Plasma kallikrein Human 4.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413831 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413831&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205567 433913931 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116066 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H23Cl2N7O3/c1-4-21(26(37)29-17-6-7-20-15(9-17)12-33(2)31-20)34-13-23(38-3)19(11-25(34)36)18-10-16(27)5-8-22(18)35-14-24(28)30-32-35/h5-14,21H,4H2,1-3H3,(H,29,37) QBWXHIMIUSZAOP-UHFFFAOYSA-N 413774 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 167::US10421742, Example 225::US11180471, Example 225 Plasma kallikrein Human 3.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413774 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413774&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205467 433913877 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116067 CCC(C(=O)Nc1ccc2nn(CC(F)F)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H23Cl2F2N7O3/c1-3-21(27(40)32-17-5-6-20-15(8-17)11-36(34-20)14-25(30)31)37-12-23(41-2)19(10-26(37)39)18-9-16(28)4-7-22(18)38-13-24(29)33-35-38/h4-13,21,25H,3,14H2,1-2H3,(H,32,40) GTOBEZUWBRGMLK-UHFFFAOYSA-N 413833 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(2,2-difluoroethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 226::US11180471, Example 226 Plasma kallikrein Human 6.00 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413833 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413833&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205643 433913932 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116068 CCC(C(=O)Nc1ccc2nn(CC(F)(F)F)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H22Cl2F3N7O3/c1-3-21(26(41)33-17-5-6-20-15(8-17)11-37(35-20)14-27(30,31)32)38-12-23(42-2)19(10-25(38)40)18-9-16(28)4-7-22(18)39-13-24(29)34-36-39/h4-13,21H,3,14H2,1-2H3,(H,33,41) DBBPDYZRKMIZOJ-UHFFFAOYSA-N 413834 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(2,2,2-trifluoroethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 227::US11180471, Example 227 Plasma kallikrein Human 6.00 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413834 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413834&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204990 433913933 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116069 CCC(C(=O)Nc1ccc2nc(C)ccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C28H24Cl2N6O3/c1-4-23(28(38)32-19-8-9-22-17(11-19)6-5-16(2)31-22)35-14-25(39-3)21(13-27(35)37)20-12-18(29)7-10-24(20)36-15-26(30)33-34-36/h5-15,23H,4H2,1-3H3,(H,32,38) AZYMEDAZJNOBLR-UHFFFAOYSA-N 413835 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methylquinolin-6-yl)butanamide (Racemate)::US10421742, Example 228::US11180471, Example 228 Plasma kallikrein Human 2.90 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413835 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413835&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205176 433913934 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116070 CCC(C(=O)Nc1ccc2nc(C)ccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H25ClF2N6O3/c1-4-24(29(40)34-19-8-9-22-17(11-19)6-5-16(2)33-22)37-15-26(41-3)21(13-27(37)39)20-12-18(30)7-10-25(20)38-14-23(28(31)32)35-36-38/h5-15,24,28H,4H2,1-3H3,(H,34,40) FVOIRKKFLDCVKH-UHFFFAOYSA-N 413836 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methylquinolin-6-yl)butanamide (Racemate)::US10421742, Example 229::US11180471, Example 229 Plasma kallikrein Human 3.90 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413836 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413836&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205284 433913935 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116071 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C26H22ClF3N6O4/c1-3-20(26(39)32-14-5-6-15(25(31)38)18(28)9-14)35-12-22(40-2)17(10-23(35)37)16-8-13(27)4-7-21(16)36-11-19(24(29)30)33-34-36/h4-12,20,24H,3H2,1-2H3,(H2,31,38)(H,32,39) OETZVLILMHLZTG-UHFFFAOYSA-N 413767 4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 160::US11180471, Example 230 Plasma kallikrein Human 17.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413767 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413767&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205282 433913870 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116072 CCC[C@@H](C(=O)Nc1ccc2nccnc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H24ClF2N7O3/c1-3-4-24(28(40)34-17-6-7-20-21(12-17)33-10-9-32-20)37-15-25(41-2)19(13-26(37)39)18-11-16(29)5-8-23(18)38-14-22(27(30)31)35-36-38/h5-15,24,27H,3-4H2,1-2H3,(H,34,40)/t24-/m0/s1 NKCIMLZZOJBOGZ-DEOSSOPVSA-N 413838 (2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(quinoxalin-6-yl)pentanamide (Enantiomer 2)::US10421742, Example 231::US11180471, Example 231 Plasma kallikrein Human 3.30 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413838 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413838&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135204967 433913937 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116073 CCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C27H23ClF3N7O3/c1-4-21(26(40)32-17-6-7-20-15(9-17)12-36(2)34-20)37-13-23(41-3)19(11-25(37)39)18-10-16(28)5-8-22(18)38-14-24(33-35-38)27(29,30)31/h5-14,21H,4H2,1-3H3,(H,32,40) YXQQDNTZJAXMNL-UHFFFAOYSA-N 413839 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 232::US11180471, Example 232 Plasma kallikrein Human 5.20 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413839 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413839&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205554 433913938 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116074 CC[C@@H](C(=O)Nc1ccc2nn(C)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C27H23ClF3N7O3/c1-4-21(26(40)32-17-6-7-20-15(9-17)12-36(2)34-20)37-13-23(41-3)19(11-25(37)39)18-10-16(28)5-8-22(18)38-14-24(33-35-38)27(29,30)31/h5-14,21H,4H2,1-3H3,(H,32,40)/t21-/m0/s1 YXQQDNTZJAXMNL-NRFANRHFSA-N 413840 (2S)-2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methyl-2H-indazol-5-yl)butanamide (Enantiomer 2)::US10421742, Example 233::US11180471, Example 233 Plasma kallikrein Human 3.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413840 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413840&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205553 433913939 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116075 CCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C26H21ClF4N6O4/c1-3-19(25(40)33-14-5-6-15(24(32)39)18(28)9-14)36-11-21(41-2)17(10-23(36)38)16-8-13(27)4-7-20(16)37-12-22(34-35-37)26(29,30)31/h4-12,19H,3H2,1-2H3,(H2,32,39)(H,33,40) XYWIPYBIIRTJMM-UHFFFAOYSA-N 413841 4-({2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 234::US11180471, Example 234 Plasma kallikrein Human 14.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413841 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413841&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205380 433913940 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116076 CC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C26H21ClF4N6O4/c1-3-19(25(40)33-14-5-6-15(24(32)39)18(28)9-14)36-11-21(41-2)17(10-23(36)38)16-8-13(27)4-7-20(16)37-12-22(34-35-37)26(29,30)31/h4-12,19H,3H2,1-2H3,(H2,32,39)(H,33,40)/t19-/m0/s1 XYWIPYBIIRTJMM-IBGZPJMESA-N 413842 4-({(2S)-2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 235::US11180471, Example 235 Plasma kallikrein Human 5.70 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413842 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413842&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206011 433913941 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116077 CCC(C(=O)Nc1ccc2nc(C)c(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C29H25ClF3N7O3/c1-5-23(28(42)36-18-7-8-21-22(11-18)35-16(3)15(2)34-21)39-13-25(43-4)20(12-27(39)41)19-10-17(30)6-9-24(19)40-14-26(37-38-40)29(31,32)33/h6-14,23H,5H2,1-4H3,(H,36,42) UDQDURKQOJZYOA-UHFFFAOYSA-N 413843 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2,3-dimethylquinoxalin-6-yl)butanamide (Racemate)::US10421742, Example 236::US11180471, Example 236 Plasma kallikrein Human 5.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413843 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413843&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205535 433913942 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116078 CC[C@@H](C(=O)Nc1ccc2nc(C)c(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C29H25ClF3N7O3/c1-5-23(28(42)36-18-7-8-21-22(11-18)35-16(3)15(2)34-21)39-13-25(43-4)20(12-27(39)41)19-10-17(30)6-9-24(19)40-14-26(37-38-40)29(31,32)33/h6-14,23H,5H2,1-4H3,(H,36,42)/t23-/m0/s1 UDQDURKQOJZYOA-QHCPKHFHSA-N 413844 (2S)-2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2,3-dimethylquinoxalin-6-yl)butanamide (Enantiomer 2)::US10421742, Example 237::US11180471, Example 237 Plasma kallikrein Human 2.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413844 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413844&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205533 433913943 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116079 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-c1cnc(o1)C(F)F InChI=1S/C27H22ClF2N3O6/c1-3-20(25(35)32-16-7-4-14(5-8-16)27(36)37)33-13-22(38-2)19(11-23(33)34)18-10-15(28)6-9-17(18)21-12-31-26(39-21)24(29)30/h4-13,20,24H,3H2,1-2H3,(H,32,35)(H,36,37) QFFBKCKFGNVYBW-UHFFFAOYSA-N 413845 4-({2-[4-{5-Chloro-2-[2-(difluoromethyl)-1,3-oxazol-5-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)benzoic acid (Racemate)::US10421742, Example 238::US11180471, Example 238 Plasma kallikrein Human 850 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413845 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413845&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205970 433913944 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116080 COc1cn(C(C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C25H19ClF4N6O4/c1-12(24(39)32-14-4-5-15(23(31)38)18(27)8-14)35-10-20(40-2)17(9-22(35)37)16-7-13(26)3-6-19(16)36-11-21(33-34-36)25(28,29)30/h3-12H,1-2H3,(H2,31,38)(H,32,39) SNUMNATTXKTJQD-UHFFFAOYSA-N 413846 4-({2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]propanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 239::US11180471, Example 239 Plasma kallikrein Human 6.90 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413846 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413846&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205033 433913945 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116081 COc1cn([C@@H](C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C24H19Cl2FN6O4/c1-12(24(36)29-14-4-5-15(23(28)35)18(27)8-14)32-10-20(37-2)17(9-22(32)34)16-7-13(25)3-6-19(16)33-11-21(26)30-31-33/h3-12H,1-2H3,(H2,28,35)(H,29,36)/t12-/m0/s1 QGNJMTPKSKWTBQ-LBPRGKRZSA-N 413847 4-{[(2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}propanoyl]amino}-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 240::US11180471, Example 240 Plasma kallikrein Human 3.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413847 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413847&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205642 433913946 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116082 COc1cn([C@@H](C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C25H20ClF3N6O4/c1-12(25(38)31-14-4-5-15(24(30)37)18(27)8-14)34-11-21(39-2)17(9-22(34)36)16-7-13(26)3-6-20(16)35-10-19(23(28)29)32-33-35/h3-12,23H,1-2H3,(H2,30,37)(H,31,38)/t12-/m0/s1 JVCAULOQATWKKF-LBPRGKRZSA-N 413848 4-({(2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]propanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 241::US11180471, Example 241 Plasma kallikrein Human 6.00 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413848 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413848&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205975 433913947 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116083 CC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H21Cl2FN6O4/c1-3-19(25(37)30-14-5-6-15(24(29)36)18(28)9-14)33-11-21(38-2)17(10-23(33)35)16-8-13(26)4-7-20(16)34-12-22(27)31-32-34/h4-12,19H,3H2,1-2H3,(H2,29,36)(H,30,37)/t19-/m0/s1 FPAKZDLGEHHCTC-IBGZPJMESA-N 413849 4-{[(2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl]amino}-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 242::US11180471, Example 242 Plasma kallikrein Human 5.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413849 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413849&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205798 433913948 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116084 CC[C@@H](C(=O)Nc1ccc2nc(C)ccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H25ClF2N6O3/c1-4-24(29(40)34-19-8-9-22-17(11-19)6-5-16(2)33-22)37-15-26(41-3)21(13-27(37)39)20-12-18(30)7-10-25(20)38-14-23(28(31)32)35-36-38/h5-15,24,28H,4H2,1-3H3,(H,34,40)/t24-/m0/s1 FVOIRKKFLDCVKH-DEOSSOPVSA-N 413850 (2S)-2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-methylquinolin-6-yl)butanamide (Enantiomer 2)::US10421742, Example 243::US11180471, Example 243 Plasma kallikrein Human 1.70 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413850 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413850&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205377 433913949 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116085 CC[C@@H](C(=O)Nc1ccc2nc(C)ccc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C28H24Cl2N6O3/c1-4-23(28(38)32-19-8-9-22-17(11-19)6-5-16(2)31-22)35-14-25(39-3)21(13-27(35)37)20-12-18(29)7-10-24(20)36-15-26(30)33-34-36/h5-15,23H,4H2,1-3H3,(H,32,38)/t23-/m0/s1 AZYMEDAZJNOBLR-QHCPKHFHSA-N 413851 (2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methylquinolin-6-yl)butanamide (Enantiomer 2)::US10421742, Example 244::US11180471, Example 244 Plasma kallikrein Human 1.40 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413851 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413851&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205851 433913950 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116086 CCC(C(=O)Nc1ccc2nn(C)c(C)c2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O3/c1-5-22(27(38)30-17-7-8-21-18(11-17)15(2)34(3)32-21)35-13-24(39-4)20(12-26(35)37)19-10-16(28)6-9-23(19)36-14-25(29)31-33-36/h6-14,22H,5H2,1-4H3,(H,30,38) SBXOMGIKOINZME-UHFFFAOYSA-N 413852 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2,3-dimethyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 245::US11180471, Example 245 Plasma kallikrein Human 5.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413852 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413852&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205409 433913951 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116087 CCC(C(=O)Nc1ccc2nn(C)c(C)c2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C28H25ClF3N7O3/c1-5-22(27(41)33-17-7-8-21-18(11-17)15(2)37(3)35-21)38-13-24(42-4)20(12-26(38)40)19-10-16(29)6-9-23(19)39-14-25(34-36-39)28(30,31)32/h6-14,22H,5H2,1-4H3,(H,33,41) MKSVLCRJUVAEQS-UHFFFAOYSA-N 413853 2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2,3-dimethyl-2H-indazol-5-yl)butanamide (Racemate)::US10421742, Example 246::US11180471, Example 246 Plasma kallikrein Human 7.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413853 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413853&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205407 433913952 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116088 CCC(C(=O)Nc1ccc2nc(ccc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C28H21Cl2F3N6O3/c1-3-21(27(41)34-17-6-7-20-15(10-17)4-9-24(35-20)28(31,32)33)38-13-23(42-2)19(12-26(38)40)18-11-16(29)5-8-22(18)39-14-25(30)36-37-39/h4-14,21H,3H2,1-2H3,(H,34,41) SEVBXRKORJAERT-UHFFFAOYSA-N 413854 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(trifluoromethyl)quinolin-6-yl]butanamide (Racemate)::US10421742, Example 247::US11180471, Example 247 Plasma kallikrein Human 17.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413854 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413854&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205363 433913953 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116089 CCC(C(=O)Nc1ccc2nc(ccc2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H22ClF5N6O3/c1-3-22(28(43)36-17-6-7-20-15(10-17)4-9-25(37-20)29(33,34)35)40-14-24(44-2)19(12-26(40)42)18-11-16(30)5-8-23(18)41-13-21(27(31)32)38-39-41/h4-14,22,27H,3H2,1-2H3,(H,36,43) SDQAOZYYHXEPNT-UHFFFAOYSA-N 413855 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[2-(trifluoromethyl)quinolin-6-yl]butanamide (Racemate)::US10421742, Example 248::US11180471, Example 248 Plasma kallikrein Human 21.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413855 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413855&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205958 433913954 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116090 CCC(C(=O)Nc1ccc2nn(C)nc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C25H22Cl2N8O3/c1-4-20(25(37)28-15-6-7-18-19(10-15)31-33(2)30-18)34-12-22(38-3)17(11-24(34)36)16-9-14(26)5-8-21(16)35-13-23(27)29-32-35/h5-13,20H,4H2,1-3H3,(H,28,37) LZHGUODYTWJFHC-UHFFFAOYSA-N 413856 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-methyl-2H-benzotriazol-5-yl)butanamide (Racemate)::US10421742, Example 249::US11180471, Example 249 Plasma kallikrein Human 7.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413856 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413856&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205352 433913955 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116091 CCC(C(=O)Nc1ccc2nn(CC)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O3/c1-4-22(27(38)30-18-7-8-21-16(10-18)13-34(5-2)32-21)35-14-24(39-3)20(12-26(35)37)19-11-17(28)6-9-23(19)36-15-25(29)31-33-36/h6-15,22H,4-5H2,1-3H3,(H,30,38) MSUOXKMCLUJSJC-UHFFFAOYSA-N 528272 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-ethyl-2H-indazol-5-yl)butanamide (racemate)::US11180471, Example 250 Plasma kallikrein Human 4.70 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=528272 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=528272&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135206108 463791812 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116092 COc1cn([C@@H](C)C(=O)Nc2ccc(C(N)=O)c(F)c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C25H19ClF4N6O4/c1-12(24(39)32-14-4-5-15(23(31)38)18(27)8-14)35-10-20(40-2)17(9-22(35)37)16-7-13(26)3-6-19(16)36-11-21(33-34-36)25(28,29)30/h3-12H,1-2H3,(H2,31,38)(H,32,39)/t12-/m0/s1 SNUMNATTXKTJQD-LBPRGKRZSA-N 413858 4-({(2S)-2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]propanoyl}amino)-2-fluorobenzamide (Enantiomer 2)::US10421742, Example 251::US11180471, Example 251 Plasma kallikrein Human 4.60 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413858 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413858&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205940 433913957 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116093 CCC(C(=O)Nc1ccc2nc(ccc2c1)C#N)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C29H22ClF2N7O3/c1-3-24(29(41)35-18-7-8-22-16(10-18)4-6-19(13-33)34-22)38-15-26(42-2)21(12-27(38)40)20-11-17(30)5-9-25(20)39-14-23(28(31)32)36-37-39/h4-12,14-15,24,28H,3H2,1-2H3,(H,35,41) DERODARCDQXYDI-UHFFFAOYSA-N 413859 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-(2-cyanoquinolin-6-yl)butanamide (Racemate)::US10421742, Example 252::US11180471, Example 252 Plasma kallikrein Human 11.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413859 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413859&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205841 433913958 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116094 CCC(C(=O)Nc1ccc2nc(ccc2c1)C#N)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C28H21Cl2N7O3/c1-3-23(28(39)33-18-7-8-22-16(10-18)4-6-19(13-31)32-22)36-14-25(40-2)21(12-27(36)38)20-11-17(29)5-9-24(20)37-15-26(30)34-35-37/h4-12,14-15,23H,3H2,1-2H3,(H,33,39) QCAYWCRUVAGYIH-UHFFFAOYSA-N 413860 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-(2-cyanoquinolin-6-yl)butanamide (Racemate)::US10421742, Example 253::US11180471, Example 253 Plasma kallikrein Human 6.80 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413860 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413860&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135211506 433913959 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116095 CCC(C(=O)Nc1ccc2nn(CCO)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C27H25Cl2N7O4/c1-3-22(27(39)30-18-5-6-21-16(10-18)13-34(32-21)8-9-37)35-14-24(40-2)20(12-26(35)38)19-11-17(28)4-7-23(19)36-15-25(29)31-33-36/h4-7,10-15,22,37H,3,8-9H2,1-2H3,(H,30,39) CJLPNFNSEYZOKO-UHFFFAOYSA-N 413861 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[2-(2-hydroxyethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 254::US11180471, Example 254 Plasma kallikrein Human 3.50 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413861 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413861&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205337 433913960 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116096 CCC(C(=O)Nc1ccc2nn(CCO)cc2c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)F InChI=1S/C28H26ClF2N7O4/c1-3-23(28(41)32-18-5-6-21-16(10-18)13-36(34-21)8-9-39)37-15-25(42-2)20(12-26(37)40)19-11-17(29)4-7-24(19)38-14-22(27(30)31)33-35-38/h4-7,10-15,23,27,39H,3,8-9H2,1-2H3,(H,32,41) ZWZWZPJQIZBWFH-UHFFFAOYSA-N 413862 2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]-N-[2-(2-hydroxyethyl)-2H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 255::US11180471, Example 255 Plasma kallikrein Human 8.90 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413862 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413862&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205193 433913961 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116097 CCC(C(=O)Nc1ccc2[nH]nc(c2c1)C(F)(F)F)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(Cl)nn1 413863 2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-N-[3-(trifluoromethyl)-1H-indazol-5-yl]butanamide (Racemate)::US10421742, Example 256::US11180471, Example 256 Plasma kallikrein Human 17.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413863 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413863&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205900 433913962 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116098 COc1cn([C@@H](CC(F)F)C(=O)Nc2ccc3nccnc3c2)c(=O)cc1-c1cc(Cl)ccc1-n1cc(Cl)nn1 InChI=1S/C26H19Cl2F2N7O3/c1-40-22-12-36(21(11-24(29)30)26(39)33-15-3-4-18-19(9-15)32-7-6-31-18)25(38)10-17(22)16-8-14(27)2-5-20(16)37-13-23(28)34-35-37/h2-10,12-13,21,24H,11H2,1H3,(H,33,39)/t21-/m0/s1 SATGRGDFTKEDOC-NRFANRHFSA-N 413864 (2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-4,4-difluoro-N-(quinoxalin-6-yl)butanamide (Enantiomer 2)::US10421742, Example 257::US11180471, Example 257 Plasma kallikrein Human 2.70 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413864 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413864&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205541 433913963 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1116099 CCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F InChI=1S/C27H23ClF4N6O4/c1-3-4-21(26(41)34-15-6-7-16(25(33)40)19(29)10-15)37-12-22(42-2)18(11-24(37)39)17-9-14(28)5-8-20(17)38-13-23(35-36-38)27(30,31)32/h5-13,21H,3-4H2,1-2H3,(H2,33,40)(H,34,41) FQRNHVWJUMYDQS-UHFFFAOYSA-N 413865 4-({2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]pentanoyl}amino)-2-fluorobenzamide (Racemate)::US10421742, Example 258::US11180471, Example 258 Plasma kallikrein Human 34.0 US Patent 10.7270/Q2W09935 aid1806149 US11180471 Jimenez Nunez, E; Ackerstaff, J; Roehrig, S; Hillisch, A; Meier, K; Heitmeier, S; Tersteegen, A; Stampfuss, J; Ellerbrock, P; Meibom, D; Lang, D 11/23/2021 4/10/2022 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=413865 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=413865&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 135205430 433913964 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3